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DNA degradation during apoptotic cell death
S Nagata
Department of Genetics, Osaka University Medical School, Osaka,
Japan
Arthritis Res Ther 2003, 5(Suppl 3):1 (DOI 10.1186/ar800)
Apoptosis is a principal mechanism in metazoans by which superfluous
or potentially harmful cells are eliminated. Deregulation of this process
leads to a variety of diseases such as cancer and autoimmune dis-
eases. Stimuli that can induce apoptosis are relatively diverse, and
include the death factors (Fas ligand, tumor necrosis factor and TRAIL),
DNA damage, and oxidative stress. Regardless of the origin of the
apoptotic stimulus, commitment to apoptosis leads to activation of cas-
pases, a family of cysteine proteases. Cleavage of a select group of
cellular substrates by caspases is responsible for the morphological
and biochemical changes that characterize apoptotic cell death. The
degradation of nuclear DNA into nucleosomal units is one of the fea-
tures of apoptotic cell death, and is mediated by a caspase-activated
DNase (CAD). Cells deficient in CAD undergo cell death without the
DNA fragmentation, but CAD-null mice did not show any adverse phe-
notypes. A close examination of the apoptotic cells in these mice indi-
cated that apoptotic cells are always in macrophages. It seems that at
an early stage of apoptosis, the dying cells present an ‘eat me signal’
on their surface. This signal is recognized by macrophages for engulf-
ment, and DNase II in the lysosomes of macrophages degrades DNA of
apoptotic cells. Mice deficient in both CAD and DNase II genes were
established, and the development of various organs was found to be
severely impaired in these mutant mice. The mice accumulated a large
amount of undigested DNA in macrophages in various tissues during
development. This accumulation of DNA in macrophages activated the
innate immunity to induce the expression of the interferon β gene. The
interferon thus produced seems to be responsible for the impaired
tissue development. These results indicate that the degradation of
DNA during apoptotic cell death is an essential step of apoptosis to
maintain mammalian homeostasis.
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Paracrine pathways of cartilage destruction in
osteoarthritis
S Abramson, M Attur, M Dave, M Leung, J Patel, P Gomez, A Amin
Division of Rheumatology, NYU School of Medicine — Hospital for
Joint Diseases, New York, USA
Arthritis Res Ther 2003, 5(Suppl 3):2 (DOI 10.1186/ar801)
Osteoarthritis (OA) has been considered a biomechanically driven,
degenerative disease of cartilage. However, the OA disease process
affects not only the cartilage, but also the entire joint structure; and within
the bone, cartilage and synovium of affected joints, profound metabolic
changes transpire, which include the production of growth factors, nitric
oxide (NO), prostaglandins (PGs), leukotrienes (LTs), IL-1β, tumor necro-
sis factor alpha, IL-6, and IL-8. The autocrine production of IL-1β by OA
cartilage has been of particular interest, since both ex vivo human and in
vivo animal studies indicate that IL-1 antagonists effectively attenuate
cartilage degradation. Microarray technology has demonstrated differen-
tial expression in OA cartilage of a variety of IL-1-induced, NFβB-depen-
dent genes. Among IL-β-induced products of OA cartilage are various
eicosanoids, which include E2, PGD2, LTB4, PGF1α, PGF2α and throm-
boxane. Treatment of OA cartilage with cyclooxygenase (COX) inhibitors
increases LTB4 production threefold to fivefold, indicating shunting of
arachidonate from the COX to the 5-LO pathway. Functional analyses of
individual eicosanoids reveals that PGD2, in contrast to its derivative
PGJ2, stimulates catabolic processes, including NO and PG production.
Lipoxin and 15-epi-lipoxin are also spontaneously released by OA carti-
lage, where they act to inhibit the spontaneous production of NO, PGE2,
IL-8 and IL-6. Consistent with the notion that OA is not simply a degener-
ative disease of cartilage, gene expression analysis of circulating periph-
eral blood mononuclear cells (PBMCs) shows upregulation of mRNA for
IL-1β, COX-2, IL-6, and IL-8 in OA (but not normal) PBMCs. OA PBMCs
produce threefold to fivefold more PGE2 in response to stimulation with
IL-1β than do normal cells. Thus, PBMCs, like chondrocytes and synovial
cells, are activated in OA, and merit evaluation as sensors of inflammatory
processes in the OA joint.
3
Fifty years’ experience in research for
pathogenesis of rheumatoid arthritis
NJ Zvaifler
Arthritis Res Ther 2003, 5(Suppl 3):3 (DOI 10.1186/ar802)
Abstract not submitted for publication
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Interferons and IRF/Stat transcription factors in
the regulation of immunity, oncogenesis and bone
remodeling
T Taniguchi, A Takaoka, H Takayanagi, K Honda
Department of Immunology, Graduate School of Medicine, University
of Tokyo, Japan
Arthritis Res Ther 2003, 5(Suppl 3):4 (DOI 10.1186/ar803)
Analysis of the interferon (IFN)-α/β system over the past two decades
revealed the critical roles of the IRF and Stat families of transcription
factors in the regulation of this and other cytokine systems. We proposed
operation of the positive feedback mechanism of the IFN gene induction,
which is mediated by IRF-3 and IRF-7. We demonstrate that this mecha-
nism is critical not only for innate immune response against viruses, but
also for adaptive immune responses through induction of the maturation of
dendritic cells. We also present our recent findings on a new link between
the IFN signaling and tumor suppressor p53. In fact, the IFN-mediated
induction of p53 gene is critical for boosting the p53-dependent apoptotic
response in tumor suppression and antiviral immunity. Bone remodeling is
central to maintaining the integrity of the skeletal system, wherein the
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developed bone is constantly renewed by the balanced action of
osteoblastic bone formation and osteoclastic bone resorption. We found
that IFNs and IRF/Stat factors are uniquely involved in the regulation of
bone remodeling, and summarize our data on how these cytokines and
transcription factors participate in maintaining the bone homeostasis.
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Delineating biologic pathways involved in skeletal
growth and homeostasis through the study of rare
Mendelian diseases that affect bones and joints
M Warman
Department of Genetics and Center for Human Genetics, Case
Western Reserve University and University Hospitals of Cleveland,
Cleveland, Ohio, USA
Arthritis Res Ther 2003, 5(Suppl 3):5 (DOI 10.1186/ar804)
We have found that the secreted glycoprotein, lubricin, is mutated in
patients with the autosomal recessive disorder camptodactyly–arthropa-
thy–coxa vara–pericarditis syndrome. To better define lubricin’s role in
articulating joints we have been studying lubricin knockout mice. Knock-
out mice recapitulate features observed in patients with campto-
dactyly–arthropathy–coxa vara–pericarditis, and therefore allow us to
learn more about the protein’s in vivo function. We find that synovio-
cytes from knockout mice have different growth characteristics than do
wild-type synoviocytes. We also find that the articular cartilage surface
in knockout mice loses superficial zone chondrocytes and becomes
covered by proteinaceous material. These results indicate that lubricin
protects cartilage surfaces and helps regulate synovial cell growth.
We had found that Wnt-inducible-secreted protein 3 (WISP3) is mutated
in patients with the autosomal recessive disorder progressive
pseudorheumatoid dysplasia. Patients with progressive pseudo-
rheumatoid dysplasia require joint replacement surgery for what resem-
bles end-stage osteoarthritis by their second decade of life. WISP3 is in
very low abundance since we have only been able to detect mRNA by
reverse transcription-polymerase chain reaction, and not by northern blot
or  in situ hybridization. Furthermore, we have not been able to detect
endogenous WISP3 protein using a sensitive polyclonal antibody. There-
fore, to determine the role of WISP3 in maintaining joints we created
Wisp3 knockout mice. Surprisingly these mice did not develop joint
failure, but they did seem to have altered timing of their secondary centers
of ossification. We are currently exploring whether this altered timing is rel-
evant to the pathogenesis of cartilage failure in human patients.
We have been searching for the gene responsible for autosomal reces-
sive acromesomelic dysplasia. This is an interesting disorder because it
primarily affects postnatal, rather than prenatal, growth. Also interesting is
the fact that many carrier parents of affected individuals appear to have
isolated short stature. Consequently, the discovery of the gene responsi-
ble for this disease may provide insights into pathways that effect growth.
Message from WHO
Assessing the burden of musculoskeletal
conditions: a joint World Health
Organization–Bone and Joint Decade project
N Khaltaev1, B Pfleger1, AD Woolf2, C Mathers1, K Akesson3, 
JM Hazes4, D Symmons5
1World Health Organization, Geneva, Switzerland; 2Royal Cornwall
Hospital, Truro, UK; 3Malmö University Hospital, Sweden; 4University
Hospital of Rotterdam, The Netherlands; 5University of Manchester, UK
Arthritis Res Ther 2003, 5(Suppl 3):174 (DOI 10.1186/ar805)
Introduction The Monitor Project of the Bone and Joint Decade (BJD)
was developed to quantify the global burden of musculoskeletal condi-
tions and to develop strategies for their prevention. Experts within the
Monitor Project have been working with officers at the World Health
Organization (WHO) to estimate morbidity and mortality associated
with rheumatic conditions.
Objectives To determine the burden of major musculoskeletal condi-
tions and limb trauma in terms of mortality and disability.
Methods A Scientific Group meeting of experts in the areas of muscu-
loskeletal conditions and limb trauma was held in January 2000 in Geneva
in order to produce a WHO Technical Report on the impact of rheumatoid
arthritis (RA), osteoarthritis (OA), osteoporosis, major limb trauma, and
spinal disorders (low back pain [LBP]). Data on incidence, prevalence and
severity for the conditions were collected by world region, gender, and
age groups. Estimates of the economic burden of each condition were
also made, as were descriptions of relevant health domains and states.
Epidemiological models were formed for RA, OA and LBP. Computer
software was used to combine the data on incidence and/or prevalence
with estimates of case fatality, case remission, and average duration to
establish the number of years of life lost for each condition in agreement
with mortality data. Estimates for the distribution of disabilities associated
with treated and untreated forms of each condition were made to help
determine the number of years living in disability for each condition.
Results The work of the WHO/BJD collaboration has resulted in a WHO
Technical Report (in press) as well as burden estimates for the WHO
Global Burden of Disease 2000 study. Results comparing years of living
with disability for 1990 data with those for 2000 data are presented in
Table 1 for RA, OA, LBP, and a residual musculoskeletal condition cate-
gory. The burden appears to have increased during the time period. Other
results show that the impact of musculoskeletal conditions varies world-
wide and is influenced by social structure, expectation, and economics.
Table 1
Years living with disability for musculoskeletal conditionsa
Global Burden of Disease Global Burden of Disease
1990 2000
Condition Male Female Total Male Female Total
RA 859 2309 3168 1205 3092 4297
Osteoarthritis 5341 7934 13,275 5549 8667 14,216
Low back pain – – – 1180 1045 2225
Other 398 1099 1437 596 1598 2194
aYears of life lost data not presented due to the low mortality associated with
these conditions. LBP was not considered in the Global Burden of Disease
1990 study. RA, rheumatoid arthritis. Sources: [1,2] and unpublished World
Health Organization data.
Conclusions The WHO/BJD collaboration has been successful in
accumulating and publishing vital data describing the burden of muscu-
loskeletal conditions and limb trauma.
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Message from APLAR
Fortieth Anniversary of APLAR
P Pispati
President — APLAR
Arthritis Res Ther 2003, 5(Suppl 3):175 (DOI 10.1186/ar806)
What an honour it is to come to this exotic Miyazaki Island in this won-
derful country of Japan. I bring to you warm greetings and felicitations
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from 22 APLAR countries ranging from Iraq/Syria in the West to
Japan/New Zealand in the East. APLAR is most proud that Japan is a
leading and outstanding member of the APLAR community of nations.
This is a significant year for APLAR. We are celebrating the 40th
Anniversary of APLAR. We find no better occasion or location to make
this announcement from the outstanding platform of the GARN
Conference.
Ladies and Gentlemen, 3.7 billion people reside in APLAR countries;
some highly developed, some economically prosperous and some
developing nations. Rheumatology as a science and practice is firmly
established in most APLAR member countries, including developing
nations. There are highly qualified well-trained rheumatologists avail-
able who enjoy adequate practical laboratory support and are given to
good therapeutics. There are centres of excellence where good educa-
tion and training in rheumatology is imparted.
Yet, there are some countries that are not yet members of APLAR and in
which organised rheumatology centres hardly exist. It is the aim of APLAR
today to undertake and help initiate rheumatology services in these coun-
tries. This is an ambitious and onerous task that we have undertaken.
Exactly a year from now APLAR will hold its outstanding International
Congress in Rheumatology in the picturesque Jeju Island in South
Korea. We promise you an innovative, creative, stimulating scientific
programme replete with warm hospitality. Do come to the APLAR Con-
gress in South Korea in September 2004 — you will never ever regret it.
The GARN Conference is certain to generate new data, new ideas with
the plethora of brilliant scientists assembled under one roof here. We
have come to learn a lot and to develop positive ideas into an action pro-
gramme in the APLAR region. This is precisely why I am here to take
away a message of advances in science and to give this message of co-
operation and goodwill to the brilliant success of this GARN Conference.
MAY PEACE AND HARMONY PREVAIL. MAY GOD BLESS US ALL.
Topics Symposium (1) Rheumatology (1): RA
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Premise: traditional disease-modifying
antirheumatic drugs are less effective and safe
than targeted therapy with biologic response
modifiers in rheumatoid arthritis
R Fleischmann
Department of Internal Medicine, University of Texas Southwestern
Medical Center at Dallas, Dallas, Texas, USA
Arthritis Res Ther 2003, 5(Suppl 3):6 (DOI 10.1186/ar807)
Introduction Multiple traditional disease-modifying antirheumatic drugs
(DMARDs), including hydroxychloroquine, gold, penicillamine, sul-
fasalazine, leflunomide, methotrexate, azathioprine, and cyclosporine, have
been approved for use in patients with rheumatoid arthritis. Most patients
discontinue these medications by 2 years due to loss of efficacy and/or
toxicity. There are currently four biologic response modifiers (BRMs) com-
mercially available: etanercept, infliximab, adalimumab, and anakinra. The
question is whether these BRMs have a superior efficacy:tolerability ratio,
allowing patients to remain on therapy significantly longer.
Objectives To compare clinical trial data of traditional DMARDs and
BRMs, alone or in combination, with respect to efficacy and safety.
Results It is impossible to compare efficacy or safety results of clinical
trials of different agents as trial designs, primary endpoints and statisti-
cal analyses have changed considerably over the years. The best
measure of the effectiveness of a particular medication, therefore, is
how long patients remain on therapy that would assume a significant
clinical benefit without serious adverse events (AE). Less than 50% of
patients treated with traditional DMARDs remain on therapy for 2 years
[1]. Combination therapy of DMARDs in patients with established
disease does not fare better. Significant AEs that occur with these
agents include hematological, hepatic, pulmonary, renal, infectious and
mucocutaneous reactions. Each of the BRMs that target tumor necro-
sis factor alpha have far superior results with respect to continuing
therapy: 60% of infliximab patients >2 years, 52% of patients with
etanercept >4 years and 56% of patients with adalimumab >5 years
[2]. Rare AE that do occur include reactivation of latent tuberculosis
and other opportunistic infections, demyelinating disease, congestive
heart failure and possibly lymphoma. With proper screening and
caution, however, patients should be identified if they are at risk and
not treated, thus sparing these AEs. Patients treated with BRMs do not
develop the multiorgan adverse events noted with traditional DMARDs
Conclusions Anti-tumor necrosis factor BRMs appear to have superior
efficacy and safety than do traditional DMARDs alone or in combination.
For this reason, the use of a BRM should be strongly considered in a
patient with rheumatoid arthritis who has not reached maximal efficacy
or who develops a significant AE with the use of traditional DMARDs.
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The use of animal models to find and understand
arthritis genes
R Holmdahl
Medical Inflammation Research, Lund University, Lund, Sweden
Arthritis Res Ther 2003, 5(Suppl 3):7 (DOI 10.1186/ar808)
Inbred animals are useful for studies of the identification of genes asso-
ciated with rheumatoid arthritis (RA) since they are more efficient tools
for identification of genes controlling complex diseases. There are
several arthritis models, which each may reflect various variants of the
heterogeneity of RA in humans. Examples are collagen-induced arthritis
(CIA) and pristane-induced arthritis, which both fulfill the clinical diag-
nostic criteria for RA.
Type II collagen (CII) is immunogenic and contains peptides that can be
bound to major histocompatibility complex (MHC) class II and can be
presented to T cells, whereas pristane is not immunogenic by itself.
Both diseases are genetically complex and the susceptibility is, as RA,
dependent on many polymorphic genes operating in concert. So far two
of these genes have been identified; the MHC class II Ab gene in the
mouse [1] and the Ncf1 gene in the rat [2]. The Ncf1 protein is a part of
the NADPH oxidase complex involved in generation of the inducible
oxidative burst. The discovery of the Ncf1 polymorphism led to a new
proposed pathway in which oxygen radicals modify antigen presentation
and the resulting activation of autoreactive T cells. This hypothesis has
now been further documented by the identification of an Ncf1 mutation
in the mouse that reproduces the effects earlier observed in the rat.
Mice with the deficient Ncf1 allele, and expressing the MHC class II
allele Aq, binding CII peptides, could be shown to be dramatically more
susceptible to CIA, and also developed a chronic form of arthritis. Inter-
estingly, the immune response to CII was enhanced by the Ncf1 defi-
ciency linking the Ncf1 pathway to the adaptive immune response.
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Synovial mast cells require C5a receptor (CD88) for
arthritis induction
D Lee1, M Brenner1, C Gerard2, C Benoist3, D Mathis3, G Watts1
1Division of Rheumatology, Immunology and Allergy, Brigham &
Women’s Hospital, Harvard Medical School, Boston, Massachusetts,
USA; 2Department of Pediatrics, Children’s Hospital, Harvard Medical
School, Boston, Massachusetts, USA; 3Section on Immunology and
Immunogenetics, Joslin Diabetes Center, Harvard Medical School,
Boston, Massachusetts, USA
Arthritis Res Ther 2003, 5(Suppl 3):8 (DOI 10.1186/ar809)
A critical role for mast cells in arthritis pathogenesis has been demon-
strated in the K/BxN serum transfer mouse model; however, the mecha-
Available online http://arthritis-research.com/supplements/5/S3S4
nisms by which synovial mast cells are activated to induce arthritis
remains unknown. Previous studies have demonstrated a requirement for
both IgG Fc receptors and complement components (C3 and C5) as well
as the receptor for the anaphylotoxin C5a (C5aR, CD88) in K/BxN serum
transfer arthritis. Knowing that human synovial mast cells express CD88
while mast cells at other anatomic sites lack CD88 expression, we hypoth-
esized that synovial mast cells may require activation via CD88 for arthritis
induction in the K/BxN model. To test this hypothesis, we engrafted wild-
type (C57BL/6 [B6]) and CD88-deficient (CD88–/–) bone marrow-
derived mast cells (BMMC) into mast cell-deficient W/Wv recipient mice.
After allowing 10 weeks for engraftment, we challenged B6 and CD88–/–
BMMC-engrafted W/Wv mice as well as control, non-engrafted W/Wv
and wild-type mice with arthritogenic K/BxN serum. We find that CD88–/–
BMMC-engrafted W/Wv mice clinically display resistance to arthritis
induction equivalent to that seen in non-engrafted W/Wv mice, while B6
BMMC engraftment restores arthritis sensitivity to W/Wv mice. Histologic
analyses confirm engraftment of mast cells in synovial and other tissues in
CD88–/– BMMC-recipient W/Wv mice. These results demonstrate an in
vivo requirement for CD88 expression by synovial mast cells for induction
of inflammatory arthritis in the K/BxN arthritis model.
9
Albumin-based drug delivery as novel therapeutic
approach for rheumatoid arthritis
A Wunder1, U Muller-Ladner2, E Stelzer3, E Neumann2, H Sinn1,
S Gay4, C Fiehn5
1Department of Radiochemistry and Radiopharmacology, German
Cancer Research Center, Heidelberg, Germany; 2Department of
Internal Medicine I, University of Regensburg, Regensburg, Germany;
3Cell Biophysics/Cell Biology Program, European Molecular Biology
Laboratory Heidelberg, Heidelberg, Germany; 4WHO Collaborating
Center for Molecular Bioliology and Novel Therapeutic Strategies for
Rheumatic Disorders, University of Zurich, Zurich, Switzerland; 5Clinic
of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
Arthritis Res Ther 2003, 5(Suppl 3):9 (DOI 10.1186/ar810)
We reported recently that albumin is a suitable drug carrier for targeted
delivery of methotrexate (MTX) to tumors. Due to pathophysiological
conditions in neoplastic tissue, high amounts of albumin accumulate in
tumors and are metabolized by malignant cells. MTX, covalently
coupled to human serum albumin (MTX-HSA) for cancer treatment, is
currently being evaluated in phase II clinical trials. Because the syn-
ovium of patients with rheumatoid arthritis (RA) shares various features
observed also in tumors, albumin-based drug targeting of inflamed
joints might be an attractive therapeutic approach. Therefore, the phar-
macokinetics of albumin and MTX in a mouse model of arthritis was
examined. Additionally, uptake of albumin by synovial fibroblasts of RA
patients and the efficacy of MTX and MTX-HSA in arthritic mice were
studied. The results show that, when compared with MTX, significantly
higher amounts of albumin accumulate in inflamed paws, and signifi-
cantly lower amounts of albumin are found in the liver and the kidneys.
The protein is metabolized by human synovial fibroblasts in vitro and in
vivo. MTX-HSA was significantly more effective in suppression of the
onset of arthritis in mice than was MTX. In conclusion, albumin appears
to be a suitable drug carrier in RA, most probably due to effects on syn-
ovial fibroblasts, which might increase the therapeutic efficacy of and
reduce side effects of MTX.
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SKG mice, a new genetic model of rheumatoid
arthritis
S Sakaguchi, T Takahashi, H Hata, T Nomura, N Sakaguchi
Department of Experimental Pathology, Institute for Frontier Medical
Sciences, Kyoto University, Kyoto, Japan
Arthritis Res Ther 2003, 5(Suppl 3):10 (DOI 10.1186/ar811)
We have established a mouse strain, designated SKG mice, which
spontaneously develop chronic autoimmune arthritis. The arthritis
resembles rheumatoid arthritis in the proliferative synovial inflammation
accompanying infiltration of CD4+ T cells, formation of pannus eroding
cartilage and bone, development of autoantibodies including rheuma-
toid factor, and various extra-articular manifestations. It can be adop-
tively transferred to histocompatible athymic mice by peripheral CD4+
T cells or thymocytes, or to histocompatible SCID mice by bone
marrow cells. Thus, the abnormality in this model seems to be
expressed in the bone marrow-derived cellular components, leading to
thymic generation and activation of CD4+ T cells recognizing/attacking
normal self-antigens in the joints. In genetic analysis, the offspring of
crosses between SKG mice (which has a BALB/c genetic back-
ground) and normal BALB/c mice, whether the mother was SKG or
BALB/c, developed no arthritis. In contrast, arthritis occurred in approx-
imately 50% of the N2 generation obtained by crossing the nonarthritic
F1 hybrids with SKG mice; the arthritides in the N2 generation showed
a similar clinical course and severity as in SKG mice. Thus, the genetic
abnormality is presumably of a single gene locus, designated as the
skg gene, and inherited in an autosomal recessive fashion with nearly
100% penetrance of the trait in homozygotes raised in our conven-
tional environment. Linkage analysis between the development of
macroscopically evident arthritis and the homozygosity of chromosome-
specific microsatellite markers by utilizing the N2 generation of back-
crossing the F1 generation of SKG and Mus musculus castaneus to
SKG mapped the skg locus to the centromeric portion of
chromosome 1, with the lod score of the locus as infinite. Positional
cloning of the skg gene revealed that the gene encodes a signal trans-
duction molecule in T cells. Altered signal transduction from the T-cell
antigen receptor through the mutated molecule changes the thresholds
of T cells to thymic selection, leading to positive selection of otherwise
negatively selected autoimmune T cells. This genetically determined
‘selection shift’ of the T-cell repertoire towards high self-reactivity and
resulting thymic production of pathogenic autoimmune T cells may be a
primary cause of and also a predisposing factor for RA in humans.
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The role of IL-17 in the development of arthritis in
mouse models
Y Iwakura, S Nakae, R Horai, S Saijo
Center for Experimental Medicine, Institute of Medical Science,
University of Tokyo, Tokyo, Japan
Arthritis Res Ther 2003, 5(Suppl 3):11 (DOI 10.1186/ar812)
Introduction IL-17 is a T-cell-derived proinflammatory cytokine, which
is suspected to be involved in the development of rheumatoid arthritis
(RA) because this cytokine is found in sera and synovial tissues of RA
patients. The pathogenic roles of IL-17 in the development of RA,
however, still remain to be elucidated.
Objective To elucidate the roles of IL-17 in the development of arthritis,
we produced IL-17-deficient (IL-17–/–) mice, and examined the effect of
deficiency on the development of arthritis in two etiologically different,
spontaneous RA models, the HTLV-I transgenic mouse model and the IL-
1 receptor antagonist (IL-1Ra)-deficient mouse model, as well as the type
II collagen-induced arthritis model [1].
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Figure 1
Development of arthritis in IL-1Ra–/– is completely suppressed by the
deficiency of IL-17.S5
Methods IL-17–/– mice were produced by replacing exon 1 and exon 2
of the il-17 gene with a neomycin resistance gene [2]. HTLV-I trans-
genic mice carrying the HTLV-I env-pX region and IL-1Ra–/– mice were
produced as described elsewhere [3,4].
Results Both HTLV-I transgenic mice and IL-1Ra–/– mice develop
arthritis spontaneously due to autoimmunity caused by excess T-cell
activation. The development of arthritis in HTLV-I transgenic mice was
markedly suppressed in IL-17–/– mice, and that in IL-1Ra–/– mice was
abolished completely (Fig.1).
Moreover, type II collagen-induced arthritis was markedly suppressed
in IL-17–/– mice. We found that crosslinking of OX40 led to promote IL-
17 production on CD4+ T cells, and OX40 expression was augmented
in IL-1Ra–/– mice due to excess IL-1 signaling, resulting in the overpro-
duction of IL-17. IL-17 was responsible for the priming of collagen-spe-
cific T cells and collagen-specific IgG2a production.
Conclusion These observations suggest that IL-17 acts downstream
to IL-1, and plays a crucial role in the development of arthritis by acti-
vating autoantigen-specific cellular and humoral immune responses.
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Cytokine production by dendritic cells genetically
engineered to express IL-4: induction of Th2
responses and differential regulation of IL-12 and
IL-23 synthesis
D Fox, Y Morita, R Gupta, K Seidl, K McDonagh
Department of Internal Medicine, University of Michigan, Ann Arbor,
Michigan, USA
Arthritis Res Ther 2003, 5(Suppl 3):12 (DOI 10.1186/ar813)
We recently showed a therapeutic effect of bone marrow-derived den-
dritic cells (DCs) retrovirally transduced with IL-4 in murine collagen-
induced arthritis, a Th1-mediated autoimmune disease. We have now
further investigated the functional characteristics of these engineered
cells. We hypothesized that the ability of DCs to regulate the type of
immune response may depend in part on their capacity to produce IL-12
and IL-23. IL-4-transduced DCs produced increased levels of IL-12p70
following ligation of CD40. Quantitative mRNA analysis revealed that IL-4-
transduced DCs expressed higher levels of IL-12p35 mRNA, but lower
levels of mRNA for IL-23p19 and the common subunit p40 found in both
IL-12 and IL-23, compared with control DCs. Thus, expression of the IL-
12 and IL-23 subunits is differentially regulated in IL-4-transduced DCs.
Similar results were obtained using in vitro differentiated myeloid DCs cul-
tured in 10–50 ng/ml IL-4. IL-4 led to diminished secretion of IL-23 protein
after activation of these cells by CD40 ligand. In vivo studies demon-
strated that IL-4-transduced, antigen-pulsed DCs led to lower antigen-
specific T-cell production of IFN-γ. Delayed type hypersensitivity induced
by IL-4-transduced antigen-pulsed DCs was diminished compared with
control DCs. Our results indicate that therapeutic suppression of Th1-
mediated autoimmunity and induction of Th2 responses in vivo by IL-4-
transduced DCs occurs despite their potential to produce increased
levels of IL-12, but reflects, in part, decreased production of IL-23.
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T-cell anergy may serve to limit autoreactive T-cell responses in vivo.
Anergy induction in vitro is blocked by calcineurin inhibitors and by
inhibition of protein synthesis. In order to look for a potential anergy
specific gene, we examined early changes in gene expression in murine
CD4+ T-cell clones after antigen-T-cell receptor signaling in the pres-
ence (activation) or absence (anergy) of B7 co-stimulation. GRAIL
(Gene Related to Anergy in Lymphocytes) was a novel transcript whose
expression was markedly induced in anergic T cells in vitro compared
with activated or resting T cells. GRAIL is a novel murine type I trans-
membrane protein that localizes to the endocytic pathway and bears
homology to several RING Zinc-finger proteins. GRAIL functions as an
E3 ubiquitin ligase. Expression of GRAIL in retrovirally transduced T-cell
hybridomas dramatically limits activation-induced IL-2 production in
vitro. Substitution of histidine for asparagine at two positions in the ring
finger (H2N2 GRAIL) blocks enzymatic function of GRAIL. Retroviral
transduction of hematopoietic stem cells to express GRAIL reiterates
the anergy phenotype in resultant CD4+ T cells, including inability to
secrete IL-2 or proliferate following antigen stimulation. Expression of
the enzymatically inactive (dominant-negative) form of H2N2 GRAIL
blocks anergy induction in T cells in vivo. These data demonstrate that
GRAIL is necessary and sufficient to induce anergy in CD4+ T cells.
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Engagement of the T-cell antigen receptor (TCR) induces the assembly
of signaling complexes comprised of adapter molecules and enzymes.
We use multiple approaches in our characterization of these com-
plexes and the process of signal transduction mediated by the TCR.
Our genetic approach is the study of mutations in a critical adapter
molecule, LAT. Some of these mutations lead to an interesting lympho-
proliferative disorder. Signaling complexes can be studied in vitro using
biochemical and biophysical methods to determine the rules of signal
complex formation. Finally, we visualize the formation and fate of multi-
protein complexes at the site of TCR activation. To do so, we express
various fluorescently-tagged signaling proteins in T cells and observe
clusters of molecules containing the TCR and important adapters and
enzymes. Direct imaging of signaling molecules has revealed the highly
dynamic nature of molecular interactions at the TCR.
15
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Toll-like receptors (TLRs) play a critical role in the detection of invading
pathogens within the body and subsequent immune response against
them. We have generated knockout mice for individual TLRs and
showed that individual TLRs recognize distinct microbial components.
TLR4 is essential for the response to LPS. TLR2 is involved in the
recognition of lipoproteins and peptidoglycan, together with TLR1 or
TLR6. TLR9, TLR3, TLR5 and TLR7 recognize deoxyribonucleotides,
ribonucleotides, flagellin, and imidazoquinolines, respectively. The TLR
is a type 1 transmembrane receptor that is composed of an extracellu-
lar leucine-rich repeat domain and a cytoplasmic domain homologous
to that of the IL-1R family. Upon stimulation, TLR recruits IL-1 receptor-
associated kinase via adaptor MyD88, and finally induces activation of
NF-κB. Cytokine production in response to each TLR ligand is com-
pletely abolished in MyD88-deficient cells, indicating that MyD88 is an
essential signaling molecule shared among the IL-1R/Toll family.
However, several novel adaptor molecules have recently been identi-
fied. Evidence is now accumulating that differential utilization of these
adaptors may activate overlapping as well as distinct signaling path-
ways, and finally may give rise to distinct biological effects exerted by
individual TLR families.
Available online http://arthritis-research.com/supplements/5/S3S6
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BAFF, a member of the family of tumor necrosis factor ligands, is
essential for the development of peripheral, mature, long-lived B lym-
phocytes. It binds to three different receptors (BCMA, TACI and BAFF-
R), which are all members of the family of tumor necrosis factor
receptors. Defects in the genes encoding either BAFF or BAFF-R
abolish the generation of mature B cells. BAFF is made by myeloid
cells while BAFF-R is expressed preferentially on B cells. BAFF
induces polyclonal maturation of resting, short-lived immature cells to
resting, long-lived mature B cells without proliferation. Lupus erythema-
todes-prone mice have elevated levels of BAFF in their blood, and
treatment of these mice with BAFF decoy receptor (BCMA-Ig) prevents
the onset of this autoimmune disease. Human lupus patients also show
elevated levels of BAFF in their blood. Treatments with BAFF-neutraliz-
ing agents should prevent, delay or, at least, slow down the disease.
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Objectives To understand immunological aspects of osteoarthritis
(OA), which has been considered a degenerative disease, we com-
pared profiles of autoimmunity comprehensively between OA and
rheumatoid arthritis (RA) using analysis of the chondrocytes’
proteome.
Methods Proteins extracted from normal articular chondrocytes were
separated by two-dimensional electrophoresis. Western blotting
(WB) was then used to detect antigenic protein spots, using
20 serum samples from either OA or RA patients. Mass fingerprinting
was used for identification of the detected autoantigens. The identi-
fied proteins were prepared as recombinant fusion proteins with
maltose binding protein (TPI-MBP) to confirm their antigenecity and
to investigate the frequency of the autoantibodies, epitope localiza-
tion, and clinical significance by ELISA and WB, using serum
samples obtained from 93 patients with OA, 54 patients with RA, and
43 patients with SLE.
Results Sixty-two autoantigens were detected in responses to OA
and RA serum samples, in which 19 protein spots were detected only
in the OA group. One of these apparently OA-specific protein spots,
detected in four out of 20 OA patients but not in RA patients, was
identified as human triose phosphate isomerase (TPI). All four positive
sera against this spot reacted to a fusion protein of TPI-MBP but not
MBP alone. Also, TPI-MBP affinity-purified antibodies from these sera
only reacted to the spot that was identified as TPI in the two-dimen-
sional electrophoresis membrane. The frequencies of the anti-TPI IgG
in the sera from OA, RA, and SLE patients were 24.5%, 5.6%, and
4.7%. Further frequencies of the autoantibody in synovial fluid from 29
OA patients and 19 RA patients were found to be 24.1% and 0%,
respectively. All the positive samples were further confirmed by WB.
In the epitope mapping using eight truncated recombinant TPI pro-
teins, multiple epitopes were identified, one of which was recognized
in more than 90% of the positive serum samples. Clinically, the X-ray
grading was lower in the anti-TPI-positive OA group than that in the
anti-TPI-negative group.
Conclusion The overall profile of autoimmunity in OA differs from that
in RA, which may reflect OA-specific pathological roles of autoimmu-
nity. The autoantibodies to TPI, detected in OA predominantly and pro-
duced by the antigen-driven mechanism, would have potential as a
diagnostic marker for OA.
Topics Symposium (3) Locomotor Science
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It has been recently demonstrated that synovial fibroblasts (SFs) contain a
multipotent mesenchymal cell population. To examine the chondrogenic
potentialities of SFs in vitro and in vivo, SFs were isolated from knee joints
of rabbits or rheumatoid arthritis patients, and infected with adenovirus
vectors carrying LacZ (control), constitutively active forms of activin recep-
tor like kinase (ALK)-3 or ALK-5 genes. Efficient gene transduction was
confirmed by β-galactosidase staining of the LacZ virus-infected SFs.
Northern blotting of type II collagen and aggrecan genes showed clear
induction of these genes in SFs infected with ALK-3 virus, while no chon-
drogenic phenotypes were observed in LacZ or ALK-5-infected cells.
ALK-3 virus-infected SFs were also positively stained by Alcian blue stain-
ing and type II collagen immunostaining. When transplanted into cartilage
defects of rabbit knee joints, ALK-3 virus-infected rabbit SFs produced
repair cartilage of hyaline morphology containing a type II collagen-positive
matrix that restored the articular surface. These results suggest that aden-
ovirus vector-mediated ALK-3 gene expression can induce chondrogenic
differentiation of synovial fibroblasts, and that they are promising candi-
dates for cell-based therapies for articular cartilage defects.
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Background Apoptosis is the physiological process used by an organ-
ism to eliminate cells that are no longer needed, have been damaged or
are dangerous. Defects in the control of apoptosis have been impli-
cated as a cause or a contributing factor in a variety of diseases. Pro-
teins of the Bcl-2 family are major regulators of this process.
We have previously shown that Bim is required for certain apoptotic
responses, for hematopoietic cell homeostasis and as a barrier against
autoimmune disease.
Objectives We study Bim-deficient mice in order to understand the
role of Bim in homeostasis and to evaluate its role in the ontogeny of
certain autoimmune and degenerative diseases.
Methods We intercrossed Bim-deficient mice with mouse strains used
as models for such diseases, namely bcl-2-KO, PKD1-KO, IL7R-KO
and Lurcher mice, and analysed double mutants.
Results We have shown that Bim is essential for the development of tol-
erance to self-antigens [1]. Using six different model systems, we have
demonstrated that, during development in the thymus, Bim plays a major
role in the elimination of the T lymphocytes that bear a T-cell receptor
(TCR)/CD3 complex that engages self-antigens (negative selection).
Thus, Bim appears essential for apoptosis of autoreactive T lymphocytes
and B lymphocytes in central as well as peripheral tolerance.
By intercrossing mice with mutations in bcl-2 and bim, we have gener-
ated mice lacking both genes and shown that all the deficiencies
caused by the absence of Bcl-2 (runting, polycystic kidneys, lymphope-
nia, hair greying) could be efficiently rescued by the concomitant
absence of Bim [2]. This result demonstrates that BH3-only proteins
can be involved in the induction of certain degenerative diseases.
By contrast, removal of Bim does not prevent the degeneration of cere-
bellar Purkinje cells and granular neurons in Lurcher mice.
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We are currently investigating the consequences of the loss of Bim in
PKD1-deficient and IL7R-deficient mice.
Conclusions Our results indicate that BH3-only proteins may be at the
origin of certain autoimmune and degenerative diseases, and may be
targets of interest for the research of new drugs against such diseases.
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Formation of osteoclasts is induced by a tumor necrosis factor family
cytokine, RANKL (receptor activator of NF-κB ligand). To maintain the
normal bone homeostasis and to prevent the pathological bone resorp-
tion, RANKL signaling must be strictly kept in control.
During the course of our study on the bone loss in rheumatoid arthritis
(RA), we found that RANKL expressed on synovial fibroblasts is
responsible for osteoclastogenesis from synoviocytes. However, it has
been also reported that RANKL-expressing T cells are involved in
osteoclastogenesis in RA. We then focused on the regulation of osteo-
clast differentiation by T cells. Using mice lacking a receptor compo-
nent for IFN-γ, we revealed that T-cell production of IFN-γ strongly
suppresses osteoclastogenesis by interfering with the RANKL signal-
ing pathway [1]. We have shed light on a new biological function of
IFN-γ, which is to protect against calcified tissue destruction upon
T-cell activation, demonstrating that activated T cells not only positively
regulate, but also negatively affect osteoclastogenesis.
To explore the molecular targets for suppressing bone destruction in
RA, we performed a genome-wide screening of RANKL-inducible
genes. We found that RANKL induces IFN-β, a critical cytokine for
antiviral defense. Mice deficient in IFN-β signaling exhibited severe
osteopenia accompanied by enhanced osteoclastogenesis, suggesting
that IFN-β is essential for normal bone remodeling by suppressing
excessive osteoclast differentiation [2]. In addition, we revealed benefi-
cial effects of IFN-β in animal models of pathological bone resorption.
We have recently identified that the transcription factor NFATc1 is
specifically induced by RANKL [3]. We demonstrate that NFATc1-defi-
cient embryonic stem cells fail to differentiate into osteoclasts in
response to RANKL stimulation, and the ectopic expression of NFATc1
causes the precursor cells to undergo efficient differentiation without
RANKL signaling. Thus, NFATc1 may be a master switch regulator for
the terminal differentiation of osteoclasts, functioning downstream of
RANKL signaling. The activation of NFATc1 by RANKL is regulated by
calcium-dependent phosphatase, calcineurin, and calcineurin inhibitors
such as FK506 and cyclosporin A strongly suppress osteoclastogene-
sis. The possibility of NFATc1 as a therapeutic target of bone destruc-
tion in RA will be discussed.
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The precise patterning of a developing skeletal framework relies on
appropriate control of chondrogenesis and on subsequent cartilage
development. This multistep process, where mesenchymal cells differ-
entiate into chondrocytes and then chondrocytes progress though
each developmental zone of the cartilage, is tightly regulated by a
number of key signaling molecules, which include PTH-related protein,
fibroblast growth factor, bone morphogenetic protein and transforming
growth factor. Importantly, these factors have been shown to promote
phosphorylation of transcription factor cAMP response element
(CREB) at its Ser133, which activates specific gene expression with
recruitment of its transcriptional co-activator CREB binding protein
(CBP). Recently, CBP has been shown to have intrinsic histone acetyl
transferase activity, which suggests a potential link between gene
expression and chromatin acetylation. In this regard, the important role
of CBP in CREB-dependent gene expression has been demonstrated
using a novel in vitro chromatinized template transcription assay.
With these findings, the importance of the CREB/CBP transcription
complex for chondrogenesis was examined by expressing a potent
dominant-negative CREB inhibitor (A-CREB). Consistent with the
robust Ser133 phosphorylation of CREB during chondrogenesis, A-
CREB blocked chondrogenesis from mesenchymal stem cells. During
chondrogenesis, specific chromatin factors are activated by the
CREB/CBP pathway and the chromatin factors promote chondrocyte-
specific gene expression via association with multiple transcription
factors that are known to be involved in chondrocyte differentiation.
These findings suggest that, in addition to DNA-binding type transcrip-
tion factors, chromatin factors, which alter the chromatin code, may
play a critical role for cell differentiation and tissue-specific gene
expression in cartilage development.
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We have identified and characterized a population of adult human mes-
enchymal stem cells (MSCs) from the synovial membrane (SM) capable
of differentiation to cartilage, bone, skeletal muscle, and adipose tissue in
vitro. SM-MSCs can be obtained without irreversible damage, are easily
expandable with limited senescence, and are phenotypically stable
throughout expansion and after storage in liquid nitrogen. The use of
MSCs is restricted by the as yet insufficient knowledge of the long-term
stability of the repair tissue and by their tendency to differentiate towards
other cell lineages. Their multilineage potential may present a risk of het-
erotopic tissue formation, and in vivo preclinical studies in experimental
models relevant to specific clinical applications should therefore be per-
formed.
Several applications will be discussed, including autologous cell trans-
plantation for the repair of joint surface defects, a procedure that
should be carried out using cells that are stably committed to the artic-
ular cartilage phenotype, naturally resistant to vascular invasion, miner-
alization, and ossification. Therefore, we investigated whether human
SM-MSCs can acquire in vitro the expression of the markers reported
to be associated with the stable-chondrocyte phenotype, and whether
this is associated with the capacity to form stable cartilage in vivo.
Further exploration of the plasticity of the SM-MSCs led to the unex-
pected finding that they participate in the repair of skeletal muscle in
two animal models. We characterized the myogenic differentiation of
this cell population in a nude mouse model of skeletal muscle regener-
ation, and demonstrated that they contributed to myofibers and to long-
term persisting functional satellite cells. When administered into
dystrophic muscles of immunosuppressed mdx mice, human SM-
MSCs restored, at least in part, muscle function in this mouse model of
Duchenne muscular dystrophy.
Many challenges remain in the area of cellular products, including
product specification and quality control, and proper prospective, multi-
center, randomized, clinical studies comparing this with standard treat-
ments. There is no doubt that a clear global regulatory path is needed
for the development of these novel approaches, as lack of transparency
and conflicting legislation in regulation is one of the major threats pre-
venting proper development of the field.
Available online http://arthritis-research.com/supplements/5/S3S8
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Development of the skeletal components of limbs is initiated by mes-
enchymal cell condensation to form primordial cartilage, followed by
endochondral ossification. Cartilage serves as the template for the for-
mation of most bones. During development, proliferating chondrocytes
differentiate into hypertrophic chondrocytes. In the final step in endo-
chondral bone formation, the hypertrophic cartilage is invaded by blood
vessels and osteoprogenitor cells, and the calcified cartilage is subse-
quently replaced by bone. Bone morphogenetic proteins (BMPs) were
originally identified as secreted signaling molecules that could induce
endochondral bone formation. Subsequent molecular cloning studies
have revealed that the BMP family consists of various molecules,
including members of the growth and differentiation factor (GDF) sub-
family. BMPs have diverse biological activities during development of
various organs and tissues, and the precise roles of BMP signals
during mammalian skeletal development have yet to be determined. We
previously isolated the promoter/enhancer sequence of the α2(XI) col-
lagen chain gene; this sequence is responsible for the chondrocyte-
specific expression during mouse development. Using this sequence,
we created transgenic mice that overexpress BMP4, GDF5 and
Noggin (a BMP antagonist) in cartilage. Overproduction of BMP4 or
GDF5 in cartilage increased cartilage production and enhanced chon-
drocyte differentiation. Noggin-expressing transgenic mice, in which
BMP signals seem to be blocked in cartilage, lacked most of the carti-
lage and mature hypertrophic chondrocytes. These results indicate that
BMP signals are essential for cartilage development.
BMP signals are mediated by Smad proteins intracellularly. We
attempted to block Smad signaling in developing cartilage by over-
expression of Smad6, an inhibitory Smad, in transgenic mice. In those
mice, the cartilage grew almost normally until birth, but osteopenia
developed after birth. Skeletal abnormalities were much less severe in
the present Smad6 transgenic mice than in Noggin transgenic mice
examined in a previous study; these two strains of transgenic mice
had identical promoter/enhancer sequences. The relatively mild phe-
notype of Smad6 transgenic mice suggests a mechanism in which
Smad6 alone cannot completely inhibit transduction of BMP signals in
cartilage.
To analyze the roles of BMPs in the final stage of endochondral bone
formation, we generated transgenic mice that expressed BMP4 or
Noggin in osteoblasts. Expression of Noggin in osteoblasts inhibited
bone formation, as expected. On the contrary, BMP4 overexpression in
osteoblasts resulted in disruption of skeletal architecture. Histological
examination revealed a reduced mineralized matrix in BMP4 transgenic
mice. These results suggest that persistent expression of BMP4 dose
not cause formation of solid bone.
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Rheumatoid arthritis (RA) is one of the common disorders character-
ized with overgrowth of articular synovial cells, so-called ‘pannus’, and
autoimmune reaction. To understand the pathomechanism of RA, we
attempted to characterize the rheumatoid synovial cell and found a
novel membranous protein, Synoviolin (synovial cell+ protein). Its over-
expression causes arthropathy, resembling RA in mice. Moreover, the
heterozygote of synoviolin (+/–) is resistant to anticollagen antibody-
induced arthritis. These ‘gain of function’ and ‘loss of function’ analyses
clearly indicate the pathogenetic role of synoviolin in arthropathy.
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Many investigators have directly examined the role of deleted/blocked
or overexpressed immune-related genes in lupus background mice.
The effects of such manipulations have provided important insights into
the crucial molecules and pathways involved in this disease and into
the development of new therapies. We report here on the effects of
two classes of genes: cyclin-dependent kinase inhibitor p21, and inter-
ferons (IFNs).
A characteristic feature of lupus in humans and mice is the accumulation
of activated/memory T cells and B cells. These G1-arrested cells
express high levels of p21, are resistant to proliferation and apoptosis,
and express high levels of proinflammatory cytokines. We hypothesized
that accumulation of these cells results from repetitive engagements by
self-molecules in vivo, and that deletion of p21 may lead to their reduc-
tion. Indeed, lupus-prone BXSB mice lacking p21 have enhanced T-cell
and B-cell proliferation but, importantly, have increased apoptosis,
resulting in a net reduction of activated/memory cells and marked inhibi-
tion of disease. Increased apoptosis of p21-deleted cells is mediated by
engagement of both the extrinsic (Fas/FasL) and intrinsic (Bcl2) related
pathways. Modulation of the cell-cycle pathway may be a novel
approach to reduce activated/memory-resistant and apoptosis-resistant
pathogenic T cells and B cells, and to ameliorate systemic autoimmunity.
Another class of molecules to ameliorate lupus is type I and type II IFNs,
since considerable evidence exists that these pleiotropic molecules are
important effectors in this disease. Our earlier studies showed decreased
serologic, cellular and histologic disease characteristics and increased
survival of MRL-Faslpr mice deleted of the IFN-γ gene or treated, even at
advanced stages, with cDNA encoding IFN-γR-Fc. More recently, we
created congenic NZB mice lacking the α-chain of IFN-α/βR, the
common receptor for the multiple IFN-α/β species. Compared with litter-
mate controls, homozygous-deleted mice had significantly reduced anti-
erythrocyte autoantibodies, erythroblastosis, hemolytic anemia, anti-DNA
autoantibodies, kidney disease and mortality. These reductions were
intermediate in the heterozygous-deleted mice. The disease-ameliorating
effects were accompanied by reductions in several immune cell subsets
(including B1 cells) and reduced dendritic cell maturation. The cumula-
tive data indicate that both type I and type II IFNs are important mediators
in the pathogenesis of murine lupus, and that reducing their activity in the
human counterpart may be beneficial.
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Systemic lupus erythematosus (SLE) appears to be a consequence of
immune dysfunction mediated by errors in self-recognition that cause
autoimmunity. A component of the environmental origin of SLE was
suggested by data showing that the earliest autoantibody recognition
structure in the anti-Sm response was very similar to and cross-reacted
with Epstein–Barr virus nuclear antigen-1 (EBNA-1). Subsequently, an
Arthritis Research & Therapy    Vol 5 Suppl 3 Abstracts of the 3rd World Congress of the Global Arthritis Research NetworkS9
earliest epitope of the anti-Ro system has been identified and this
structure also imitates a structure of EBNA-1. The initial structures
bound by anti-Sm and anti-Ro generate SLE-like autoimmunity in
animals immunized with these peptides. In pediatric SLE, anti-EBNA-1
is more frequently present and its fine specificity is qualitatively more
diverse in SLE than in normals. Anti-EBNA-1 responses also precede
the onset of SLE. The well-known association of Epstein–Barr virus
infection with SLE may be present because of the particular
immunoregulatory details of the anti-EBNA-1 response in SLE patients.
The genetic origins of SLE are the other major component of SLE etiol-
ogy. At this time, to our knowledge, 11 genetic linkages have been
both established and independently confirmed. For three of these link-
ages, an associated candidate gene is known. They are located in the
human genome as follows: 1q23 (FcγRIIIA), 1q41, 2q34, 2q37
(PDCD-1), 4p16, 5p15, 6p21 (HLA-DR), 10q22, 11p13, 11q14, and
16q13. Genetic effects tend to concentrate in the major human racial
groups (e.g. 1q23, 2q34, 11p13, and 11q14 dominate in African-
Americans). Some clinical and laboratory features of SLE have power-
ful genetic influences and can be used to generate genetic
homogeneity (e.g. nephritis with 2q34 and 10q22, hemolytic anemia
with 11q14, and pedigrees multiplex for self-reported rheumatoid
arthritis with 5p15). The origins of SLE are obviously complicated and
involve multiple influences from the environment, the host immune
response, perhaps involving EBNA-1, and the genetic constitution of
the patient.
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Abnormalities in humoral immunity play a significant role in systemic
lupus, mandating further studies in B-cell autoimmunity in this entity.
Disease activity in systemic lupus erythematosus (SLE) is usually
assessed with complex disease activity scores composed of a variety of
different parameters. To determine whether SLE disease activity corre-
lated with abnormal B-lymphocyte activity, B-cell subsets were analyzed
and related to clinical measures. The distribution of B-cell subsets was
determined by fluorescence-activated cell sorting analysis and com-
pared with the autoantibody profile, with the disease activity measured
by the SLE disease activity index (SLEDAI) and the European Consen-
sus Lupus Activity Measurement (ECLAM), disease duration and
therapy. The number and frequency of CD27high plasma cells were sig-
nificantly correlated with the SLE disease activity indices (SLEDAI and
ECLAM) and the titer of anti-dsDNA autoantibodies. Circulating B-cell
subsets were not influenced by age or gender, but appeared to relate to
the duration of disease and the therapeutic regimen, with the numbers
and frequencies of CD27high plasma cells increasing and those of
CD27-naïve B cells decreasing over time. Patients were divided into
those with a SLEDAI score of 0–8 (low activity) and those with a
SLEDAI score >8 patients (high activity). High-activity patients were
found to have an increased frequency of CD19+ B cells as well as
CD27high plasma cells. Using a nonparametric data sieving algorithm,
these B-cell abnormalities exhibited predictive values for nonactive and
active disease of 78.0% and 78.9%, respectively. The predictive value
of the B-cell abnormalities was greater than that of the humoral/clinical
data pattern, including anti-DNA antibody levels, circulating immune
complexes, increased erythrocyte sedimentation rate, mucocutaneous
and acute renal involvement, which showed predictive values of 77.8%
and 70.0% for active and nonactive disease. Flow cytometric monitoring
of B-cell subsets in the peripheral blood provides new insights into the
abnormalities in B-cell function in SLE, and may also be a diagnostically
valuable option to follow disease activity in this autoimmune disease.
28
Antiphospholipid antibodies and thrombosis:
pathogenesis of antiphospholipid syndrome
T Koike
Department of Medicine II, Hokkaido University Graduate School of
Medicine, Sapporo, Japan
Arthritis Res Ther 2003, 5(Suppl 3):28 (DOI 10.1186/ar829)
Antiphospholipid antibodies are present in a wide range of infectious
and autoimmune diseases. Antiphospholipid antibodies, in particular
anticardiolipin antibodies (aCL), lupus anticoagulants and antipro-
thrombin antibodies, are of considerable clinical importance because of
the close association with predominant clinical features of venous and
arterial thrombosis and pregnancy morbidity. The term antiphospholipid
syndrome (APS) has been used to define this set of pathologic fea-
tures. Recognition of this syndrome is now better understood world-
wide as related clinical implications are now more well defined.
aCL found in APS patients are directed against phospholipid-binding
plasma or serum proteins, in particular, β2-glycoprotein I (β2-GPI). Such
aCL (anti-β2-GPI autoantibodies) recognized epitopes appearing on the
β2-GPI molecule when β2-GPI interacts with a lipid membrane composed
of negatively charged phospholipids or when β2-GPI is adsorbed on a
polyoxygenated polystyrene plate treated with γ-irradiation or electrons.
Anti-β2-GPI antibodies have been found to activate endothelial cells by
inducing a proinflammatory and procoagulant phenotype sustained by
the upregulation of adhesion molecule (E-selectin, intracellular adhesion
molecule-1 and vascular cell adhesion molecule-1) expression, synthesis
and secretion of cytokines, chemokines, endothelin-1 and tissue factor.
Anti-β2-GPI antibody binding has been shown to induce NF-κB transla-
tion, leading to proinflammatory cell phenotypes similar to that elicited by
interaction with lipopolysaccharide and proinflammatory cytokines (IL-1β,
tumor necrosis factor alpha). Very recently, it was reported that anti-β2-
GPI antibodies activate cells through the MyD88-dependent pathway,
therefore implicating members of the Toll-like receptors family.
In this lecture, we will discuss the relation between the anti-β2-GPI
antibodies, the Toll-like receptors/IL-1 receptor family on the cell
surface and the pathogenesis of APS.
29
A Phase I trial of B-cell depletion with anti-CD20
monoclonal antibody (rituximab) in the treatment
of systemic lupus erythematosus
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We have tested whether the removal of B cells could suppress the
manifestations of systemic lupus erythematosus (SLE). Rituximab is a
chimeric monoclonal antibody that targets the pan-B-cell marker CD20.
Administration of this biologic causes profound depletion of B cells
from the peripheral blood for periods of several months. Rituximab has
been shown to be efficacious against B-cell malignancies, particularly
non-Hodgkins B-cell lymphoma. To begin to determine whether B-cell
depletion with rituximab in SLE could be of benefit, we have initiated a
phase I safety trial in 12 patients. Patients with SLE with moderate
disease activity who had failed at least one cytotoxic drug were eligible
for treatment. Nine patients have been entered to date. The first two
patients received a low, subtherapeutic dose, but six of the next seven
patients received the full approved regimen of 375mg/m2 once a week
for four doses. The first two patients developed human antichimeric
antibodies, but the next five patients tested did not. The first patient
showed an unusual post-infusion reaction, including bradycardia. The
other patients tolerated their infusions well. The first five patients who
received the full regimen had >95% depletion of B cells from their
peripheral blood 4 weeks after the final dose of rituximab. All patients
had lower SLE disease activity index scores after treatment. Three
patients with rash and alopecia had improvement. Patient 3 was partic-
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ularly striking. She had had a recent history of serious renal, pulmonary
and infectious complications, treated with cyclophosphamide and high-
dose steroids. After rituximab, patient 3 showed the disappearance of
activated T cells from the peripheral blood. One year post rituximab
treatment she remains off steroids and cytotoxics, and clinically quies-
cent. The patient’s B cells have now returned, with lower levels of
CD27 and CD86 than before treatment, and her T cells are still largely
unactivated. These uncontrolled data suggest that rituximab is well tol-
erated in SLE and that it may have some therapeutic benefit. A con-
trolled trial with appropriate outcomes will be necessary to prove
whether this approach is indeed efficacious.
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Systemic lupus erythematosus (SLE) is a prototype of autoimmune dis-
eases characterized by B-cell hyper-reactivity and production of various
autoantibodies. It has recently been found that the recombination acti-
vating gene (RAG) is re-expressed in activated mature B cells, and
RAG-expressing B cells revise their surface immunoglobulin or die by
failure of productive secondary rearrangement, leading to elimination of
the autoreactive B cells. We have investigated the expression of RAG
proteins in mature B cells in patients with SLE. Although normal mature
B cells did not express RAG proteins spontaneously, activated B cells
expressed RAGs. In SLE, whole mature B cells spontaneously
expressed RAG proteins excessively. Because we had found that failure
of receptor editing of the Vk gene with autoreactive potential (A30-Vk2)
is associated with the development of anti-DNA antibody in SLE, we
next focused on anti-DNA autoantibody secreting B cells. We found that
anti-DNA autoantibody secreting B cells failed to re-express RAGs
spontaneously, even after activation with mitogen. Thus, anti-DNA
autoantibody secreting B cells did not revise their immunoglobulin gene
nor die via apoptosis, leading them to develop and persist with autoanti-
body secretion. These findings indicate the importance of appropriate
RAG re-expression for the elimination of autoreactive B cells even at the
mature stage, and the absence of such events in anti-DNA secreting
B cells may be important for autoantibody production in SLE.
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Chemokines in rheumatoid arthritis: novel,
potential therapeutic targets of the CCR2
chemokine receptor signaling pathway
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Several chemokine receptor antagonists are in phase I/II clinical trials.
Macrophages play a pivotal role in rheumatoid arthritis, and the mono-
cyte chemoattractant protein (MCP)-1/CCR2 axis determines the
macrophage recruitment into inflamed joints. We have recently discov-
ered molecules specifically associated with CCR2.
We incidentally discovered that an organic germanium, propagermanium
(3-oxygermylpropionic acid polymer), which has been used as a therapeu-
tic agent against chronic hepatitis associated with hepatitis B virus  in
Japan, very specifically inhibits CCR2-mediated monocyte chemotaxis.
The effect of propagermanium requires glycosylphosphatidylinositol (GPI)-
anchored proteins, as cleavage of GPI anchors by phosphatidylinositol-
phospholipase C eliminated the inhibitory activity of propagermanium. In
addition, anti-GPI-anchored protein CD55 antibody and anti-CD95 anti-
body selectively inhibited MCP-1-induced monocyte chemotaxis. Further-
more, GPI-anchored proteins were co-localized with CCR2 on monocytes
under fluorescence microscopy. Moreover, a synthetic peptide corre-
sponding to the N-terminal portion of CCR2 specifically blocked the
action of propagermanium, suggesting that propagermanium may bridge
GPI-anchored proteins and the N-terminal portion of CCR2, and may
interfere with the action of MCP-1 (collaboration with Ishiwata et al.,
Sanwa Kagaku, Mie, Japan). The biological meaning of the close associa-
tion of GPI-anchored proteins with CCR2 is unclear at present, but this
finding corresponds well with the notion that some of chemokine recep-
tors exist in the lipid raft of leukocyte cell membrane.
Critical roles of C-terminal portion of chemokine receptors in regulating
leukocyte chemotaxis have been suggested. To seek CCR2-interacting
proteins, we have adopted a yeast two-hybrid system and found a cyto-
plasmic protein, FROUNT, that specifically interacts with CCR2. Dis-
rupting the interaction through the expression of FROUNT antisense
mRNA or a truncated FROUNT mutant specifically abolished the
chemotactic response to MCP-1 in human monocytes. FROUNT seems
to be critically involved in receptosome formation based on confocal
microscopic analysis. Suppression of endogenous FROUNT in a murine
model of peritonitis markedly impaired CCR2-dependent recruitment of
macrophages into the peritoneal cavity. Those results implicate that
FROUNT regulates CCR2-mediated chemotactic signaling and the
FROUNT could be a novel therapeutic target for macrophage-mediated
chronic inflammatory diseases including rheumatoid arthritis.
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cytokines IL-1, tumor necrosis factor-α α and IL-17
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The list of cytokines that may contribute to joint destruction in rheuma-
toid arthritis is growing extensively. At the same time, inhibition of a
single cytokine such as tumor necrosis factor (TNF)-α or IL-1 was able
to control disease in a significant proportion of patients. Accordingly,
the mode of interactions between these cytokines has to be clarified in
order to understand how a single cytokine inhibition can still be effec-
tive. These interactions were studied with mesenchymal cells, which
are targets of cytokines (synoviocytes, osteoblasts, myoblasts), as well
as with the respective organ samples (synovium, bone, muscle) in order
to keep intact interactions as seen in vivo. Cells and explants were
exposed to cytokines used at low concentrations and high concentra-
tions in order to look at their effect alone and a possible additive or syn-
ergistic effect when combined. Their respective soluble receptors were
used as specific inhibitors alone and in combination.
Effects on AP-1, NF-κB and Egr-1 activation were explored by RT-PCR
and immunocytochemistry. IL-1 and TNF-α induced most of these tran-
scription factors while IL-17 had a weak effect on the different mes-
enchymal cells. More importantly, when these cytokines were used at
low concentrations with no effect alone, their combinations showed a
synergistic effect on transcription and nuclear translocation of AP-1
members, Egr-1 and NF-κB. Moreover, cytokine combinations allowed
an enhanced recruitment of factors not expressed by cytokines used
alone. Conversely, combination of specific inhibitors (p75 TNF and type
II IL-1 soluble receptors) was needed to completely abrogate NF-κB
nuclear translocation in myoblasts stimulated with both IL-1 and TNF-α.
Low concentrations of cytokines can have a significant biological effect
through their interactions mediated by synergistic mechanisms.
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Human adipose tissue is an important novel source
of IL-1Ra: a new connection between immuno-
inflammatory diseases and lipid metabolism
J Dayer1, C Meier2
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Arthritis Res Ther 2003, 5(Suppl 3):33 (DOI 10.1186/ar834)
The increased production of IL-1, tumor necrosis factor (TNF)-α and
IL-6 is implicated in the pathogenesis of various immuno-inflammatory
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diseases (i.e. rheumatoid arthritis), often accompanied by metabolic
and cardiovascular complications. Cachexia and obesity may accom-
pany these diseases, and IL-1, TNF-α, IL-6 are said to be increased in
white adipose tissue (WAT). Fewer studies devolve on counter-regula-
tory mechanisms by cytokine inhibitors. Sera of obese patients showed
a more than sevenfold increase in IL-1 receptor antagonist (IL-1Ra),
which matches levels present in inflammatory autoimmune diseases
and sepsis, and correlating with body mass index and insulin resis-
tance. Subcutaneous and visceral human WAT of obese patients con-
tained 0.4 and 0.7ng IL-1Ra/mg protein, respectively. Thus, in an
obese individual weighing 120kg with 50% body fat, the total WAT is
estimated to contain 0.6mg IL-1Ra protein (i.e. 200 times the amount
of IL-1Ra in total serum), thus representing one of the main sources of
IL-1Ra production. The increased IL-1Ra expression — not associated
with increased IL-1β — argues for an anti-inflammatory, compensating,
mechanism associated with obesity. Our experiments with human WAT
explants showed a strong stimulatory effect of phorbol myristate
acetate and, more importantly, of IFN-β (as much as fivefold to 10-fold).
Since the latter is considered a fibroblast-derived IFN, it is tempting to
speculate that stromal cells and adipocytes might be part of a
paracrine mechanism regulating IL-1Ra secretion. In fact, newly formed
adipose tissue is often found close to inflammatory lesions (i.e. synovial
tissue). The functional consequences of the increased production of IL-
1Ra by adipose tissue may represent an important counter-regulatory
mechanism to inflammation at the local level. Furthermore, IL-1RI and
IL-1RacP were also expressed in human WAT. Thus, substances that
increase the production ratio of IL-1Ra/IL-1β by adipose tissue might
serve as a novel target for therapeutic strategies in immune disease.
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IFN-β is emerging as a pivotal molecule involved in synovial inflamma-
tion and bone homeostasis. We conducted in vitro studies as well as
studies using the collagen-induced arthritis model to investigate the
effects of IFN-β.
DBA/1 male mice were immunized intradermally with bovine type II col-
lagen in complete Freund’s adjuvant. On the first clinical sign of
disease, mice were treated for 7 days by daily intraperitoneal injections
of recombinant mouse IFN-β or saline. Disease progression was moni-
tored by validated visual clinical scoring and by measurement of paw
swelling using calipers. Inflammation and joint destruction were
assessed histologically 8 days after the onset of arthritis on decalcified
wax-embedded paw sections and quantified. Safranin O staining was
performed to determine proteoglycan depletion. In addition, cytokine
profiles in the synovium were evaluated by immunohistochemistry.
Cytokine expression was also measured in supernatants of rheumatoid
arthritis (RA) and osteoarthritis fibroblast-like synoviocytes (FLS) in
culture after incubation with IFN-β. We incubated RA FLS, which were
transfected with a NF-κB/luciferase construct, with IFN-β and mea-
sured luciferase activity to determine the effects on NF-κB activity.
In two independent experiments with eight to 10 mice per treatment
group in each experiment, IFN-β at doses from 0.25µg/injection and
higher significantly reduced disease severity. Moreover, IFN-β-treated
animals had significantly less cartilage and bone destruction than
control animals, demonstrating a protective effect of the treatment.
There was a significant reduction in c-Fos expression and osteoclast
numbers. The proinflammatory cytokines tumor necrosis factor alpha
and IL-6 were significantly reduced, and IL-10 production was
increased after IFN-β treatment. In vitro studies revealed reduced NF-
κB activity and expression of proinflammatory cytokines in RA FLS after
IFN-α treatment.
Taken together, our data show that frequent exogenous administration
of IFN-β protein may reduce synovial inflammation and protects against
cartilage and bone destruction by inhibition of NF-κB activity,
immunomodulation, and impairment of osteoclastogenesis through inhi-
bition of c-Fos. Continuous IFN-β expression at the site of inflammation
may be required to reach these therapeutic effects in RA patients. The
exciting biological effects could translate into clinically meaningful
improvement if the cytokine is administered frequently, when pegylated
IFN-β is used, or when IFN-β gene therapy is used. Therefore, IFN-β
gene therapy studies are now underway.
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PPARγ γ ligands inhibit catabolic and inflammatory
responses in articular joint cells
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Overproduction of inflammatory and catabolic mediators in articular
joint tissues is a hallmark of many rheumatic diseases such as
osteoarthritis and rheumatoid arthritis. Peroxisome proliferator-activated
receptor gamma (PPARγ) is a ligand-activated transcription factor
belonging to the nuclear hormone receptor superfamily. In addition to
their roles in lipid and glucid metabolism, PPARγ ligands have also
been shown to modulate inflammatory responses in many cell types.
We examined the expression of PPARγ and the effect of its ligands on
inflammatory and catabolic responses in articular joint cells.
We showed that PPARγ is expressed and transcriptionally active in
human chondrocytes and synoviocytes. Pretreatment of human chon-
drocytes with PPARγ ligands (15d-PGJ2 and BRL 49653) inhibited IL-
1-induced nitric oxide and matrix metalloproteinase (MMP)-13
production. The induction of both inducible nitric oxide synthase and
MMP-13 mRNA was inhibited in the presence of 15d-PGJ2. The
inhibitory effect of PPARγ ligands was not restricted to IL-1, since
tumor necrosis factor alpha and IL-17-induced nitric oxide and MMP-
13 production were also inhibited by 15d-PGJ2. Similarly, pretreatment
of synoviocytes with PPARγ ligands inhibited IL-1-induced MMP-1 at
the protein and mRNA levels. The inhibitory effect of 15d-PGJ2
occurred at least in part through a PPARγ-dependent pathway, proba-
bly by interfering with the transcriptional activity of AP-1 and NF-κB.
We also examined the effect of 15d-PGJ2 on cyclooxygenase-2
expression and prostaglandin E2 production, which are key players in
the physiopathology of arthritis. We found that 15d-PGJ2 inhibits IL-1-
induced cyclooxygenase-2 expression and prostaglandin E2 production
in both cell types. Taken together, our data indicate that PPARγ activa-
tors may be useful in the development of new anti-arthritic agents.
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The effectiveness of nonsteroidal anti-inflammatory drugs and specific
cyclooxygenase (COX)-2 inhibitors for treatment of arthritis provides
clinical evidence that increased local prostaglandin (PG) production in
joint tissues contributes to symptoms of pain, swelling, and stiffness.
Despite improved gastrointestinal safety of specific COX-2 inhibitors,
unwanted effects associated with inhibition of COX-2 continue to
occur in patients treated with these agents. Since production of stable
PGs requires synthase enzymes that function downstream of COX,
there are other potential targets for therapeutic intervention in arthritis
patients.
PGE2 is the most abundant prostanoid in synovial fluid and tissues, and
its biosynthesis is catalyzed by the coordinate action of COX enzymes
and PGE synthases (PGES). There are constitutive forms (COX-1,
microsomal PGES-2 [mPGES-2] and cytosolic PGES) and inducible
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forms (COX-2 and mPGES-1) of both biosynthetic enzymes, all of
which are expressed in human fibroblast-like synoviocytes (FLS). For
this reason, FLS are ideal for the study of PGE2 biosynthetic pathways
in a clinically relevant cell.
Both COX-2 and mPGES-1 are increased by the proinflammatory
cytokines IL-1 and tumor necrosis factor. However, we have shown that
the time frame of their stimulated expression is distinctly different.
mPGES-1 mRNA expression lags COX-2 by 2 hours and is sustained
up to 48 hours, while mPGES-1 protein lags COX-2 by 4 hours and is
sustained to 72 hours. Upregulation of mPGES-1 protein is required
for high-level PGE2 production as measured by enzyme immunoassay
and HPLC, and PGE2 biosynthetic capacity remains robust at
48 hours. At the 48 hour time point, PGE2 production is blocked by the
selective COX-1 inhibitor, suggesting that mPGES-1 is capable of effi-
ciently generating PGE2 from COX-1-derived substrate.
In contrast to COX-2, IL-induced transcription of mPGES-1 is blocked
by the protein synthesis inhibitor cyclohexamide, suggesting a require-
ment for new protein synthesis. It was recently reported that the tran-
scription factor early growth response gene 1 (Egr-1) binds to the
murine mPGES-1 promoter and regulates transcription. Total and
nuclear Egr-1 expression is upregulated by IL-1 in FLS. This expression
is blocked by the inhibitors of MAPK, as is upregulation of mPGES-1.
Two tandem GC boxes are present in the mPGES-1 promoter region,
with the proximal GC box overlapping a potential Egr-1 binding site.
Under basal conditions, at least three complexes (CI, CII and CIII) bind
to this region of the mPGES-1 promoter (–125 to –98) by elec-
trophoretic mobility shift assay. We identified the induced CII complex
as Egr-1 by supershift assay. Egr-1 binds to the proximal GC box as
determined by competition assays using mutated oligonucleotides. CI
and CIII contain Sp3 by supershift assay. It is not yet clear that Sp3 is
displaced by Egr-1. We confirmed the functional significance of Egr-1
binding for induced endogenous mPGES-1 expression using plasmids
containing wild-type and mutant Egr-1.
In summary, mPGES-1 is a cytokine-inducible enzyme required for pro-
duction of PGE2 in FLS. mPGES-1 deficiency in null mice completely
blocks PGE2 production and susceptibility to collagen-induced arthri-
tis. mPGES-1 represents a novel therapeutic target for treatment of the
inflammation associated with arthritis.
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Objectives IL-21R is a class I cytokine receptor associated with the
common γ-chain. In mice, IL-21R was detected in fibrotic lungs but not
in healthy lungs, suggesting a possible role for IL-21R in fibrotic disor-
ders.
Methods Skin biopsies were obtained from 12 patients with sys-
temic sclerosis (SSc) and 11 healthy controls. Total RNA was iso-
lated from these tissues, reverse transcribed, and IL-21/IL-21R
mRNA was quantified using real-time PCR. The expression patterns
of IL-21/IL-21R were analyzed by in situ hybridization. Stimulation
experiments were performed with cultured dermal fibroblasts from
SSc patients and healthy controls as well as keratinocytes using IL-
1β, platelet derived growth factor-BB (PDGF-BB), monocyte
chemoattractant protein-1 (MCP-1), transforming growth factor
(TGF)-β and IL-21. Human skin biopsies from SSc patients were
transplanted onto SCID mice. After 60 days, the expression of IL-21R
was determined by in situ hybridization. Cultured keratinocytes were
stimulated with IL-21 and assessed for differential expression com-
pared with nonstimulated controls using a human Atlas cDNA expres-
sion array (Clontech, Palo Alto, CA, USA).
Results IL-21R was detected in all biopsies from SSc patients and
controls with a 4.7-fold increase in SSc samples (threshold cycle: SSc
patients, 17.9±1.1; healthy, 20.1±1.4). In situ hybridization showed
an upregulation of IL-21R in the epidermis of SSc patients, whereas no
signal was detected in healthy skin specimens. These results were con-
firmed  in vitro, in that cultured keratinocytes expressed significant
levels of IL-21R, whereas no signal was found in fibroblasts. Interest-
ingly, mRNA for IL-21, the proposed ligand for IL-21R, was not
detected by real-time PCR and in situ hybridization. Various concentra-
tions of IL-1β, PDGF-BB, MCP-1, TGF-β and IL-21 did not stimulate
the expression of IL-21R in cultured keratinocytes and dermal fibrob-
lasts. In the SCID mouse transplantation model, the overexpression of
IL-21R in SSc keratinocytes remained unchanged as long as 60 days
after transplantation, whereas no signals for IL-21R were detected in
fibroblasts. Differentially expressed genes confirmed by SYBR Green
real-time PCR after stimulation with IL-21 included vascular endothelial
growth factor, vascular endothelial growth factor-C and integrin a6.
Conclusion This is the first human disease-related report regarding IL-
21R in vivo. These results indicate that, in addition to fibroblasts and
endothelial cells, the expression pattern of keratinocytes is altered in
patients with SSc. Interestingly, the expression of IL-21R appears to be
independent of inflammatory cytokines in vitro and independent of both
humoral and cellular factors circulating in SSc patients, because the
expression of IL-21R mRNA in human epidermal keratinocytes did not
change after implantation onto SCID mice.
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Recent attention has been focused on selective cyclooxygenase
(COX)-2 inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) that
inhibit COX-2 without inhibition of COX-1, resulting in fewer inci-
dences of adverse reactions. Various clinical studies have confirmed
that the efficacy of selective COX-2 inhibitors for the patients with
rheumatoid arthritis (RA) is similar to that of conventional NSAIDs;
however, they cause fewer severe gastrointestinal complications.
Recently, we found that some conventional NSAIDs such as
indometacin and diclofenac induced apoptosis in association with acti-
vation of peroxisome proliferator-activated receptor gamma (PPARγ) in
rheumatoid synovial fibroblasts (RSF). We also found that celecoxib, a
selective COX-2 inhibitor, specifically induced apoptosis and inhibited
proliferation of RSF in COX-2-independent and PPARγ-independent
manners. Other selective COX-2 inhibitors such as etodolac, meloxi-
cam, nimesulide, NS-398, and rofecoxib, even in very high concentra-
tions, did not induce apoptosis in RSF at all. These results suggested
that some NSAIDs including a selective COX-2 inhibitor might be used
as disease-modifying antirheumatic drugs if they could be delivered
with good efficiency to the affected synovia of patients with RA. It is
well known that administration of celecoxib decreases the number of
colon polyps in patients with familiar adenomatous polyposis. The pro-
apoptotic effect of celecoxib was also observed in several kinds of cell
lines derived from colon cancer and ovarian cancer, suggesting a
common mechanism of action of celecoxib-induced apotosis among
RSF and cancer cell lines. Inactivation of Akt might explain the pro-
apoptotic effect of celecoxib on at least colon cancer cell lines.
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The innate immune system provides essential host defense against a
wide variety of microbial pathogens. In addition, the innate immune
system is responsible for the recognition of necrotic and apoptotic
cells and self-antigens that are released from the large number of cells
that undergo apoptosis for the maintenance of physiologic homeosta-
sis. The complement system is essential to initiate and drive the
acquired immune response.
Until recently, two pathways for complement activation were recog-
nized, namely the classical pathway and the alternative pathway.
Recent studies from a large number of laboratories indicate the exis-
tence of a third pathway of complement activation, namely the lectin
pathway. This third pathway is initiated by the interaction of, for
example, mannan binding lectin and a number of other pattern recogni-
tion molecules called ficolins, with carbohydrate domains on a wide
variety of pathogens such as bacteria and viruses.
Studies in complement-deficient individuals have indicated a strong
association between complement deficiencies and infections or with
immune complex disease and autoimmunity. Deficiencies in the lectin
pathway are associated with serious bacterial infections in immunocom-
promised individuals, while deficiencies in the early classical pathway
components are associated with immune complex disease and autoim-
munity. Especially, deficiencies in C1q, the recognition unit of the classi-
cal pathway, are associated strongly with systemic lupus erythematosus.
Studies in C1q knockout mice also implicate C1q with autoimmunity.
Various studies indicate that C1q, but also a number of other molecules
of innate immunity, such as C-reactive protein, serum amyloid P-compo-
nent, pentraxin-3, and possibly mannan binding lectin and ficolins, all in
concert, may be involved in the recognition and clearance of harmfull
potentially pathogenic apoptotic and necrotic cells. It is thought that the
deficient removal or the mode of presentation of self-antigens may
determine whether autoimmune responses take place or whether toler-
ance is induced. In this scenario, it is suggested that the method of
engagement and subsequent signal induction may ultimately determine
the final outcome of the ensuring immune response.
Acknowledgement These studies were supported in part by the Euro-
pean Union, grant number QLG1-CT-2001-01039.
40
Activation of synovial fibroblasts via Toll-like
receptor signaling
D Kyburz1, M Pierer1, J Rethage1, R Seibl1, RE Gay1, DA Carson2,
S Gay1
1Center of Experimental Rheumatology, Department of Rheumatology,
University Hospital, Zurich, Switzerland 2Department of Medicine,
UCSD, La Jolla, California, USA
Arthritis Res Ther 2003, 5(Suppl 3):40 (DOI 10.1186/ar841)
Toll-like receptors (TLRs) are pattern recognition receptors of the
innate immune system. TLR activation has a profound influence on the
subsequent adaptive immune responses by influencing T-cell differenti-
ation towards a Th1 phenotype. Whether TLR signaling is involved in
autoimmune phenomena is not known. The presence of TLR ligands in
the joints of patients with rheumatoid arthritis and the fact that direct
injection of bacterial peptidoglycan, a TLR2 agonist, and bacterial
DNA, a TLR9 agonist, results in a transient arthritis in mice suggests
that TLR signaling is of importance in the development of arthritis. Fur-
thermore, recent evidence indicates that stimulation of TLR9 on B lym-
phocytes by immune complexes containing chromatin drives
production of autoantibodies. We have detected TLR2 expression on
synovial fibroblasts of patients with rheumatoid arthritis by immunohis-
tochemistry. Cultured human synovial fibroblasts expressed functional
TLR2 in vitro. Stimulation of synovial fibroblasts with the TLR2 ligand
peptidoglycan induced a significant upregulation of the expression of
matrix metalloproteinases and the cytokine IL-6. Furthermore,
chemokine secretion by rheumatoid arthritis synovial fibroblasts was
significantly increased. These results argue that the local presence of
bacterial products may induce a local inflammatory response by signal-
ing via TLR2. Blockade of TLR signaling pathways may therefore repre-
sent a promising new therapeutic option for rheumatoid arthritis.
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Background T-cell IL-17 is a proinflammatory cytokine present in the
synovium of rheumatoid arthritis patients. Through the binding of IL-17
to its receptor (IL-17R) and the subsequent activation of a signaling
pathway through TRAF-6 and NF-κB, IL-17 can induce other cytokines
such as IL-1 and tumor necrosis factor (TNF). IL-17 can have both addi-
tive and synergistic effects on cytokine induction and tissue destruction
with these cytokines, but may have direct pathological effects as well.
Purpose In the present study, we examined the relative dependency of
TNF in the IL-17-induced joint inflammation and cartilage damage
under naive and various arthritis conditions in vivo, including Toll-like
receptor-2 (TLR-2)-dependent inflammation.
Methods An adenoviral vector expressing murine IL-17 was used to
intra-articularly overexpress IL-17 in the knee joints of control mice or
mice deficient for IL-1 or TNF. Experiments were performed under naive
conditions and during TLR-2-dependent streptococcal cell wall-
induced arthritis (SCW) and passive immune complex-mediated arthri-
tis (ICA) with lysozyme as an antigen.
Results IL-17 overexpression in the knee joint of naive mice resulted in
joint inflammation and cartilage proteoglycan depletion, which gradually
increased over time. No effects were noted with the same dose of control
vector. IL-17 strongly upregulated IL-1 mRNA and protein levels in the
synovium compared with the control group. However, no difference in IL-
17-induced joint pathology was noted in IL-1-deficient mice (P=0.39).
Interestingly, when TNF-deficient mice were used, the IL-17-induced joint
inflammation and cartilage damage were almost completely absent
(P<0.005). This indicates that, under naive conditions in vivo, the IL-17-
induced joint inflammation and cartilage destruction are mediated by syn-
ergism with TNF and not with IL-1. Similar experiments were performed
under SCW and ICA conditions. SCW arthritis runs through TLR-2,
since arthritis was highly reduced in TLR-2-deficient mice, but not in TLR-
4–/– mice. In addition, SCW arthritis is fully suppressed in mice deficient
in the crucial Toll-like receptor signaling molecule Myd88. Overexpres-
sion of the T-cell cytokine IL-17 in the macrophage-mediated SCW
model resulted in an elevation of joint inflammation and cartilage proteo-
glycan depletion compared with the control vector group (P<0.005).
Furthermore, IL-17 turned this acute model into a more chronic one.
Remarkably, IL-17-enhanced SCW arthritis was not reduced in TNF–/–
mice, identifying circumvention of TNF dependency in the presence of
TLR-2 activation. Intriguingly, IL-17-induced enhancement of FcγR-medi-
ated ICA still remained TNF dependent, since joint swelling was signifi-
cantly reduced in TNF-deficient mice.
Conclusions These data show TNF dependency of IL-17-induced joint
pathology under naïve conditions and during ICA. However, this is lost
during SCW arthritis. TLR-2 shares the same signaling pathway
through TRAF-6 and NF-κB as the IL-17R. It suggests that TNF depen-
dency can be bypassed by IL-17 in combination with TLR-2 triggers.
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rheumatoid arthritis: CD64 and IL-15
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At present, blockade of cytokines represents one approach to treat
rheumatoid arthritis (RA). Anti-tumor necrosis factor (TNF)-α therapy
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results in impressive protection against joint inflammation and joint
damage in RA patients, although a significant number of patients do
not respond. We evaluated blockade of targets more upstream in the
inflammation cascade, of activated macrophages and of IL-15.
Inflammatory macrophages exhibit enhanced expression of FcγRI
(CD64), the high-affinity receptor for IgG. We observed the pres-
ence of CD64 on activated macrophages in RA patients, and their in
vitro elimination using a CD64-targed immunotoxin. In addition, we
demonstrated  in vivo elimination of CD64-expressing activated
macrophages, resulting in significant inhibition of disease activity in
an adjuvant arthritis model, in newly generated human CD64 trans-
genic rats. IL-15 triggers inflammatory cell recruitment, angiogenesis
and production of other inflammatory cytokines, including IFN-γ,
TNF-α and IL-17, which are all upregulated in inflammation. We gen-
erated monoclonal antibodies using human immunoglobulin-trans-
genic mice. One of the IL-15-specific antibodies, HuMax IL-15, did
not compete with IL-15 for binding to its receptor, but potently inter-
fered with the assembly of the IL-15 receptor α,β,γ complex. This
antibody blocked IL-15-induced T-cell proliferation, and monocyte
TNF-α release in vitro. HuMax IL-15 effectively inhibited inflamma-
tion in SCID-RA models and is currently clinically evaluated in
human RA.
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The activation of synovial fibroblasts (SF) is a hallmark of rheumatoid
arthritis, and the resistance of rheumatoid arthritis (RA)-SF against
Fas-induced cell death is one of their characteristic features.
However, the mechanisms that are responsible for the low susceptibil-
ity of RA-SF to programmed cell death and, specifically, the pathways
that link altered apoptosis to their aggressive behavior are only incom-
pletely understood. In our present studies, we have compared the sus-
ceptibility of synovial fibroblasts from RA and osteoarthritis (OA)
patients to Fas-induced apoptosis, and have studied mechanisms that
contribute to both the invasiveness of RA-SF and their resistance
against apoptosis.
As determined by different techniques (measurement of cytoplasmatic
mononucleosomes and oligonucleosomes, FACS analysis), RA-SF
were significantly less susceptible to Fas-induced cell death than OA-
SF despite their abundant expression of Fas. Stimulation of RA-SF with
tumor necrosis factor alpha (TNF-α) did not induce apoptosis, but in a
dose-dependent manner reduced Fas-mediated cell death. This was
accompanied by the activation of NF-κB and the upregulation of
disease-relevant matrix metalloproteinases. Of interest, adenoviral gene
transfer of TIMP-3 reduced the invasiveness of RA-SF in the SCID-
mouse in vivo model of RA, and completely reversed the apoptosis-
inhibiting effect of TNF-α, in part by reducing the activation of NF-κB.
The effects of TNF-α on apoptosis were similar in OA-SF. However,
RA-SF differed from OA-SF by their elevated expression of the small
ubiquitin-like modifier sentrin-1/SUMO-1. Retroviral gene transfer of
antisense and expression constructs of sentrin-1/SUMO-1 confirmed
its involvement in the altered susceptibility of RA-SF to apoptosis.
Analysis of the subcellular localization of sentrin-1/SUMO-1 and gene
transfer of SUMO-1-specific proteases revealed that modifications of
transcriptionally active nuclear proteins by sentrin-1/SUMO-1 con-
tribute to the regulation of apoptosis and the production of matrix-
degrading enzymes.
Collectively, our data suggest that in RA-SF there is a close functional
association between pathways that confer the resistance against apop-
tosis and that mediate the progressive destruction of cartilage. Both
cytokine-dependent and cytokine-independent mechanisms contribute
to these processes. While TNF-α-mediated prevention of cell death is
not specific for RA and is seen in a variety of fibroblast-like cells, activa-
tion of signaling pathways involving sentrin-1/SUMO-1 appears to be a
characteristic feature of RA-SF.
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It is increasingly clear that patients suffering from systemic lupus ery-
thematosus and rheumatoid arthritis are at significantly greater risk of
developing atherosclerotic cardiovascular disease than otherwise unaf-
fected individuals. Recent studies in our laboratory demonstrate that
immunologic reactants such as immune complexes that have fixed C1q
and IFN-γ diminish the capacity of macrophages to appropriately
metabolize and transport lipoproteins. The effect of these agents on
macrophage function suggests a role for these reactants in the prema-
ture development of atherosclerotic cardiovascular disease in
rheumatic diseases. It was recently observed that methotrexate, unlike
any other disease-modifying antirheumatic drugs studied, diminished the
risk for development of atherosclerotic cardiovascular disease.
Although the explanation for this phenomenon may be that methotrex-
ate is simply a more effective anti-inflammatory agent, recent work in
our laboratory suggests an alternative explanation. We have demon-
strated that many, if not most, of the anti-inflammatory effects of
methotrexate are due its capacity to increase release of adenosine,
which interacts with its receptors on the cell surface to modulate
inflammation. Adenosine, acting at its receptors on the surface of
macrophages, increases the expression of enzymes involved in metab-
olizing cholesterol and of transporters involved in export of cholesterol
from the vessel wall to the liver for elimination. The adenosine receptor-
mediated effect on expression of these molecules is associated with
diminished foam cell formation in an in vitro assay. These results
suggest an explanation for the effect of methotrexate therapy on the
development of atherosclerotic cardiovascular disease and, more
importantly, indicates a novel target for the development of new anti-
atherosclerotic agents.
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Rheumatoid arthritis (RA) is a representative autoimmune disease char-
acterized by lymphocyte accumulation and synovial proliferation, which
are induced by inflammatory cytokines and adhesion molecules.
Although periarticular as well as systemic osteoporosis and subse-
quent joint destruction are major complications of RA, the precise
mechanisms remain unclear. Osteoblasts not only play a central role in
bone formation by synthesizing bone matrix proteins, but they regulate
osteoclast maturation by cognate interaction, resulting in bone resorp-
tion. RANKL expressed on osteoblasts provides essential signals to
osteoclast progenitors for their maturation. We have proposed that the
LFA-1/ICAM-1-mediated adhesive pathway of osteoblasts is required
for juxtacrine stimulation of osteoclast maturation by membrane-bound
RANKL on osteoblasts. Moreover, proinflammatory cytokines such as
IL-1 produced abundantly in rheumatoid synovium induce both RANKL
and ICAM-1 on osteoblasts, leading to an efficient juxtacrine stimula-
tion for the osteoclastogenesis. However, ICAM-1-positive osteoblasts,
induced by IL-1, arrest at the G0/G1 phase of the cell cycle, which is
involved by upregulation of p21 and reduced activities of cdk6. IL-1-
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induced ICAM-1-positive osteoblasts can bias bone turnover to bone
resorption, committing their growth arrest, in the context of the balance
between survival and apoptosis of the cells. Such a regulation of the
cell cycle is regulated by H-Ras, a small G-protein. H-Ras signals fol-
lowed by Raf-1/MAPK induce cell-cycle arrest of osteoblasts via Fas
upregulation and bcl-2 downregulation, whereas H-Ras followed by
PI3K induces their proliferation. Taken together, during bone remodel-
ling processes, proinflammatory cytokines cause an imbalance in bone
metabolism by favouring bone resorption via the expression of RANKL
and ICAM-1, as well as apoptosis of osteoblasts, which are differen-
tially regulated by intracellular signals via H-Ras. Such osteoclast matu-
ration mediated by the adhesion with osteoblasts is coordinated with
immune signaling, and thereby is relevant to pathological events such
as secondary osteoporosis observed in RA.
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Objective To study the effect of oral treatment with PD200347, a
gabapentinoid (GBP), on osteoarthritis (OA) progression and OA medi-
ators, matrix metalloproteases (MMPs) and the inducible form of nitric
oxide synthase (iNOS) expression in a dog experimental model of OA.
Methods OA was surgically induced in dogs by sectioning the anterior
cruciate ligament. OA dogs were divided into three groups after
surgery: group 1, placebo-treated (OA); group 2, oral treatment with
15mg/kg/day GBP; and group 3, oral treatment with 90mg/kg/day
GBP. Dogs were killed 8 weeks after surgery. The severity of lesions
was scored macroscopically and histologically. Cartilage specimens
from femoral condyles and tibial plateaus were processed for RNA
extraction and quantitative RT-PCR or immunohistochemistry. Specific
probes and specific antibodies were used to study IL-1β, iNOS, MMP-
1, MMP-3 and MMP-13 mRNA and protein levels, respectively.
Results GBP treatment at both dosages tested (15 or 90mg/kg/day)
dose-dependently reduced the development of cartilage lesions. Quan-
titative RT-PCR and immunohistochemical analysis showed that GBP
treatment also significantly reduced key OA mediator (IL-1β, iNOS,
MMP-1, MMP-3 and MMP-13) gene expression and synthesis.
Conclusion This study demonstrated for the first time the effectiveness
of a GBP on the reduction of the development of structural changes in
the dog OA model. The effect of GBP is mediated through the inhibi-
tion, at the transcriptional level, of major mediators of pathophysiologi-
cal pathways.
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In cartilage, collagen type II is of particular importance as its breakdown
results in the irreversible loss of structural integrity of the tissue. Within
the protease, the collagenases have a major involvement in this colla-
gen network degradation. Evidence demonstrates that collagenase-3 is
the major enzyme accounting for collagen degradation in osteoarthritic
(OA) cartilage.
Collagenase-3 has a greater effect (five to 10 times) on type II collagen
than collagenase-1, and, in OA, is localized predominantly in the lower
intermediate and deep layers of the cartilage, where type II collagen
fibers are of the largest size and chondrocytes possess the most effi-
cient capacity to reconstitute the extracellular matrix. Collagenase is
upregulated in OA cartilage and is suggested to be implicated in carti-
lage remodeling in pathological conditions. Various factors induce its
transcription, including proinflammatory cytokines and growth factors
such as IL-1β, IL-17, tumor necrosis factor alpha, transforming growth
factor beta and hepatocyte growth factor. Interestingly, we recently
reported that transforming growth factor beta, but not IL-1β, treatment
of normal cartilage mimicked the in situ collagenase-3 distribution in
OA cartilage.
The proximal promoter sequence contains a TATA box, as well as AP-
1, Ets/PEA-3, and OSE-2 binding sites. The AP-1 site is essential for
both basal and proinflammatory cytokine inducible transcription, and
the PEA-3 site exerts a cooperative effect. We also demonstrated that
some AP-1 proteins play a different role in terms of collagenase-3 pro-
duction according to the stimulator. Indeed, IL-17-induced collage-
nase-3 resulted in FosB activation, whereas IL-1β stimulated c-Fos,
which may explain the different capacities of these cytokines in produc-
ing this enzyme. Our data also suggest that JunB protein plays a rate-
limiting step in cytokine-induced collagenase-3 production in OA
chondrocytes. Moreover, we recently identified a novel protein-binding
site on the collagenase-3 promoter that appears to be directly impli-
cated in the repression of its basal transcription. This site was desig-
nated AGRE for AG-rich element. This site was not found in other
human metalloprotease genes or in the mouse collagenase.
Contrary to the other human collagenase genes that are transcribed
into one mature mRNA, human cells expressed collagenase-3 tran-
scripts of 3.0, 2.5 and 2.2/2.0kb as demonstrated by northern blot.
We recently identified five different collagenase-3 RNA species in
humans; each could be translated in a cellular environment, indicating
that they could be synthesized in response to specific cellular events.
For two of the RNA species, the enzyme synthesized would differ from
the original collagenase-3 and will have potentially different
function/activity. Moreover, one of the transcripts appears to be an
alternative transcription start site. Start sites are known to regulate
gene expression by affecting the level of transcription initiation, the
translation efficiency of the mRNA produced, and the generation of
protein isoforms differing at their amino termini, or may respond differ-
ently to the cellular environment.
At present, a therapeutic intervention based on the inhibition of metallo-
proteases is under intensive investigation, and collagenase-3 appears
to be an attractive target for the development of disease-modifying OA
drugs. However, the human collagenase-3 is subjected to different
levels of regulation and constitutes a more complex system than origi-
nally thought. It would be interesting to verify whether compounds that
block only one pathway, such as the synthesis/activity of the original
collagenase-3, are sufficient to block all the effects of this enzyme, or
whether all the enzyme transcripts should rather be targeted in order to
achieve maximum therapeutic efficacy.
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Degradation of articular cartilage seriously impairs the function of joints
and it is a hallmark of various types of arthritides. The primary cause of
this process is due to elevated proteolytic enzyme activities that
degrade aggrecan proteoglycan and type II collagen fibrils, major com-
ponents of the extracellular matrix in cartilage. While the network of col-
lagen fibrils is degraded primarily by collagenases and possibly by
other matrix metalloproteinases (MMPs), such as MMP-2 and MMP-14,
aggrecan is degraded by MMPs and the more recently discovered
‘aggrecanases’ that belong to the ADAMTS (a disintegrin and metallo-
proteinase with thrombospondin motifs) family.
To investigate the relative contribution of MMPs and ADAMTSs in carti-
lage aggrecan degradation during the progression of joint destruction,
we have used the pig articular cartilage explants treated with IL-1 as an
in vitro cartilage degradation model and have tested the ability of tissue
inhibitors of metalloproteinases (TIMPs), TIMP-1, TIMP-2 and TIMP-3,
to block the release of aggrecan. MMPs are inhibited by all three
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TIMPs, but aggrecanases (ADAMTS-1, ADAMTS-4 and ADAMTS-5)
are inhibited only by TIMP-3.
Treatment of pig articular cartilage in culture with IL-1 for 3 days
resulted in approximately 70% of aggrecan degradation, and the frag-
ments were released into the medium. The degradation of aggrecan
was completely inhibited by the addition of recombinant N-terminal
inhibitory domain of TIMP-3 (N-TIMP-3) at the concentration of 0.1mM,
but not by TIMP-1 or TIMP-2. This indicates that aggrecan degradation
in this model is due to aggrecanases, but not due to MMPs. TIMP-3 is
known to cause apoptosis of several cell types. N-TIMP-3 caused
apoptosis of pig chondrocytes only at concentrations above 0.75µM.
Our mutagenesis studies of N-TIMP-3 also revealed that N-TIMP-3
contains the metalloproteinase reactive site common among TIMPs
and the unique sites that interact with aggrecanases, suggesting that it
may be possible to design TIMP variants that selectively inhibit aggre-
canases.
Our studies suggest that TIMP-3 and the related molecules may be
potential therapeutics to prevent articular cartilage from degradation
during the progression of osteoarthritis and rheumatoid arthritis.
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Fos proteins such as Fos, FosB, Fra-1 and Fra-2 are key regulators of
bone development. Transgenic mice expressing Fos develop
osteoblastic bone tumors, whereas mice lacking Fos (Fos–/–) are
osteopetrotic and lack bone-resorbing osteoclasts [1]. The Fos-related
protein Fra-1, itself a Fos target gene, is essential for mouse develop-
ment, whereas transgenic mice overexpressing Fra-1 develop an
osteoblastic bone disease, osteosclerosis [2]. Interestingly, gene
replacement of Fos by Fra-1 showed functional equivalence of these
two proteins [3]. To better understand how Fos and Fra-1 control
osteoblast and osteoclast differentiation, we generated conditional
alleles of Fos and Fra-1. The embryonic lethality of the Fra-1 knockout
mice was rescued with a conditional allele of Fra-1 using MORE-cre
mice. The mutant mice are viable but are osteopenic. Interestingly, con-
ditional deletion of JunB with the same MORE-cre line also rescued the
lethality, and the mutant mice developed severe osteoporosis. Finally,
inactivation of Fra-2 gives rise to pups that also exhibit severe osteo-
porosis and die at birth, probably due to heart failure. The signal trans-
duction pathways operating in osteoclastogenesis have been
extensively studied and the events downstream of RANKL signalling
are well described [1]. Positive and negative regulatory loops are in
place, which involve the activation NF-κB and JNK, eventually leading
to the expression of Fos, an essential gene for osteoclast differentiation
[1]. Micro-array analysis revealed that the expression of NFATc1 is
abolished in Fos–/– precursors [4]. However, introduction of an acti-
vated form of NFATc into Fos–/– precursor cells rescued the bone
resorptive function and restored transcription of osteoclast marker
genes. Recent experiments addressing the molecular events during
osteoclast formation will be discussed.
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Rheumatoid arthritis (RA) is associated with focal and systemic bone
loss involving RANKL, which is secreted by both osteoblasts and acti-
vated lymphocytes, whereas osteoprotegerin (OPG) inhibits bone
resorption in osteoclast precursors. RANKL expression is increased by
inflammatory cytokines. The aim of our studies is to evaluate the respec-
tive effect of OPG, on one hand, and either IL-4 or antibody, on the other,
on inflammation and on bone tumor necrosis factor alpha (TNF-α) remod-
elling. Indeed, we hypothesised that inhibiting inflammation could be suf-
ficient to inhibit bone loss. Moreover, we tested whether the combination
of OPG with either IL-4 or TNF-α antibody had an additive effect on bone
loss. IL-4 and TNF-α antibodies were tested in two independent experi-
ments. We used a model of collagen-induced arthritis (CIA) in DBA/1
mice by immunisation (bovine type II collagen). Bone mineral density
(BMD) was measured at the total body (Piximus Lunar) at baseline before
immunization and at sacrifice, allowing one to measure the bone gain
(∆BMD). Deoxypyridinolin changes (∆D-Pyr) were measured in urine. His-
tomorphometric parameters were measured at the femur metaphysis.
OPG had no effect on clinical arthritis score in any experiment. By con-
trast, OPG was able to increase the ∆BMD and to decrease the ∆D-Pyr
and trabecular spacing evaluated by histomorphometry. By contrast, both
IL-4 and TNF-α antibody decreased the arthritis score but did not induce
a change in ∆BMD and decrease in bone resorption evaluated by ∆D-Pyr
and trabecular spacing. There was no additive effect of OPG and TNF-α
antibody on any parameter related to bone, whereas we observed a sig-
nificant additive effect of IL-4 and OPG on the inhibition of bone resorp-
tion and the increase in ∆BMD.
In conclusion, these data show that, in this model of inflammatory arthri-
tis, systemic bone loss is prevented only by treatment directly decreas-
ing osteoclast differentiation. Furthermore, treatment with one
anti-inflammatory cytokine, IL-4, but not with TNF-α antibody had an
additive bone-sparing effect with OPG.
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Introduction IL-6 regulates several functions, including immunological
reactions in host defense or inflammation. Accumulating evidence sug-
gests that IL-6 is implicated in rheumatoid arthritis and in osteoarthritis.
IL-6 may contribute to the destructive changes of cartilage accompany-
ing joint diseases, but its mechanism of action on the cartilage and the
pathways whereby it controls their gene expression are unknown.
However, until recently, the IL-6 signaling pathway for these cells has
not been identified nor has the functional significance of their effects
on the major extracellular matrix components been investigated.
Objectives The aim of this study was to analyze the signaling pathways
of IL-6/sIL-6R in articular chondrocytes, and their involvement in the
control of matrix gene expression.
Methods Bovine articular chondrocytes were treated by IL-6
(100–500ng/ml) with or without IL-6sR (200–500ng/ml) for increasing
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periods. Western blotting and gel retardation assays were performed
with or without mitogen-activated protein kinase inhibitor (PD 98059)
and STAT inhibitor (parthenolide). Collagen type II and aggrecan core
and link protein mRNA levels were determined by northern blots.
Results In the absence of sIL-6R, IL-6 (500ng/ml) had a slight effect
on JAK-1 and JAK-2 phosphorylation. Addition of sIL-6R at 500ng/ml
dramatically increased these effects, with a peak at 15 min. STAT1 and
STAT3 were also found to be phosphorylated and translocated to the
nucleus. Increased binding of protein factors to specific STAT respon-
sive elements was observed. ERK1 and ERK2 were activated by IL-
6/sIL-6R treatment, with a maximum at 30 min. Exposure of cells to
IL-6/sIL-6R induced an inhibition of collagen type II, aggrecan core and
link protein expression. This downregulation was abolished in the pres-
ence of STAT inhibitor but not in the presence of mitogen-activated
protein kinase inhibitor, indicating that the STAT signaling pathway is
implicated in the control of these two cartilage-specific matrix genes.
Conclusions To exert a significant effect on chondrocytes, IL-6
requires the presence of its soluble receptor. The cytokine plays a role
in the cartilage breakdown through a STAT-induced inhibition of colla-
gen type II, aggrecan core and link protein expression.
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IL-1b is one of the main cytokines leading to the degradation of articu-
lar cartilage. One mechanism through which this cytokine exerts its
effects is by articular chondrocytes being induced to produce nitrite
oxide (NO). These findings are supported by clinical studies revealing a
significant increase of NO production in the synovial fluid of patients
with rheumatoid arthritis and osteoarthritis. Modulating IL-1b-induced
NO in articular chondrocytes appears to be an interesting challenge for
reducing or inhibiting the cartilage destruction.
Heme oxygenase-1 (HO-1) is an inducible enzyme catalyzing the
degradation of heme. The beneficial effects of HO-1 have been
described for several diseases. This enzyme confers protection mainly
through its antioxidant and anti-inflammatory functions.
The objectives of this work were to investigate the expression and
activity of HO-1 in IL-1b-treated articular chondrocytes, and the corre-
sponding molecular mechanism.
We used high-density primary cultures of rabbit articular chondrocytes.
HO-1 expression was evaluated by Western blotting. HO-1 activity on
IL-1b-induced NO was evaluated with use of the Griess reaction. Tran-
sient transfection of and Western blotting for IkBa, NF-κB, inducible
nitrite oxide synthase and HO-1 elucidated the molecular mechanism
of the HO-1 activity on IL-1b-induced NO.
We found evidence, for the first time, of the inducible expression of
HO-1 in articular chondrocytes. Overproduction or overexpression of
HO-1 is able to decrease dramatically in a dose-dependent manner the
IL-1b-induced NO release in the culture medium from articular chon-
drocyte culture. The inhibition of NO production occurs at the tran-
scriptional level through an NF-κB-dependent pathway.
These results demonstrate the critical role of HO-1 in inhibiting the IL-
1b-induced NO. In vivo experiments are under investigation.
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Introduction Osteoarthritis (OA) is characterized by fibrillation and
erosion of hyaline cartilage, subchondral bone sclerosis and osteophyte
formation at the joint margins. These changes, resulting from poorly
understood events, lead to both cartilage matrix degradation and inhibi-
tion of matrix component synthesis. Moreover, cartilage hypocellularity
due to cell death (apoptosis or necrosis) contributes to the development
of OA. Heat shock protein 70 (Hsp70) plays a protective role as a mole-
cular chaperone in cells by facilitating the folding, intracellular transport,
assembly, and disassembly of proteins. An increase in the expression of
Hsp70 in chondrocytes has been associated with the severity of OA
lesions and could be an indicator of the early stages of OA. Some
experiments recently demonstrated that Hsp70 protects cells from
death induced by stresses, mechanical and biological factors.
Objectives To determine whether Hsp70 overexpression is able to
protect rat chondrocytes towards mono-iodoacetate (MIA) cytotoxicity,
in vitro and in vivo.
Methods Induction of Hsp70 was performed with MG132, a protea-
some inhibitor, and overexpression of Hsp70 was realized by the non-
viral gene transfer method. The chondroprotective effect of Hsp70 was
assessed  in vitro by exposing cells to MIA and the protection was
determined by MTT/lactate dehydrogenase analyses. An antisense
strategy was used to confirm that Hsp70 played the major role in pro-
tecting chondrocytes from MIA toxicity. In a second step, the relevance
of a preventive induction or overexpression of Hsp70 was assessed in
vivo, during experimental OA in the rat induced by intra-articular injec-
tion of MIA.
Results In vitro, the increase of Hsp70 by proteasome inhibitor expo-
sure or by gene transfer was able to efficiently protect chondrocytes
from MIA toxicity. The antisense strategy confirmed that Hsp70 mainly
mediated this chondroprotective effect. In vivo, the induction (intra-
articular injection of MG132) or overexpression of Hsp70 (electric
gene transfer) was sufficient to decrease the severity of the OA-lesions
induced by MIA exposure, as demonstrated by histological and bio-
chemical analyses.
Conclusions Overexpression of Hsp70 in cartilage could be an inter-
esting way to protect in vitro chondrocytes from cell death and to
reduce in vivo the progression of OA-related chondral erosions.
54
Role of HC-gp39 in chondrogenesis: upregulation
of SOX-9 expression by HC-gp39 in mouse
chondrocytes
C Jacques1, A Recklies2, A Levy1, A Labat1, F Berenbaum1
1Department of Physiology and Physiopathology, UMR 7079 CNRS,
University of Paris, France; 2Shriners Hospital for Children, Montreal,
PQ, Canada
Arthritis Res Ther 2003, 5(Suppl 3):54 (DOI 10.1186/ar855)
Introduction Increased levels of the chitinase 3-like protein human car-
tilage glycoprotein 39 (HC-gp39) have been demonstrated in synovial
fluids of patients with rheumatoid or osteoarthritis. Recently, this
protein has emerged as a potential growth factor for synovial cells and
chondrocytes, but little is known about its role in differentiation. The
transcription factor SOX-9 has been demonstrated to be a master reg-
ulator of the differentiation of mesenchymal cells into chondrocytes.
Aim We investigate the effects of two growth factors, insulin-like growth
factor-I (IGF-I) and HC-gp39, on SOX-9 expression, and we sought to
identify transduction signalling pathways involved in SOX-9 expression.
Methods Expressions of SOX-9 and type II collagen were analysed in
primary culture of mouse costochondral chondrocytes using Western
blot analysis. Chondrocytes were stimulated by IGF-I and/or HC-gp39
during 24 hours. The kinetics with IGF-I and/or HC-gp39 (up to
60 min) was assessed with different antibodies against phosphorylated
and nonphosphorylated forms of p38 MAPK, ERK1/2 MAPK,
SAPK/JNK and AKT.
Results IGF-I (25ng/ml) and HC-gp39 (1µg/ml) were found to
markedly upregulate SOX-9 protein expression at 24 hours, which was
in parallel with an increased expression of type II collagen protein. An
IGF-I and HC-gp39 cotreatment showed an additive effect on SOX-9
protein expression. IGF-I and HC-gp39 were found to rapidly activate
the phosphorylation of ERK1/2 MAPK and AKT (peak at 2 min),
whereas p38 MAPK and SAPK/JNK pathways were not involved.
Conclusions These results indicate that the expression of the gene for
the master chondrogenic factor SOX-9 is stimulated by IGF-I and HC-
Available online http://arthritis-research.com/supplements/5/S3S18
gp39 in chondrocytes, and strongly suggest that this regulation is
mediated by the ERK1/2 MAPK and AKT pathways. Because SOX-9 is
essential for chondrocyte differentiation, we propose that HC-gp39
could be considered a novel actor involved in chondrogenesis.
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Recent studies have documented the role of the natural ligand (15d-
PGJ2) of peroxisome proliferator-activated receptor gamma (PPARγ) as
an anti-inflammatory agent in IL-1-treated cartilage cells and synovial
fibroblasts in culture. Similar but less pronounced effects have been
reported with pharmacological concentrations of synthetic PPARγ
ligands, such as thiazolidinediones. These anti-IL-1 effects were attrib-
uted to the transcriptional inhibition of NF-κB and/or AP-1-dependent
genes, while PPARγ implication remained questionable. We studied the
effects of rosiglitazone, a thiazolidinedione with high affinity for PPARγ,
in IL-1-treated rabbit articular chondrocytes (ARC) in culture. When
used at 10µM, rosiglitazone inhibited IL-1-induced nitric oxide produc-
tion, COX-2 mRNA, decreased the degradative effect of IL-1 on 35S-sul-
fated proteoglycans and the 55kDa gelatinolytic activity secreted by
ARC, and downregulated MMP-1 mRNA. By contrast, when used at
0.1–1µM, rosiglitazone decreased proteoglycan degradation and MMP-
1 gene expression, whereas it did not modify chondrocyte nitric oxide
production nor COX-2 mRNA expression. Transient transfection of ARC
with MMP-1-Luc showed that IL-1 stimulation was inhibited in a dose-
dependent manner by rosiglitazone from 0.1µM to 1µM, indicating that
rosiglitazone was acting at the transcriptional level. The electrophoretic
mobility shift assay showed that IL-1-induced NF-κB binding activity was
not changed by rosiglitazone, while IL-1-induced AP-1 binding activity
was reduced. We analysed rosiglitazone’s effect on MMP-1 promoter
activation in cells transiently cotransfected with MMP-1-Luc vector. We
showed that the inhibitory effect of rosiglitazone was significantly more
pronounced in cells cotransfected with wild-type PPARγ than without,
while this effect was completely suppressed by cotransfecting cells with
the dominant-negative PPARγ. Altogether, these data show for the first
time that rosiglitazone has a selective inhibitory effect on IL-1-induced
MMP-1 in chondrocytes, which involves a mechanism whereby PPARγ
and AP-1 are implicated.
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Aim Cyclooxygenase-2 (COX-2) selective inhibitors are being widely
used in the treatment of osteoarthritis, with their favorable efficacy and
safe profiles. The proliferative role of COX-2 has been recognized in
several human cancers and its inhibitors were found to induce apopto-
sis in these cancer cells. Since the apoptosis of chondrocytes is an
important contributor to the development of the osteoarthritis, we
determined to investigate the effect of selective COX-2 inhibitors on
the proliferation and apoptosis of human chondrocytes.
Methods Human chondrocytes from osteoarthritis patients were treated
with selective COX-2 inhibitors (celecoxib, MF-tricyclic) and nonselec-
tive inhibitors (sulindac and indomethacin) under various conditions. Cell
proliferation was assessed by MTT assay and the apoptosis was quanti-
fied by flow cytometry analysis after propidium iodide staining.
Results The COX-2 selective inhibitor celecoxib strongly inhibited the
proliferation of chondrocytes in a dose-dependent and time-dependent
manner. When compared with dimethylsulfoxide controls, chondro-
cytes proliferated 49.1±9.7% under 40µg/ml celecoxib, 80.4±28.3%
under 40µ/ml sulindac sulfide, 93.1±13.3% under 40µg/ml
indomethacin and 113.7±8.9% under another COX-2 selective
inhibitor, MF-tricyclic. Incubation with 80µg/ml celecoxib for 12 hours
lead to apoptosis in 6.6% of the chondrocytes, while incubation with
80µg/ml MF-tricyclic lead to apoptosis in 4.8% of the cells.
Conclusions In this study, we found that the COX-2 selective inhibitor
celecoxib could inhibit proliferation of chondrocytes from osteoarthritis
patients, while another COX-2 selective inhibitor, MF-tricyclic, does not
affect the proliferation of the cells. Further study will be warranted on
the clinical effects of different COX-2 selective inhibitors in osteoarthri-
tis patients. Furthermore, our results suggest that celecoxib may induce
apoptosis of chondrocytes via other pathways than COX-2 inhibition.
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A complex environment controls the metabolism of chondrocytes in the
inflammatory joint. Although mechanical stimuli are essential for the
chondrocyte metabolism, excessive mechanical force contributes to
the release of inflammatory mediators leading the cartilage destruction
under the arthritic condition. IL-4 is a chondroprotective cytokine,
which is also involved in the integrin-mediated chondrocyte mechano-
transduction. We examined the effects of cyclic mechanical stress on
the gene expression profile of rat chondrocytes, and tested the in vitro
effects of recombinant IL-4. Chondrocytes were obtained from the
knee joints of 7-day-old Wister rats. Cyclic mechanical stress was
applied on the cultured chondrocytes for 24 hours using Flexercell
strain unit (Flexcell International Co., Hillsboro, NC, USA) with 0.5Hz,
7% elongation, with or without treatment by recombinant IL-4. The
cDNA microarray analysis revealed that, of 1080 genes, 37 genes
were upregulated and 46 genes were downregulated after mechanical
stress. RT-PCR and real-time PCR analysis confirmed that treatment by
IL-4 resulted in the significant downregulation of mRNA expression of
cysteine proteinase cathepsin B, and the inducible form of nitric oxide
synthase. Next, an osteoarthritis model was created in the knee joints
of Wistar rats (200g) with anterior cruciate ligament and medial collat-
eral ligament transection. The rats were killed 2, 4, or 6 weeks after the
surgery, and the gross morphology and histology of the knee joint carti-
lage were examined. The preliminary results showed that intra-articular
administration of IL-4 exerted a protective effect on the development of
osteophytes, and cartilage lesions in this model of osteoarthritis. These
results suggested the possible role of IL-4 in the control of mechanical
stress-induced inflammatory mediators in vitro and in vivo.
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Background Therapeutics employing knowledge on various signaling
pathway are being developed, with NF-κB one of the most promising
targets. NF-κB has been suggested to play a role not only in the induc-
tion of inflammatory mediators, but also in the protection of apoptosis.
Objectives This study pursued the role of the NF-κB pathway in the
regulation of chondrocyte death induced by tumor necrosis factor
alpha (TNF-α) and the pertinent target molecules involved.
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Methods NF-κB activation was specifically inhibited using an adenovi-
ral vector encoding the transgene for IκB super-repressor (ad-IκB-SR).
The human juvenile costal chondrocyte cell line (C28/I2) was used for
the experiment. Infection with ad-IκB-SR was performed for 360 min
using a multiple of infection of 1:200, after which the cells were incu-
bated for 18 hours in medium containing 10% FCS. The cultures were
then changed to serum-free medium, and treated with 10ng/ml TNF-α.
The proportion of cell death was analyzed by MTT assay. Activation of
p38 mitogen-activated protein (MAP) kinase and phosphatidylinositol
3-kinase (PI3K) was inhibited by preincubation for 1 hour with
SB202190 and Ly 294002, respectively. The expression of apoptosis-
related protein was analyzed with Western blot assay. The activation of
c-JUN N-terminal kinase was analyzed by gel kinase assay.
Results Despite complete inhibition of NF-κB activation, treatment with
TNF-α led to cell death in only about 23% of ad-IκB-SR-infected chon-
drocytes after 24 hours. Preincubation with SB202190 and Ly 294002
led to a significant increase in cell death, resulting in 53% and 30%
cell death after 24 hours, respectively. The expression of Bcl-XL and
XIAP significantly decreased, and activation of c-Jun N-terminal kinase
was prolonged up to 4 hours in infected cells treated with TNF-α.
Conclusion In our experimental system, specific inhibition of NF-κB
activation rendered chondrocytes susceptible to cell death induced by
TNF-α. However, completion of cell death required inhibition of another
signaling pathway such as p38 MAP kinase and PI3K. The expression
of Bcl-XL and XIAP, and activation of c-Jun N-terminal kinase was
affected by ad-IκB-SR transduction, implying its role in the NF-κB-regu-
lated cell survival signaling in human chondrocytes.
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Introduction Functional genomics represents a new challenging
approach in order to analyze complex diseases such as osteoarthritis
on a molecular level. In particular, the identification and characterization
of new target molecules for therapeutic intervention is of interest. Also,
potential molecular markers for diagnosis and monitoring of osteoarthri-
tis will contribute to a more appropriate patient management.
Objectives In our analyses, we attempt to establish a broader gene
expression profile of osteoarthritic chondrocytes by modern screening
technologies in order to characterize more properly the cellular events
and regulatory pathways directly involved in cartilage destruction.
Methods Cartilage from human femoral condyles of the normal knee
joints were obtained from donors at autopsy. Late-stage osteoarthritic
cartilage was obtained from patients undergoing total knee replace-
ment surgery. Gene expression analysis was performed by various
array technologies and by quantitative PCR. For normalization we
applied a novel computational normalization method [1].
Results Our first focus in looking at chondrocyte gene expression is
always linked to the main function of this cell type, the preservation and
turnover of the cartilage matrix. Thus, for a start, matrix components and
matrix-degrading proteases were the focus of our interest [2]; the analy-
sis of the extracellular matrix proteins showed the largely absent expres-
sion of cartilage collagens in normal cartilage and very much increased
mRNA levels of several collagen genes in advanced osteoarthritis. With
regard to the cartilage-matrix-degrading metalloproteinases, a character-
istic pattern was observed in osteoarthritic cartilage versus normal articu-
lar cartilage. Future studies will focus on the investigation of pathogenetic
pathways based on bioinformatic modelling of their involved genes.
Conclusions Overall, cDNA technology offers cartilage research a
powerful tool for investigating gene expression patterns of a high
number of different genes simultaneously. Despite constitutive draw-
backs of gene expression technologies, still existing technical prob-
lems, and the lack of broadly applicable tools in biostatistics and
bioinformatics, even now gene arraying and subsequent technologies
initiate new research strategies for understanding pathogenesis and
development of drug targets.
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Introduction IL-1β is one of the major proinflammatory cytokines
involved in arthritis joints. IL-1β promotes the arachidonic acid cascade,
resulting in production of prostaglandin. In addition, IL-1β represses the
expression of matrix proteins in cartilage, such as type II, type IX and
type XI collagen and cartilage-derived retinoic acid-sensitive protein
(CD-RAP), leading to degradation of the cartilage structures.
Objective To investigate the transcriptional mechanism by which CD-
RAP expression is repressed by IL-1β.
Methods and results Deletion constructs of the CD-RAP promoter
were transfected into rat chondrocytes and incubated in the absence
or presence of IL-1β. The results revealed an IL-1β-responsive element
located between –2138 and –2068bp. As this element contains the
CCAAT/enhancer-binding protein (C/EBP) motif, the function of
C/EBP-β was examined. IL-1β stimulated the expression of C/EBP-β.
The direct binding of C/EBP-β to the C/EBP motif was confirmed by
electrophoretic mobility shift assay. Expression of the –2251 bp CD-
RAP promoter construct was downregulated by cotransfection with
C/EBP-β expression vectors in a dose-dependent manner. Mutation of
the C/EBP motif within the –2251bp construct abolished the inhibitory
response to IL-1β. These results suggest that C/EBP-β is a critical
factor mediating IL-1β-induced repression of CD-RAP transcription.
C/EBP-β expression vectors were also found to downregulate the
reporter construct containing the promoter and enhancer of the type II
collagen gene. The IL-1β-induced repression of CD-RAP and type II
collagen genes via stimulation of C/EBP-β were confirmed in chondro-
cytes from normal human articular cartilage. Finally, the enhancer
factor, Sox9, known to be downregulated by IL-1, was shown to bind
adjacent to the C/EBP site competing with C/EBP binding.
Discussion C/EBP-β is known to mediate the arachidonic acid
cascade induced by IL-1β. These results suggest that C/EBP-β play an
important role in the distinct effects of IL-1β: the promotion of inflam-
matory reaction and the repression of cartilage-specific proteins in joint
disease. Expression of matrix proteins are influenced by availability of
both positive and negative trans-acting factors.
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We devised a tissue-engineered cartilage using thermoresponsive
gelatin, poly(N-isopropylacrylamide)-grafted gelatin (PNIPAAm-gelatin).
Available online http://arthritis-research.com/supplements/5/S3S20
An aqueous solution of the PNIPAAm-gelatin can spontaneously gel
above 34°C. This character of the PNIPAAm-gelatin might fit a gel to a
given shaped chondral defect.
For in vitro study, chondrocytes isolated from the articular cartilage of
Japanese White Rabbits were three-dimensionally cultured in
PNIPAAm-gelatin gel for up to 12 weeks. The chondrocyte–PNIPAAm-
gelatin constructs were evaluated at cell and tissue levels. At the cell
level, cellular viability and the degree of cellular differentiation were
assessed. At the tissue level, the appearance of the tissue, the amount
of extracellular matrices (ECMs), and the mechanical properties were
assessed by comparison with those of native hyaline cartilage. During
3 weeks of culture, the cellular viability was more than 95%. Confocal
laser scanning microscopic images demonstrated that round-shaped
cells, which are found in hyaline cartilage, were predominant in the con-
struct. With an increase in culture time, the population of the cells
arrested in the G1/G0 phase of the cell cycle in a three-dimensional
condition was significantly higher than that in a monolayer condition. As
type II collagen and sulfated-glycosaminoglycan specific to hyaline car-
tilage were detected in sections of the construct, little type I collagen,
which is a marker of dedifferentiated chondrocytes, was detected.
These results indicate that the inoculated cells could express their dif-
ferentiated phenotype. Moreover, the amounts of ECMs increased and
closed to that of native hyaline cartilage with time. Mechanical proper-
ties of the constructs tended to close towards those of native cartilage
with culture time. These results indicate that cartilaginous tissue using
PNIPAAm-gelatin can be reconstructed in in vitro conditions.
In animal studies, the combination of chondrocyte–PNIPAAm-gelatin
constructs precultured for 2 weeks and the cell-incorporated
PNIPAAm-gelatin solution were used as implants for chondral defects
in the patellae of rabbits. Macroscopic evaluation of the implant har-
vested at 24 weeks postoperatively showed that, at the rough surface
of the implants, tissue continuity to adjacent cartilage with minimal
concave deformation was acquired. Tissue sections showed a homo-
geneous distribution of ECMs in the implanted tissue and no inflamma-
tory cells. Moreover, mechanical properties of the constructs became
closer to those of native cartilage.
These results indicate that PNIPAAm-gelatin should serve as an ade-
quate scaffold for articular cartilage regeneration.
Poster Discussion (2) Cytokines, Growth
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Objective The enhancement of tissue repair by growth factor stimula-
tion is of potential therapeutic interest. Given the importance of carti-
lage-derived morphogenetic protein (CDMP)-1 and CDMP-2 in
ligament formation and repair, we studied the effects of these growth
factors on the proliferation and metabolism of ligament fibroblasts as
well as their osteogenic/chondrogenic differentiation potential.
Methods Ligament fibroblasts were obtained from 3-month-old calves,
plated as monolayers or micromass cultures and stimulated with
CDMPs. The expression of the indicated growth factors was assessed
either by RT-PCR or by Western immunoblotting. The presence of their
respective type I and type II receptors, as well as lineage-related
markers were investigated in stimulated and unstimulated cells by RT-
PCR and by northern blotting. The biosynthesis of matrix proteoglycans
was assessed by [35S]sulfate incorporation in monolayers. Alcian-blue
staining as well as toluidin-blue was performed in micromass cultures.
The cell proliferation rate was measured by the use of [3H]thymidine
incorporation.
Results The presence of CDMP-1 and CDMP-2 was detected on
mRNA as well as on the protein level. Type I and type II receptors were
endogenously expressed in unstimulated ligament fibroblasts. The
growth factors stimulated cell proliferation as measured by [3H]thymidine
incorporation and total proteoglycan synthesis as assessed by [35S]
incorporation. Alcian-blue and toluidin-blue staining showed the differ-
entiation into chondrocytes in the growth-factor-treated ligament fibro-
blasts. Moreover, transcription analysis of stimulated ligament fibroblasts
demonstrated an upregulation of chondrogenic markers (aggrecan,
collagen type II, type IX and type X) but not of osteogenic markers.
Conclusion CDMP-1 and CDMP-2 induce matrix synthesis and cell
proliferation in cells derived from bovine ligament. The expression of
chondrocyte markers suggests that adult cells from ligaments and
tendons have the capability of differentiation into chondrocytes under
the influence of CDMPs. Given our current dilemma in the treatment of
osteoarthritis, CDMP-1 and CDMP-2 could therefore contribute an
interesting therapeutic molecule for osteoarthritis.
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Introduction The subchondral bone plays a prominent role in the
pathophysiology of osteoarthritis (OA), possibly related to abnormal
osteoblast metabolism. In particular, abnormal responses to insulin-like
growth factor-1 (IGF-1) were noted in OA osteoblasts.
Objectives To investigate whether IGF-1 signaling is abnormal in OA
osteoblasts compared with normal osteoblasts.
Methods We used primary human subchondral osteoblasts from
normal and OA individuals. Cells were stimulated, or not, with
100ng/ml IGF-1 for up to 5 min. Proteins were separated by SDS-
PAGE or immunoprecipitated with anti-insulin receptor substrate-1
(anti-IRS-1) antibodies followed by SDS-PAGE, and detected with
selective antibodies.
Results Upon binding to its receptor (IGF-1R), IGF-1 activates the
p42/44 mitogen-activated protein kinase (MAPK) pathway using SHC
or phosphorylation of IRS-1 via Grb2. The interaction of IRS-1 with
IGF-1R is also modulated via the binding of a tyrosine phosphatase,
Syp. IGF-1R α-subunits, SHC, IRS-1, Syp, Grb2 and p42/44 MAPK
levels, by Western blot analysis, were similar in normal and OA
osteoblasts under basal condition and following IGF-1 treatment. IGF-1
stimulated IGF-1R autophosphorylation in normal and OA osteoblasts
similarly. However, IRS-1 phosphorylation was reduced whereas
p42/44 MAPK phosphorylation was higher in OA osteoblasts than
normal osteoblasts in response to IGF-1. In normal osteoblasts, Syp
was poorly phosphorylated under basal conditions and rapidly became
phosphorylated upon IGF-1 stimulation, while Syp was already highly
phosphorylated under basal conditions in OA osteoblasts and was
dephosphorylated upon IGF-1 stimulation. Co-immunoprecipitation of
Syp using IRS-1 antibodies showed that this interaction is poor under
basal conditions in normal cells yet increases following IGF-1 treat-
ment, while in OA osteoblasts this interaction was very strong and
rapidly dropped with IGF-1 treatments, indicating that phospho-Syp is
the trigger. Co-immunoprecipitation of Grb2 using IRS-1 antibodies
showed that Grb2 interaction with IRS-1 was increased in OA
osteoblasts compared with normal osteoblasts under basal conditions
and following IGF-1 stimulation.
Conclusion These results suggest that an abnormal interaction of
phospho-Syp with IRS-1 in OA osteoblasts leads to a reduced activity
of IRS-1-dependent pathways. In addition, the increased interaction of
Grb2 with IRS-1 suggests that the SHC–Grb2 interaction is reduced
in OA osteoblasts, and hence could not explain the stimulation of
p42/44 MAPK.
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A derivative of prostaglandin D2, 15-deoxy-delta12,14-prostaglandin J2
(15d-PGJ2) is one of the cyclooxygenase (COX) products in the arachi-
donic acid cascade. PGJ2 series have been reported to exert various
bioactivities, including modulation of viability of a wide array of cells, and
are known to act as an active ligand for the nuclear receptor peroxisome
proliferator-activated proteins gamma. 15d-PGJ2 is also suggested to
play a role in cartilage metabolism; however, this issue is still not fully
understood. We investigated the potential role of the 15d-PGJ2 in the
induction of apoptotic death in human articular chondrocytes. Cartilage
samples were obtained from patients who underwent joint surgery.
Articular chondrocytes were isolated from the cartilage by mincing and
enzymatic treatment, and the cells were further cultured in a monolayer
system in vitro. Confluent cells at the first passage were stimulated with
the 15d-PGJ2, and the effect of the 15d-PGJ2 in the viability of chondro-
cytes were assessed using Hoechst staining, flow cytometric analysis
and the caspase-3 activity assay. The results showed that the 15d-PGJ2
was potent to induce chondrocyte apoptosis characterized by cellular
shrinkage and nuclear condensation, along with an increased activity of
caspase-3 in the treated cells. Involvement of the 15d-PGJ2 in chondro-
cyte apoptosis may have an important implication in the pathogenesis of
inflammatory and degenerative joint diseases.
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Introduction Membrane-associated prostaglandin E synthase (mPGES)
is a recently identified terminal enzyme of arachidonic acid cascade that
catalyzes prostaglandin (PG)H2 to PGE2. We recently reported that
expression of mPGES in rheumatoid synovial fibroblasts (RSF) was
upregulated by IL-1β, and that the time-course of its expression was
delayed and prolonged when compared with that of cyclooxygenase-2
(COX-2).
Objective To identify the regulating factors of mPGES expression in
RSF.
Methods RSF from patients with rheumatoid arthritis (RA) on surgery,
who gave written consent to the use of tissues for this research, were
treated with IL-1β, rofecoxib, NS-398, and meloxicam (selective COX-2
inhibitors). The effects of PGE2 and selective EP1, EP2, EP3, and EP4
receptor agonists (DI-004, AE1-259-01, AE-243, and AE1-329, respec-
tively; Ono Pharmaceutical Co., Osaka, Japan) were also studied in
various conditions. Expression of the mRNA and protein of mPGES and
COX-2 were analyzed by northern and Western blot analyses, respec-
tively. Expression of PGE2 receptor mRNA in RSF was determined by
RT-PCR. PGE2 and cAMP production was measured by an ELISA.
Results Enhanced expression of mPGES mRNA and protein in IL-1β-
stimulated RSF was attenuated by rofecoxib, NS-398, or meloxicam.
This attenuation was restored by addition of PGE2. Exogenous PGE2
only (without IL-1β stimulation) did not induce expression of mPGES in
RSF, indicating that PGE2 was an enhancer of mPGES expression in
the IL-1β-stimulated condition.
We then examined which PGE2 receptor was important in the enhanc-
ing action of PGE2 in RSF. EP2 and EP4 receptor mRNA was
detected in RSF; however, EP1 and EP3 were negative. Addition of
AE1-259-01 (EP2 agonist) or AE1-329 (EP4 agonist) as well as PGE2
restored the inhibitory effects of mPGES expression by rofecoxib. In
addition, the restoration by PGE2 was mimicked by forskolin, a direct
activator of adenylate cyclase. Intracellular cAMP was increased by IL-
1β and it was inhibited by rofecoxib.
Conclusions The enhancing property of PGE2 via EP2/EP4 receptors
on mPGES expression may play an important role in the cytokine-stimu-
lated articular inflammation in RA patients. It also seems that COX-2
inhibitors effectively decrease PGE2 production not only by COX-2
inhibition, but also by reduction of mPGES expression.
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Introduction IL-18, a member of the IL-1 family, seems to be involved in
bone destruction observed in rheumatoid arthritis (RA). Synovial prolifer-
ation secondary to an apoptosis defect and the RANK/RANKL system
may be implicated in IL-18-induced bone destruction. Therefore, we
examined IL-18, IL-1β and tumor necrosis factor (TNF)-α effects on
RANKL, the pro-apoptic factor TRAIL, and osteoprotegerin (OPG), the
soluble receptor of RANKL and TRAIL in synovial fibroblasts.
Materials and methods Synovial fibroblasts (SFB) isolated from RA
patients were stimulated with IL-18, IL-1β or TNF-α for 24 hours. Con-
ditioned media was collected and mRNA was then extracted. Expres-
sion of OPG and soluble RANKL (RANKLs) were assessed by
quantitative RT-PCR (Sybr Green) and by ELISA. IL-18, IL-1β and TNF-
α did not induce RANKLs mRNA and protein expression. TRAIL
expression was examined by semi-quantitative RT-PCR.
Results Unstimulated fibroblasts constitutively expressed OPG
2±0.364ng/ml. IL-18 did not increase mRNA and protein OPG
expression. IL-1β induces OPG mRNA expression and a 14-fold
increase of OPG protein (P<0.05; n=4). TNF-α also increases OPG
mRNA and protein levels, but not significantly as compared with
unstimulated RA SFBs (P=0.21; n=4). For TRAIL, IL-18 again does
not induce TRAIL mRNA, whereas TNF-α-stimulated and IL-1β-stimu-
lated synovial fibroblasts produce TRAIL mRNA.
Conclusion IL-18 does not regulate the RANKL/OPG system and
TRAIL in RA SFBs. IL-1β and TNF-α induce expression of OPG and
TRAIL but not of RANKL. These results contrast with the known impli-
cation of these cytokines in bone destruction. Since OPG can also
bind to TRAIL, a cytokine involved in apoptosis, OPG may block the
pro-apoptotic function of TRAIL.
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Angiogenesis is an essential component of proliferative synovitis
leading to joint destruction in rheumatoid arthritis (RA). Recent studies
have demonstrated the presence of hypoxia and the accumulation of
pro-angiogenic growth factors, including vascular endothelial growth
factor (VEGF), in the synovium from patients with RA, indicating a pos-
sible involvement of those factors in synovial angiogenesis. The
hypoxia-inducible transcription factor-1α (HIF-1α) is a key regulator of
VEGF gene expression and angiogenesis under hypoxic conditions [1].
We have recently demonstrated abnormal expression of HIF-1α and
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VEGF in the synovium from patients with RA, indicating a potential con-
tribution of the HIF-1α–VEGF system to angiogenic processes of syn-
ovitis in RA. The precise mechanism of HIF-1α-mediated control of
VEGF expression and angiogenesis, however, is largely unknown.
Given this background, we aimed to elucidate the molecular mecha-
nism underlying hypoxia-inducible VEGF expression via HIF-1α, and
identified a novel basic helix–loop–helix/Per, Arnt, Sim protein
(inhibitory Per, Arnt, Sim domain protein [IPAS]) that has high structural
similarity to HIF-1α [2]. In sharp contrast to HIF-1α, IPAS was not
capable of activating hypoxia-inducible gene expression. Co-expression
of IPAS and HIF-1α resulted in repression of hypoxia-inducible VEGF
gene expression, demonstrating a dominant-negative regulatory activity
of IPAS on HIF-1α-mediated control of gene expression. In situ
hybridization analysis of various mouse tissues showed predominant
IPAS expression in the avascular corneal epithelium, correlating with
low levels of VEGF gene expression under hypoxic conditions. Strik-
ingly, application of an IPAS antisense oligonucleotide to the mouse
cornea induced angiogenesis under normoxic conditions, and
unmasked hypoxia-dependent induction of VEGF gene expression in
hypoxic cornea cells. Moreover, ectopic expression of IPAS in
hepatoma cells impaired induction of genes involved in adaptation to a
hypoxic environment, and resulted in retarded tumor growth and tumor
vascular density in vivo. Taken together, IPAS, a dominant-negative
regulator of HIF-1α function, would define a novel anti-angiogenic
mechanism under hypoxic conditions, providing a possible therapeutic
strategy for angiogenic diseases including RA.
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Host immune and inflammatory factors contribute to progression of
inflammatory synovitis — targeting specific factors such as tumour
necrosis factor brings about substantial clinical benefit. We have
focused on the effector function of innate immune response cytokines
in synovitis including IL-15 and members of the IL-1/IL-1 receptor
superfamily, particularly IL-18. Our strategy has been to identify media-
tors with plausible bioactivity, to establish that they or their target
ligands are present in inflammatory synovial tissues and, thereafter, to
target them in vivo using appropriate inflammatory rodent models.
Thus, IL-15 is a 4a-helix inflammatory cytokine with plausible biologic
effects on synovial cell subsets, expressed in synovial tissues in
rheumatoid arthritis (RA) and psoriatic arthritis, and when targeted in
vivo leads to suppression of collagen-induced arthritis in DBA/1 mice.
A recent phase I/II study in patients with RA in which HuMaxIL-15 was
administered weekly for 4 weeks suggested that IL-15 blockade was
well tolerated and provided preliminary evidence for efficacy, suggest-
ing our approach is valid. We recently gathered a similar evidence base
for IL-18, demonstrating widespread IL-18 expression in synovial
tissues in RA and psoriatic arthritis effector function in T cells,
macrophages, fibroblasts and neutrophils in synovial tissues, and finally
providing in vivo evidence that IL-18 has an effector function in vivo by
showing that IL-18-deficient mice have reduced the severity of colla-
gen-induced arthritis. A striking feature is the synergy exhibited by IL-
18 with IL-12 and IL-15. Studies in which IL-18 is targeted in human
inflammatory arthropathies are now awaited. Finally, since IL-15 and IL-
18 are both key mediators of dendritic cell (DC) effector function, and
are expressed in synovial DCs, we have focused on the means
whereby DCs could promote or sustain inflammatory synovitis. To this
end, we have shown that collagen-pulsed DCs adoptively transferred
into naïve DBA/1 recipients initiate a remitting relapsing arthritis, medi-
ated in part via innate response cytokines, including tumour necrosis
factor. By facilitating transfer of gene-targeted cell donors, or adminis-
tration of cytokine inhibitors, this model provides a novel system in
which to test the relative role of innate response cytokines during initia-
tion of but also during chronic phases of inflammatory arthritis.
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Serum amyloid A (SAA) is an acute-phase protein and inflammatory
marker of rheumatoid arthritis, which has recently become recognized
as a cytokine-like reactant. SAA has been shown to bind to the ALXR
(FPRL1/LXA4R) receptor and to elicit proinflammatory activities. Indeed,
we have determined that SAA elicits the proinflammatory activation of
human fibroblast-like synoviocytes, with a profile of activity similar to that
of IL-1β. Uteroglobin is a ubiquitously expressed secretory protein with
anti-inflammatory properties that shares specific sequence motifs with
annexin-1, a steroid-induced anti-inflammatory peptide that is also
capable of interacting with ALXR. Data obtained by flow cytometry,
ELISA and plasmon resonance, using ALXR stably transfected CHO
cells, suggest that uteroglobin can downmodulate SAA proinflammatory
effects by specifically interfering at the ALXR receptor level. In agree-
ment with the ability to bind to the same receptor used by SAA, a func-
tional antagonism between uteroglobin and SAA was observed, with
uteroglobin causing inhibition of SAA-induced release of both IL-8 and
IL-6, and blockage of SAA-induced PLA2 activation. Beside the receptor
antagonism between proinflammatory ALXR ligands (SAA, urokinase
proteolytic plasminogen peptides [uPA], MK1, etc.) and anti-inflamma-
tory ALXR ligands (LXA4, annexin-1, uteroglobin) so far identified,
results also suggest that each of these mediators can modify ALXR
expression levels as well as other genes. In fact, present studies
suggest that SAA acts in a positive autoregulatory feedback mechanism
by increasing SAA 1+2 expression, while maintaining unchanged levels
of its constitutively expressed isoform SAA4, as demonstrated by RT-
PCR. Following SAA treatment, upregulation is extended to the expres-
sion of the ALXR mRNA, a response common to LXA4 and IL-1β. The
antagonistic activities of SAA, uPA, uteroglobin, annexin-1 and LXA4
might constitute a novel complex signaling mechanism by which these
mediators sharing a common receptor could achieve opposing roles in
the regulation of the joint inflammatory processes.
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Background To investigate the safety and efficacy of a recombinant
human anti-IL-6R monoclonal antibody (MRA) for children with sys-
temic-onset juvenile idiopathic arthritis (So-JIA), a long-term administra-
tion of MRA was performed in three children with So-JIA.
Case report Two boys and one girl with recurrent spiking fever, rash, and
arthritis diagnosed as So-JIA (case 1, 7 years old; case 2, 8 years old;
case 3, 13 years old) have been treated for 2.6 years, 2.5 years, and
1.9 years, respectively, with MRA after long-term treatment with pred-
nisone and cyclosporin A, being complicated with macrophage activation
syndrome during the course of the disease, and resulting in short stature,
obesity and destruction of vertebrae. Serum levels of C-reactive protein
were persistently high, The white blood cell count was over 15,000/µl
with marked neutrophilia, and increased levels of IL-6 were detected. Intra-
venous administration of MRA was initiated, and prompt responses were
obtained in both clinical and laboratory findings. Before accumulation of
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MRA in serum, fluctuations of C-reactive protein, the erythrocyte sedimen-
tation rate and serum amyloid A levels were observed, but the clinical
status of spiking fever, rash, and arthritis became stable. MRA was admin-
istered once every other week, and therapeutic effects were persisted
during the observation period in all three cases. Around 100 days after the
initiation of therapy, the white blood cell count was decreased to a normal
number, and they started to grow in height (+18cm, +13cm, and
+11cm, respectively). Cyclosporin A was discontinued, and prednisone
was tapered and ceased. Increased bone density was demonstrated, and
an uptake of the marker isotope in an epiphyseal plate by Ga-scintigram
gradually emerged, suggesting that IL-6 or IL-6/sIL-6R complexes had
previously interrupted the bone growth at epiphysis. Three episodes of
infection were clearly assessed by increased serum IL-6 levels. JIA core
set and C-HAQ scores were remarkably improved. No definite findings of
tuberculosis was determined.
Conclusion For patients with So-JIA, administration of MRA dramatically
improved inflammatory disease within 1 week, which indicated a patho-
genic role of serum IL-6 and IL-6/sIL-6R complexes in So-JIA. This demon-
strated MRA to be the first-line drug for the treatment of the disease.
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Oncostatin M (OSM) is an IL-6 family cytokine that we have previously
shown to synergise with IL-1 to induce cartilage proteoglycan and colla-
gen degradation in a cartilage explant culture system, and these observa-
tions now extend to IL-6 [1,2]. A significant finding of these studies was
the synergistic induction of the collagenase, matrix metalloproteinase
(MMP)-1, which occurs via interplay between the JAK/STAT, AP-1 and
MAPK pathways [3]. These studies have important implications for inflam-
matory joint disease since OSM (and, indeed, IL-6) have been proposed
to be protective in rheumatoid arthritis. Recently, we also demonstrated
that OSM can exacerbate the effects of another important proinflamma-
tory mediator, tumour necrosis factor (TNF)-α [4]. In order to assess the
effects of these cytokine combinations in vivo, we have assessed the
effects of intra-articular gene transfer of OSM in combination with either
IL-1 or TNF-α on murine knee joints using recombinant adenovirus.
Engineered adenoviruses were administered for only 7 days, after
which time joints were fixed, decalcified and sectioned. Histological
analyses indicated marked synovial hyperplasia and inflammatory cell
infiltration for IL-1-treated, TNF-α-treated and OSM-treated joints, but
not in controls (joints treated with an ‘empty’ adenovirus). The inflam-
mation was more pronounced for both the OSM+IL-1 and
OSM+TNF-α combinations with evidence of cartilage and bone
destruction. Significant loss of both proteoglycan and collagen was
also seen for these combinations, and immunohistochemistry revealed
an increased expression of MMPs with decreased tissue inhibitors of
metalloproteinases in both articular cartilage and synovium. The effects
of these combinations were significantly greater than those seen with
any of the cytokines alone. Taken together, these data confirm that, in
vivo, OSM can significantly exacerbate the effects of both IL-1 and
TNF-α, resulting in inflammation and tissue destruction characteristic of
that seen in rheumatoid arthritis. This study provides further evidence to
implicate the upregulation of MMPs as a key factor in joint pathology,
and further supports the concept of combinatorial therapeutic
approaches for the treatment of inflammatory joint diseases.
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IL-1 receptor antagonist (IL-1Ra) is a member of the IL-1 family that com-
petitively inhibits the binding of IL-1 to its cell surface receptors, and thus
acts as a natural IL-1 inhibitor. Four different IL-1Ra peptides are pro-
duced from the same gene by the use of alternative first exons, mRNA
splicing, and alternative translation. One isoform is secreted (sIL-1Ra),
while the three other isoforms remain intracellular (icIL-1Ra1, icIL-1Ra2,
icIL-1Ra3). In a previous study, we observed that icIL-1Ra1 is produced
in high amounts in the joints of mice with collagen-induced arthritis (CIA)
and that the expression of icIL-1Ra1 coincided with the resolution of
articular inflammation. Recently, we showed that mice transgenic for icIL-
1Ra1 were protected from CIA in a similar manner to sIL-1Ra transgenic
mice. However, as icIL-1Ra1 was also detected in the circulation, it was
impossible to determine whether icIL-1Ra1 exerted its anti-inflammatory
effect inside cells or through its interaction with cell surface receptors. To
address this question, we examined the intracellular effects of icIL-1Ra1
on endothelial cell migration. IL-1a is produced as a 31kDa protein (pre-
IL-1a) that is cleaved to generate C-terminal mature IL-1a. The N-terminal
region of pre-IL-1a contains a nuclear localization domain, and both pre-
IL-1a and the 16kDa N-terminal IL-1a are able to migrate into the nuclei
and to modulate endothelial cell migration. The migration of the endothe-
lial cell line ECV was significantly increased in cells transfected with pre-
IL-1a or N-terminal IL-1a propiece. In contrast, the addition of mature
IL-1a in culture medium was devoid of any effect on cell migration, indi-
cating that the effect of pre-IL-1a and 16kDa N-terminal IL-1a was inde-
pendent of their interaction with cell surface receptors. Most interestingly,
expression of icIL-1Ra1 in ECV cells completely reversed the effects of
pre-IL-1a and N-terminal IL-1a. Immunofluorescence studies indicated
that the N-terminal IL-1a was located in the nuclei. icIL-1Ra1 was located
both in the cytoplasm and in the nuclei, and co-expression of icIL-1Ra1
modified the intracellular localization of the N-terminal IL-1a. In conclu-
sion, this study demonstrates for the first time that icIL-1Ra1 may carry
out important intracellular regulatory functions in endothelial cells.
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Introduction RANKL and IL-6 participate in osteoclast differentiation
and activation, and therefore regulate bone resorption. The biological
activity of RANKL is inhibited by its natural decoy receptor osteoprote-
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gerin (OPG), while IL-6 activity is either enhanced by soluble IL-6
receptor (sIL-6R) or inhibited by soluble glycoprotein 130 (sgp130), an
extracellular domain of the signaling chain of the IL-6 receptor complex.
Objectives To compare the levels of RANKL, OPG, IL-6, sIL-6R and
sgp130 in bone marrow plasma isolated from rheumatoid arthritis (RA)
and osteoarthritis (OA) patients.
Methods Bone marrow samples isolated from 29 RA patients and
12 OA patients (mean age 51±14.3 years and 56.3±10.5 years,
respectively) undergoing hip replacement surgery were diluted twice in
heparinized PBS. The levels of cytokines were measured using specific
ELISAs.
Results The levels of tested cytokines, the ratio of respective ligands
to their receptors and the statistical significance of the data are pre-
sented in Table 1.
The levels of RANKL in RA patients were elevated by 53% in compari-
son with those in OA patients. In contrast, the levels of OPG were
diminished by 20%. Thus, the ratio of OPG/RANKL, thought to better
reflect environmental signals promoting bone resorption than levels of
individual cytokines, is diminished in RA patients in comparison with
OA patients. Similarly, the 115% increase of IL-6 and the 102%
increase of sIL-6R is not compensated for by only the 59% increase of
sgp130 in RA patients in comparison with OA patients.
Conclusion The present data indicate that the bone marrow microenvi-
ronment of RA patients in comparison with OA patients is enriched in
factors promoting osteoclastogenesis, osteoclast activation and bone
resorption. At the same time, the levels of corresponding natural decoy
receptors is diminished. Thus, RA-associated osteoporosis and bone
erosions may, at least partially, be related to unbalanced production of
RANKL, IL-6 and sIL-6R in the bone marrow.
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Joint pain in patients with rheumatoid arthritis (RA) and osteoarthritis
(OA) is only in part explained by inflammatory processes. Neuropep-
tides and opioids play an important role in the pathogenesis of pain
besides proinflammatory cytokines. Molecules like serotonin, histamin,
bradykinin and prostaglandins and their receptors are of particular
interest. Several research groups have found that these mediators can
also be produced from non-neuronal cells. Nerve fibers in RA appear to
undergo degenerative processes that lead to a reduction of these
fibers [1]. Our group reported the expression of secretoneurin in syn-
ovial tissue of patients with RA and OA [2]. In a randomized, double-
blind trial, Stein and colleagues demonstrated the efficacy of
intra-articular opioid application in chronic arthritis [3]. Other investiga-
tors confirmed the antinociceptive and anti-inflammatory effect of
opioids [4]. Other neuropeptides, such as the pituitary adenylyl cyclase
activating polypeptide, also show anti-inflammatory actions [5]. Evalu-
ated by Taqman real-time PCR, we found a significant reduction of the
δ-opioid receptor and the κ-opioid receptor mRNA in synovial fibro-
blasts in seven patients with RA (κ-opioid receptor, 0.09-fold±0.0276,
P=0.037;  δ-opioid receptor, 0.05-fold±0.0134, P=0.040) and in
seven patients with OA (κ-opioid receptor, 0.15-fold±0.0315,
P=0.040; δ-opioid receptor, 0.18-fold±0.0561, P=0.040) compared
with in healthy controls.
The investigation of pain-modulating molecules is an important task in
pain research. The search for novel pathogenetic mechanisms involving
neuropeptides and opioids/opioid receptors should improve the man-
agement of pain in patients with RA and OA.
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Introduction  Previous studies of rheumatoid arthritis (RA) indicated
that the risk of disease in the siblings of affected individuals (lsib) is
increased twofold to 17-fold, suggesting that genetic factors are impor-
tant. Recently, five sib-paid linkage studies from Europe, North America
and Japan were published. Although there was no locus suggested by
all the studies in common, some loci were suggested by multiple
studies. Chromosome 1p36 was one such loci. Within 10 Mb cen-
tromeric from these microsatellite markers, there was a region contain-
ing clusters of enzymes that were very likely to be functionally relevant
to RA-specific autoantibody production. These enzymes were peptidyl-
arginine deiminases (PADIs). PADIs are enzymes that post-translation-
ally convert arginine residues to citrulline. Citrullination and citrullinated
peptides have been recognized to be one of the most RA-specific phe-
nomena because citrullination was revealed to be related to the most
RA-specific autoantibodies. The clinical importance of the measure-
ment of anti-citrullinated peptide antibodies and the specificity of the
autoantibodies suggest a specific role of citrullination and PADIs in RA
pathophysiology.
Methods and results We performed a case–control association study,
using single nucleotide polymorphisms discovered by the Japanese
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Table 1
Levels of RANKL, osteoprotegerin (OPG), IL-6, soluble IL-6 receptor (sIL-6R), and soluble glycoprotein 130 (sgp130) in the bone marrow of
rheumatoid arthritis and osteoarthritis patients
RANKL OPG  OPG:RANKL  IL-6  sIL-6R  sgp130  sgp130:sIL-6R  sIL-6R:IL-6 
Patients (pg/ml) (ng/ml) ratio (pg/ml) (ng/ml) (ng/ml) ratio ratio
Rheumatoid arthritis 61±50 9.9±3.3 163:1 284±370 33.7±19 195±111 5.8:1 118:1
Osteoarthritis 40±34 12.4±3.2 311:1 132±76 16.7±6.9 123±55 7.3:1 126:1
Rheumatoid arthritis  NS P<0.05 Not significant P<0.0002 P<0.009
vs osteoarthritis
NS, not significant.S25
Millennium Genome Project in the 1p36 region, containing the genes
for PADI1, PADI2, PADI3 and PADI4. We identified a RA-susceptibility
haplotype in the PADI4 gene, but no RA association in the neighboring
PADI genes. Expression of the PADI4 gene was confirmed in hemato-
logical cells by northern blot hybridization and in synovial tissue of RA
patients by in situ RT-PCR and immunohistochemistry. Moreover, the
susceptibility haplotype of PADI4 was related to anticitrullinated filag-
grin antibody levels in sera of RA patients. We then found a difference
in mRNA stability between nonsusceptibility and susceptibility variants.
Conclusions Our results imply that the RA-susceptibility haplotype of
PADI4 increases production of the citrullinated peptides that act as
autoantigens, resulting in an increase of the risk of developing RA.
Acknowledgement This work is performed with the collaboration of
several hospitals and Sankyo Co. Ltd, Japan.
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IL-10 is known for its anti-inflammatory and regulatory function on dif-
ferent cell types involved in the pathogenesis of rheumatoid arthritis.
Taking advantage of a stable intermediate phenotype (IL-10 induced by
lipopolysaccharide-stimulated blood cultures), large interindividual dif-
ferences in IL-10 production were found. In two separate large studies
including a total of >50 twins, 70% of the variation between individuals
could be explained by genetic factors. Differences in IL-10 protein pro-
duction were present at the level of mRNA production, and analysis of
the half-life of mRNA indicated that differences in transcription
accounted for the interindividual differences. To test whether the differ-
ent haplotypes were transcribed at a different rate, allele-specific tran-
script quantification was performed, and preliminary data indicated that
some donors exhibited a 1:1 region of the respective mRNA species,
and some donors a 1:1.2 ratio. To determine the length of the genomic
region associated with different production of IL-10, eight single
nucleotide polymorphisms (SNPs) and two CA repeats in the IL-10
gene, and six SNPs in the IL-10 homologues IL-19, IL-20 and IL-24
were analysed in 53 families in relation to IL-10 production. The prelimi-
nary data suggest that the region associated with differences in IL-10
production is a region of limited size around the IL-10 gene. Transient
transfection assays of the –1413 to +31 fragments of the different
haplotypes of the 5′ region of the IL-10 gene in the myeloid cell lines
U937 and Monomac6, in the B-cell line RAJI and in the T-cell line Jurkat
showed no difference in promoter activity in response to stimulation for
any of the haplotypes. However, a SNP outside this region, the
–A2849G SNP, was associated with differences in IL-10 production.
Next, a higher rate of joint destruction was observed in patients with
the genotype associated with high IL-10 production (mean joint
damage score of 20vs7; P<0.001), most probably due to higher
autoantibody titers in patients with the high IL-10 genotype.
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Objective Three independent genome scans have established the
presence of a significant systemic lupus erythematosus (SLE)-linked
locus on chromosome 16q12, which overlaps with the intervals identi-
fied in several other autoimmune diseases. To identify the putative SLE
susceptibility gene within this interval, we fine-mapped a 10 cM interval
of 16q12 containing nine densely spaced microsatellite markers
(D16S419, D16S3044, D16S409, D16S540, D16S517, D16S3136,
D16S416, D16S3034, and D16S415) using a cohort of 240 Chinese
SLE patients and their parents.
Methods Evidence for linkage disequilibrium was assessed using the
ETDT and GeneHunter programs. TaqMan real-time quantitative PCR
was used for detecting mRNA expression of a positional candidate
gene. Five single nucleotide polymorphisms (SNPs) located within the
candidate gene were genotyped by allelic discrimination-PCR using a
5′-nuclease assay.
Results Our data showed overall skewing of the transmission (t) of alleles
of maker D16S517 (P=0.000008,  Pc=0.00001) from heterozygous
parents to affected offspring, and showed preferential transmission of one
of the alleles of D16S517 to affected offspring (transmission:nontransmis-
sion=68:21,  P=0.000001,  Pc=0.00001). The marker D16S517 is
located within an intron of a positional candidate gene, OLF1/EBF-associ-
ated zinc finger protein (OAZ), which may be involved in lymphocyte early
development and regulation. Elevated levels of the OAZ gene expression
were found in SLE patients (mean ∆CT±SEM=5.21±0.85, n=42) com-
pared with in normal controls (mean ∆CT±SEM=6.22±0.95,  n=36;
P<0.001). The gene expression level of OAZ was not correlated with
SLE disease activity index scores and the treatment status. Genotyping of
five SNPs within OAZ gene introns in an extended Chinese cohort of 325
families also indicated preferential transmission of a certain four SNP
haplotypes (haplotype T-A-G-G, transmission:nontransmission=43:26,
P=0.04). Haplotypes combining SNPs and the SLE-associated
D16S517 allele showed significant association with SLE susceptibility
(transmission:nontransmission=58:15,  P=0.000001; transmission:non-
transmission=54:15, P=0.000003; transmission:nontransmission= 41:13,
P=0.000139, respectively).
Conclusion These data suggest the presence of a SLE susceptibility
gene physically close to marker D16S517 in a Chinese cohort. The
high expression of OAZ and the significant association of OAZ haplo-
types with SLE susceptibility suggested OAZ might be a novel candi-
date susceptibility gene within the 16q interval.
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Chondrocytes are critical components for the precise patterning of a
developing skeletal framework and articular joint formation. Sox9 is a
key transcription factor that is essential for chondrocyte differentiation
and chondrocyte-specific gene expressions; however, the precise tran-
scriptional activation mechanism of Sox9 is not fully understood. Here
we demonstrate that Sox9 utilizes CBP/p300 to exert its effects. Sox9
associates with CBP/p300 in chondrocyte cell line SW1353 via its
carboxyl termini activation domain in a cell type-specific manner. In pro-
moter assays, CBP/p300 enhances Col2a1, which encodes cartilage-
specific type II collagen gene, the promoter activity via Sox9. Chromatin
immunoprecipitation shows that p300 is bound to the Col2a1 pro-
moter region. Furthermore, the CBP/Sox9 complex disrupter peptide
suppresses Col2a1 gene expression and chondrogenesis from mes-
enchymal stem cells. These data demonstrate CBP/p300 functions as
a coactivator of Sox9 for cartilage tissue-specific gene expression and
chondrocyte differentiation.
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Sox9 is a transcription factor that is essential for chondrocyte development.
Previously we have shown that p300, a ubiquitously expressed co-acti-
vator, interacted with Sox9 to activate gene expression. Even though
Available online http://arthritis-research.com/supplements/5/S3S26
both Sox9 and p300 are expressed in some other tissue, it is only
chondrocyte that expresses type II collagen.
To clarify the mechanism that prevents Sox9 from activating chondro-
cyte-specific gene expression in those tissues, we examined the inter-
action between co-repressors and Sox9. Among the co-repressors,
some HDACs interacted with Sox9 both in vitro and in vivo. Over-
expression of those HDACs reduced the transcriptional activity of
Gal4-fused Sox9. TSA, but not TPX-B, caused de-repression of
transcription regulated by Sox9. These data identify Sox9 as the first
transcription factor to interact with HDACs, and suggest that HDAC
may bind to Sox9 to regulate tissue-specific gene expression.
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GATA-3 is a zinc finger protein that is preferentially expressed in
T cells in adult animals. Previous studies have shown that GATA-3 is
essential for the transition from common lymphoid precursors to the
most immature thymocytes. In addition, GATA-3 is selectively
expressed in Th2 cells. Overexpression of GATA-3 forced developing
Th1 cells to produce Th2 cytokines, including IL-4, IL-5, and IL-13.
However, it remains unclear whether GATA-3 is also important at the
later stages of T-cell development. Nor do we understand whether
GATA-3 is essential for the differentiation of Th2 cells or for the main-
tenance of the Th2 phenotype. The lack of GATA-3-deficient mice or
T cells has precluded further studies to address these important ques-
tions. We have recently generated conditional GATA-3-deficient mice.
Studies on the conditional GATA-3-deficient mice has uncovered
several novel roles of GATA-3 in regulating the development and func-
tion of T cells.
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Objective Current approaches to analyze and track disease-related
genes and proteins in synovium or in animal models for arthritis includ-
ing gene transfer models are based on RNA isolated either from cul-
tured synovial cells or from synovial biopsies. This strategy does neither
allow one to distinguish between specific gene expression of cells orig-
inating from different synovial compartments due to a potential mixture
of different expression profiles nor to track these genes or gene prod-
ucts in the synovium. Therefore, we established laser-mediated
microdissection (LMM) and differential display for analysis of gene
expression profiles of histologically defined areas in rheumatoid syn-
ovium, and established novel molecular imaging techniques to track the
molecules associated with pathogenic synovial processes.
Methods Synovial cryosections derived from different human arthri-
tides were used to obtain cell samples from distinct synovial areas
using LMM. RNA was isolated and analyzed using differential display
fingerprinting. Differential expression of identified sequences was con-
firmed by in situ hybridization and immunohistochemistry. Molecular
imaging using different fluorescence-based techniques was per-
formed to track molecules of interest such as human serum albumin-
coupled molecules and circulating cells such as T-cell hybridomas
and dendritic cells following adoptive cellular gene transfer within the
synovium.
Results Microdissected synovial tissue sections containing about 600
cells yield enough RNA for a stable, reproducible RNA fingerprint.
Several genes — known and unknown ones with regard to rheumatoid
arthritis pathophysiology — could be identified as being expressed dif-
ferentially between the synovial lining, the sublining, and the microvas-
culature (e.g. thrombospondin-4 in the lining layer, ciz-1 in the
sublining, and CD82 around the microvasculature). In addition, molecu-
lar bioluminescence-based imaging revealed that T-cell hybridomas
and dendritic cells home to the synovium. It was found that the arthritic
joint is the primary target of adoptive cellular gene transfer and that the
synovial fibroblasts are the target of albumin-coupled molecules.
Conclusion High-sensitivity molecular analysis methods such as LMM
and differential display, in combination with molecular imaging of
‘vehicle’ cells, genes and proteins of interest, present a valuable tool to
obtain novel insights into compartment-dependent synovial pathways.
In addition, the results also demonstrate the potential of these novel
analytic strategies in a nonmalignant multifactorial inflammatory
disease.
Acknowledgement  Supported by the German Research Society
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Tumor necrosis factor (TNF)-α and IL-1β belong to the key mediators in
the pathogenesis of rheumatoid arthritis (RA). Neutralization of these
cytokines with biologicals like anti-TNF (etanercept) and IL-1 receptor
antagonist (IL-1ra) (anakinra) induces a rapid and sustained decline in
disease activity in RA patients. However, about 30% of patients receiv-
ing these therapies are nonresponders.
Here we report the application of DNA array technology (Affymetrix) in
monitoring the modulation of gene expression of cells from peripheral
blood under anti-TNF (etanercept) and IL-1ra (anakinra) treatment.
Blood samples were taken from 14 RA patients before and 72 hours
after initiation of etanercept (n=10) or anakinra (n=4) therapy. Total
RNA from mononuclear cells (peripheral blood mononuclear cells) was
prepared with the RNeasy kit (Qiagen). Affymetrix chip technology was
used to analyse the expression levels. The therapy response was deter-
mined by changes in the disease activity score (DAS28) 3 months after
the start of treatment.
Under anti-TNF therapy, the expression of genes for cytokines such as
TNF-α, IL-1β, IL-1ra and PBEF, and for chemokines like IL-8, MIP-1α
and MIP-1β, as well as for other disease-associated proteins like
cyclooxygenase-2, intracellular adhesion molecule-1 and manganese
superoxide dismutase, changed differentially. Interestingly, changes in
the expression profile detected 3 days after the start of treatment were
found to be closely associated with the outcome of therapy as
reflected 3 months later by the disease activity score. Using real-time
PCR, Affymetrix data were confirmed and expression of low abundant
transcripts, which were not detected on microarrays such as IL-6, were
observed. The application of anakinra influenced the expression levels
of L-1β, IL-8, and cyclooxygenase-2 in a similar fashion, this being in
contrast to anti-TNF treatment expression levels of TNF-α, MIP-1α and
MIP-1β, which remained unchanged.
Our data give new insights into the effects of biologicals used in RA
treatment on the transcriptional level. Early expression profiling of bio-
logical treatment can be a useful tool for monitoring changes at the
mRNA level after neutralization of TNF-α and IL-1β, and thus for the
predicting the outcome of therapy at an early stage of treatment. The
data indicate the presence of genetic heterogeneities within the group
of RA patients, suggesting the presence of genetic polymorphisms in
the identified genes.
Acknowledgement Supported by BMBF (FZK 01GG0201).
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Rheumatoid arthritis (RA) is one of the complex diseases that showed
multiple progression stages. At first, inflammatory response occurs by
self-antibodies, and then the proliferation of synoviocytes is abnormally
promoted. These synoviocytes invade into articular structures and,
finally, articular cartilage is destroyed. To analyze growth-promoting
factors in synovial cells from articular tissues of RA, we performed DNA
chip analysis and compared the expression pattern of mRNA with that
of synoviocytes from osteoarthritis (OA) tissue or normal tissue. The
results showed that the expression of many genes, including some
novel genes, was upregulated in RA synoviocytes compared with OA
synoviocytes or normal synoviocytes. RT-PCR analysis and immunohis-
tochemical analysis showed that some genes and their products were
highly distributed in active synoviocytes of articular tissues of RA. Fur-
thermore, we compared the protein chip patterns of RA and OA, and
found several markers of RA. These results show the utility of chip
technology for analysis of rheumatoid disease.
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Primary osteoarthritis (OA) has a large genetic component, with heri-
tability estimates of at least 50% for most joint sites. Identifying the
genes encoding for OA susceptibility will shed considerable light on
the causes of this common debilitating disease and will suggest new
avenues for the development of novel therapeutics. My group is actively
hunting for OA susceptibility genes. We conducted the first and so far
the largest OA genome-wide linkage scan, on over 500 affected sibling
pairs ascertained by large-joint replacement surgery. We identified a
number of regions of the human genome that harbour OA susceptibil-
ity. We have been conducting extensive gene-based association
studies within these linkage intervals on a case–control cohort contain-
ing more than 2000 individuals, using single nucleotide polymorphisms
and microsatellite repeats. We are now beginning to identify the genes
that are mutated in OA. Mutations include common missense changes
and effects on gene expression. Some of the mutated genes are regu-
lators of chondrocyte development, which implies that an inability of the
articular chondrocyte to maintain a prehypertrophic phenotype may be
a critical factor in the disease. I report our latest findings within the
context of the results from other OA genetic studies.
85
New approach to chemical biology for drug
discovery: construction of new affinity beads and
their application
H Handa
Department of Biological Information, Graduate School of Bioscience
and Biotechnology, Tokyo Institute of Technology, Kanagawa, Japan
Arthritis Res Ther 2003, 5(Suppl 3):85 (DOI 10.1186/ar886)
Affinity purification is an established technique used to identify ligand-
binding proteins; however, its widespread use has been limited by the
inefficiency and instability of conventional matrices. The unstable nature
of conventional matrices narrows the spectrum of ligands that can be
used. Moreover, nonspecific binding of proteins to the solid support has
complicated identification of target proteins. Another difficulty is fre-
quent low purification efficiency, which requires partial purification of the
source material prior to affinity chromatography to improve results.
The present article describes the preparation and use of affinity beads
for identification of drug receptors. The drugs of interest are immobi-
lized to the matrix, which consists of latex beads covalently coupled
with spacers. The latex beads are composed of glycidylmethacrylate-
covered glycidylmethacrylate–styrene copolymer cores (SG beads)
that were developed originally for the affinity purification of DNA-
binding proteins. To reduce steric hindrance, divalent epoxide, ethyl-
eneglycol diglycidylether molecules are introduced to the SG beads
(SGE beads) as spacers after aminolysis of epoxy groups on the sur-
faces of the beads.
The new SGE beads offer several distinct advantages compared with
commonly used supports such as agarose beads. These advantages
have enabled us to identify drug receptors directly from crude cell
extracts within a few hours. Drug derivatives with a reactive group are
then covalently coupled to the SGE beads. Crude cell extracts are
incubated with the drug affinity beads. The desired drug-binding pro-
teins are then purified in a batchwise manner. The desired drug-binding
proteins bind to the drug on the affinity beads, while other proteins flow
through the beads. The drug-binding proteins are eluted from the affin-
ity beads with a high salt solution or a detergent containing solution fol-
lowing brief centrifugation. A typical target protein is purified more than
1000-fold with a yield of 70%. If necessary, the batchwise step can be
repeated, enabling further purification. This procedure is not only effec-
tive, but is also simple and straightforward to perform. Using the affinity
beads, we have identified multiple drug receptors, which could be uti-
lized for drug screening, drug design, evaluation of drug efficiency for a
given individual, and so on.
Poster Discussion (4) Immunology Group (1)
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Patients with active systemic lupus erythematosus (SLE) have atypical
CD19loIgD+ peripheral blood B cells that require 100-fold more anti-
immunoglobulin or recombinant CD154 to induce in vitro proliferation.
Additional phenotypic and in vitro functional analyses strongly sug-
gested that the CD19loIgD+ cells are anergic. Since anergy is one of
the mechanisms by which the function of autoreactive B cells can be
downregulated, a comparison of the productive B-cell repertoires of
CD19loIgD+ and CD19hiIgD+ subsets from the same lupus patient
was undertaken to determine whether the anergic B cells were oligo-
clonal or otherwise enriched in cells expressing genes known to
encode autoantibodies. To accomplish this, the usage of VHDJH, VkJk
and VλJλ gene elements by individual B cells was determined for each
subset. The two subsets exhibited low mutational frequencies
(CD19hiIgD+, VH=0.6%, Vk=0.05%, Vλ=0.1%; CD19loIgD+,
VH=0.2%, Vk=0.05%, Vλ=0.2%) and involved substitutions that
rarely increased the basic amino acid content. The immunoglobulin
heavy and light chain repertoires of each subset were polyclonal and
very similar. However, some differences from the normal repertoire
were noted. For example, the Vk1 family was under-represented and
Vk4 B3 and Vk5 B2 were over-represented in both subsets. Multiple
small clones (average size 3.5) were present in the VH, Vk and Vλ reper-
toires of both subsets. A large (n=32) clone using VH 4-34, D3-22 and
JH 6 gene elements, containing FR mutations, was found. Notably, it
was split two-thirds within the CD19hiIgD+ subset and one-third within
the CD19loIgD+ subset. In spite of the overwhelming similarities
between subsets, there were three distinct differences. The VH4 family
was significantly (37% versus 17%) more abundant in the CD19loIgD+
subset. Second, CD19loIgD+ VλJλ clones were two-fold more numer-
ous and more diverse in gene utilization than the CD19hiIgD+ subset.
Third, B cells utilizing Vk5 B2 genes were significantly (16% versus
7%) more abundant in the CD19hiIgD+ subset. Because of the poly-
clonal distribution of immunoglobulin heavy and light chain genes, and
the overall similarity between the two subsets, it is likely that anergy in
the CD19loIgD+ subset is not antigen specific.
Available online http://arthritis-research.com/supplements/5/S3S28
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Introduction The immunology of transplantation is of general interest,
because “it offers one of the few negotiable pathways into the central
regions of biology” (Medawar, 1957). The holy grail of transplantation
immunology is tolerance induction. This might be achieved in the clinic
by blocking the T-cell costimulation using CTLA-4Ig, a fusion protein
consisting of the extracellular domain of CTLA-4 linked to the constant
region of IgG1. CTLA-4Ig proved to be effective in prolonging the trans-
plant survival in various transplantation models [1] and in the treatment
of autoimmune diseases. CTLA-4Ig is currently under investigation in a
clinical trial to determine its safety and efficacy for patients suffering
from rheumatoid arthritis [2].
Experiment CTLA-4Ig was administered on days 3 and 4 after rat liver
transplantation in a MHC-mismatched donor–recipient combination.
We also studied the therapeutic effect of donor-specific splenocyte
transfusions on day 4 alone and in combination with CTLA-4Ig on
days 3 and 4. We achieved a prolonged transplant acceptance in the
animals receiving the combination of cells and CTLA-4Ig, and investi-
gated whether a Th1/Th2 immune deviation might be responsible for
this phenomenon.
Methods A rat liver transplantation model in a high-responder rat strain
combination was used. The Th1 cytokines IL-2 and IFN-γ and the Th2
cytokines IL-4 and IL-10 were analysed by RT-PCR.
Results CTLA-4Ig prolonged the survival of the recipients from
10 days median in the untreated control group to 30 days median.
Donor-specific splenocytes alone had no influence on the survival, but
the combination of CTLA-4Ig and donor-specific splenocytes resulted
in a survival of >150 days in all animals. A Th1/Th2 immune deviation
was not observed in the animals with long-term graft acceptance. The
Th1 cytokines IL-2 and IFN-γ and the Th2 cytokines IL-4 and IL-10
were equally expressed in the control group and in the group with pro-
longed transplant acceptance.
Conclusions The combination of CTLA-4Ig and donor-specific spleno-
cytes results in a long-term transplant acceptance (>150 days), which
cannot be achieved by CTLA-4Ig or a splenocyte transfusion alone.
The Th2 cytokines are not dominant protective in preventing the trans-
plant rejection.
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Chronic inflammation in several human autoimmune diseases, such as
rheumatoid arthritis, is driven by activated Th1 cells. The delineation of
the mechanisms controlling the evolution of Th1-mediated immune
responses in autodestructive immune reactions is therefore crucial for
the understanding of the pathogenesis of autoimmune diseases.
However, analysis of such mechanisms in humans is hampered by the
inability to address these questions directly in vivo. We developed a
novel in vivo model for human Th1-mediated inflammation and analyzed
the regulation of human Th1 inflammation in vivo. Peripheral blood
mononuclear cells (PBMC) from healthy human individuals were trans-
ferred by intraperitoneal injection into female NOD/SCID mice that lack
T cells and B cells and that express reduced natural killer cell activity.
At different time points, human PBMC were recovered from the
intraperitoneal cavity and analyzed phenotypically and functionally.
Human PBMC developed a stongly Th1-biased immune response, as
indicated by spontaneous proliferation of CD4 and CD8 T cells, by
increased expression of the T-cell activation markers HLA-DR and
CD25, and by massive expansion of IFN-γ-producing T cells. In con-
trast, Th2 cells were absent in the recovered human T cells.
Histopathological analysis revealed infiltration of activated human lym-
phocytes into the portal tracts of the liver and into the perigastrointesti-
nal and perirenal fatty tissues, which was frequently organized in
granuloma-like structures resembling Th1-mediated granulomas in
sarkoidosis or Wegener’s disease. The development of the human Th1-
biased immune response in the mice could be blocked by cyclosporine
and was dependent on antigen-presenting cells. Further analysis of the
regulation of the human Th1 immune response in vivo revealed that the
development of the Th1 immune response was tightly controlled by the
endogenously produced cytokines IL-4 and IL-10, as neutralization of
these cytokines markedly exaggerated the Th1 response. Interestingly,
treatment of established inflammation with daily intraperitoneal injec-
tions of recombinant IL-4 or IL-10 markedly decreased T-cell activation
and IFN-γ production, indicating that the anti-inflammatory cytokines
IL-4 and IL-10 are able to interrupt established human Th1-mediated
inflammation. These data suggest that potent regulatory mechanisms
involving IL-4 and/or IL-10 control the development of Th1-mediated
human inflammation in vivo, which might have an important implication
for future therapies of chronic autoimmune inflammatory diseases.
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T-cell response to type II collagen (CII) is essential in collagen-induced
arthritis, a murine model of autoimmune arthritis. Collagen-induced
arthritis is induced in mice by immunization with heterologous CII.
However, T cells in these animals respond only to heterologous CII but
not to homologous CII, suggesting T-cell tolerance to self-CII. In addi-
tion, we have found that the T-cell response to heterologous CII is also
reduced in heterologous CII transgenic mice. In this study, we crossed
the heterologous CII transgenic mice with anti-heterologous CII-
specific TCR transgenic mice to verify the mechanism of T-cell toler-
ance to self-CII. Surprisingly, T cells in the TCR and heterologous CII
double transgenic mice showed no evidence of tolerance. We found
that the transgenic TCR recognizes the heterologous CII epitope only
when lysine at position 266 is post-translationally hydroxylated. We
also found CII prepared from the joint cartilage is dominated by the gly-
cosylated form of lysine at position 266, which may result in the lack of
T-cell tolerance in the TCR and heterologous CII double transgenic
mice. These data imply the importance of post-translational modifica-
tion of CII in the induction of T-cell tolerance to self-CII.
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Does sustained downregulation of the TCRzeta
chain define the transition from antigen mode to
inflammation mode in effector T lymphocytes?
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The molecular events that define the early phase of activation and differ-
entiation of effector T cells have been well characterized. Those events
promoting the effector function of chronically activated T cells at sites of
inflammation are less well understood. Using in vitro and in vivo models,
we have explored the effects of the chronic inflammatory process on T-
cell differentiation by studying the effects of tumor necrosis factor (TNF)
Arthritis Research & Therapy    Vol 5 Suppl 3 Abstracts of the 3rd World Congress of the Global Arthritis Research NetworkS29
on T-cell activation and effector responses. These studies have revealed
that TNF-stimulated T cells resemble rheumatoid arthritis synovial T cells
since they express cell surface activation antigens, but are profoundly
hyporesponsive to T-cell receptor (TCR) engagement. This may be
explained, at least in part, by the observation that TNF selectively targets
the expression of the TCRzeta chain. Loss of TCRzeta expression per-
turbs the assembly, expression and stability of the TCR/CD3 complex,
leading to attenuation of membrane proximal tyrosine phosphorylation,
intracellular calcium mobilisation and the transcription of cytokine genes
upon TCR engagement, when compared with untreated T cells.
We set out to explore whether TCRzeta expression could be used to
identify chronically activated, hyporesponsive T cells in vivo. Using a
FACS-based assay, we have identified subsets of CD3+ T cells
expressing low levels of TCRzeta (hereafter termed TCRzetadim cells)
in the peripheral blood of healthy donors, as well as patients with
inflammatory arthritis. Subsequent experiments revealed that, when
compared with TCRzetabright cells, the TCRzetadim population is
enriched for cells expressing effector memory cell surface markers. By
staining with HLA class I/peptide tetramer complexes, CD8+TCR-
zetadim cells are enriched for antigen-specific T cells after stimulation
in vitro with specific peptide. While TCRzetadim cells are hyporespon-
sive to TCR engagement, they retain effector potential, since a signifi-
cant proportion are TNF-α and IFN-γ producers upon stimulation with
phorbol ester and calcium ionophore. In contrast, fewer produce IL-10
when compared with the TCRzetabright subset. These data suggest
that TCRzetadim T cells, which are abundant at sites of inflammation,
may represent a subset of circulating antigen experienced effector
memory cells. Sustained downregulation of TCRzeta may define a
checkpoint where the intracellular signals driving T-cell differentiation
switch from antigen mode to inflammation mode.
Acknowledgments This work was funded by the Wellcome Trust UK,
and the Arthritis Research Campaign.
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Accumulating evidences suggest that β1 integrin-dependent cell acti-
vation and migration pathways are critical points of intervention in
several inflammatory and autoimmune diseases, such as rheumatoid
arthritis (RA). Indeed, in RA patients, increased expression of β1-inte-
grins and their ligands have been reported on the surface of synovial
fluid lymphocytes and synovium cells, respectively, suggesting that β1
integrins play an important role in triggering and maintaining the inflam-
matory response of the disease.
It is reported that tyrosine phosphorylation of cellular proteins is an
early obligatory event in cell activation and signal transduction. Our
study showed that PLC-γ, focal adhesion kinase (FAK), paxillin, Fyn,
Lck, ERK1/2, and pp105 are phosphorylated on their tyrosine residues
upon engagement of β1 integrins in T cells. Moreover, we have demon-
strated that the pp105 has been shown to associate with FAK that is
autophosphorylated and activated upon the engagement of β1 inte-
grins. In addition, isolation of cDNA encoding pp105 has revealed that
this protein belongs to the Crk-associated substrate (Cas) family,
hence designated the Cas-lymphocyte type (Cas-L). Cas-L is a 105
kDa docking protein that is heavily tyrosine phosphorylated by FAK and
Src family kinases upon the engagement of β1 integrins in T cells.
Transfection of Cas-L into Jurkat T cells markedly enhances cell motility
and IL-2 production upon the engagement of β1 integrins through its
tyrosine phosphorylation. These results clearly indicate the involvement
of Cas-L in β1 integrin-mediated costimulation of signal transduction
and cell migration. Our current study on Yeast-Two-hybrid analysis
identified HTLV-I Tax and Smad-7 as new candidates for the Cas-L
binding partner. I would now like to review β1 integrin-mediated signal
transduction through Cas-L, a novel docking protein, and its role in the
pathophysiology and therapeutic intervention of RA.
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Objective Although (self)antigen-directed T cells are thought to be key
mediators of many autoimmune diseases, a functionally distinct popula-
tion of CD4+ T cells, T regulatory (Treg) cells, dominantly inhibit induc-
tion and progression of autoimmunity as shown in several autoimmune
models. In humans, the presence of Treg cells has been shown, but
their role in autoimmune disease is not known. Likewise, no (auto)anti-
gens recognized by Treg cells have yet been identified at the molecular
level. The aim of these studies is to gain a better understanding of the
identity of (auto)antigens recognized by Treg cells.
Results When analyzing the natural T-cell response against a candi-
date autoantigen in rheumatoid arthritis, human cartilage glycoprotein-
39 (HC gp-39), we found that healthy donors, although displaying a
typical Th1 reaction against a mixture of recall antigens, reacted
against HC gp-39 by production of IL-10. The IL-10 production was
mediated by CD4+ T cells. When HC gp-39-directed immunity of RA
patients was analyzed, a marked contrast was observed as Th1-like
reactivity was observed in a substantial number of patients as deter-
mined by the production of IFN-γ. More importantly, we found that HC
gp-39-directed immunity in healthy donors inhibits the T-cell response
against a mixture of recall antigens. Likewise, HC gp-39-specific
immunity as well as HC gp-39-directed, IL-10-producing CD4+ T-cell
lines were able to suppress MHC class I-restricted cytotoxic T
lymphocyte reactivity.
Conclusion Together, these data point to a disease-associated bias
in the type of T-cell response against HC Gp-39, and identify HC
gp-39 as a naturally occurring autoantigen recognised by Treg cells
in humans.
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Initial antigen contact is known to trigger an instructive developmen-
tal program by which naive CD8 T cells differentiate into effector
and memory cells. However, it remains to be determined how initial
cytokine signals act on the generation of effector and memory CD8
T cells. Here, we demonstrate that IL-12 treatment during initial
antigen contact results in the significant increase of both primary
and memory CD8 T-cell populations. These quantitative differences
were associated with qualitative changes in CD8 T cells directly
caused by IL-12. Initial IL-12 priming also improved the intrinsic
properties of memory CD8 T cells, leading to better protective
immunity and vaccine-induced memory CD8 T-cell responses. Our
results suggest that IL-12 is an important regulatory factor for devel-
opmental programming of CD8 T cells. Future application of IL-12
priming will be discussed.
Available online http://arthritis-research.com/supplements/5/S3S30
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Immunoablation (i.e. complete destruction of a patient’s autoreactive
immune system) in combination with autologous stem cell transplanta-
tion (ASCT) is used for treatment of severe autoimmune diseases. If
successful, the patients will undergo long-term remission. We have
analysed reconstitution of the immune system in such patients, to deter-
mine whether it recovers by expansion of surviving lymphocytes or
develops from stem cells de novo. During a follow-up period of up to
60 months after ASCT, one polychondritis patient and two systemic
lupus erythematosus patients in clinical remission were analysed for
reappearance of naïve, activated and memory B lymphocytes and T lym-
phocytes, for reactivity against pathogens and autoantigens, and for
presence of autoantibodies. Titers of disease-specific autoantibodies
decreased after ASCT with the half-life of secreted antibodies, and did
not reappear. Naive T cells and naive B cells reappeared and reached
normal levels within several months after ASCT. The repertoire of the
naive T cells was not restricted. The numbers and frequencies of recent
thymic emigrants (CD31+/CD45RA+/CD4+), marked by expression of
T-cell receptor recombination excision circles, equalled those of cord
blood and were considerably higher than in normal probands of the age
of the patients. Thus, the thymus is reactivated and the reconstituted
immune system rejuvenated and tolerized in those patients. The
immunological memory has to be and is indeed generated de novo.
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A complex cellular system like the human immune system only functions
in a tightly regulated balance between activation and inhibition. We there-
fore hypothesise that defects in immunosuppression might contribute to
the pathogenesis of autoimmunity in man. In our work we established a
broad basis for testing the function of various immunosuppressive mech-
anisms in health and autoimmune disease. Signals through certain CD45
epitopes are strongly immunosuppressive in vitro. We therefore hypothe-
sised that we will be able to induce anergy in CD45-treated lymphocytes.
As control we used a human leukocyte antigen DR (HLA DR) antibody
with equal inhibitory capacities on cell proliferation. We found that HLA
DR signals, but not CD45 signals, could induce lymphocytic anergy,
which was monocyte dependent. Moreover, these anergic lymphocytes
were extremely sensitive for protein kinase C-mediated apoptosis, indi-
cating that immunosuppressive mechanisms are inter-related. We are
currently studying the exact prerequisites for this new mode of anergy
and apoptosis in cells from normal donors and autoimmune patients. This
is especially interesting as we have shown in our previous work that regu-
lation of apoptosis might be disturbed, especially in systemic lupus ery-
thematosus. Shedding of activating surface molecules represents
another physiological way to prevent hyperactivation. We have recently
identified a family with a mutation close to the protease docking site of
tumor necrosis factor alpha converting enzyme in the tumor necrosis
factor receptor p55 molecule, leading to a periodic fever syndrome with
autoimmune phenomena. Based on our working hypothesis, we postu-
lated that chronically activated lymphocytes need to acquire modulated
signaling complexes with proinhibitory capacities. To test this hypothesis
we purified lipid microdomains of chronically superantigen-activated lym-
phocytes. First data seem to confirm this as we have found altered
protein composition of raft-associated proteins with inhibitory capacity.
Depletion of CD4+CD25+ regulatory T cells (Treg) in mice leads to a
polyglandular autoimmune syndrome (PGAIS). We have tested the func-
tion of Treg in normal donors, and in patients with PGAIS or only type I
diabetes mellitus. The data suggest that the function of Treg might be
compromised in patients with PGAIS. This is currently being further
analysed in more detail. In conclusion, these data clearly provide evi-
dence that a disturbance of physiological immunosuppressive mecha-
nisms might contribute to the pathogenesis of autoimmune diseases.
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A CD19lowIgD+ B-cell population that was observed in the periphery of
active systemic lupus erythematosus (SLE) patients, but not in nonauto-
immune normal individuals, was examined to determine its functional and
phenotypic characteristics. Whereas CD19lowIgD– cells in the periphery
of SLE patients are intracytoplasmic (IC) Ig+ plasma cells, CD19lowIgD+
cells are IC Ig–. In contrast to CD19highIgD+ B cells, CD19lowIgD+ B cells
are small, in the G0/G1 phase with very few cells in the S/G2/M phase or
undergoing apoptosis, remain viable in the G0/G1 phase in short-term
culture without additional stimulation, and are positive for the anti-apop-
totic gene A20. Additionally, in contrast to CD19highIgD+ B cells,
CD19lowIgD+ B cells are less activated, as assessed by lower expression
of activation markers such as CD69, CD154, CD38, CD27, CD86 and
CD11c. Moreover, CD19lowIgD+ B cells express a higher level of CD5,
CD21 and CD23 when compared with CD19highIgD+ B cells. Further-
more, CD19lowIgD+ B cells have less mutated heavy chain Ig genes as
assessed by single-cell PCR of genomic DNA, and do not express AID
when compared with CD19highIgD+ B cells. Whereas CD19highIgD+
B cells were rescued from apoptosis and driven into the S/G2/M phase
following stimulation with a low amount of anti-IgM antibody or rCD154,
CD19lowIgD+ B cells required 100-fold more stimulation to rescue them
from apoptosis and drive them into cell cycle. Of interest, CD19lowIgD+
B cells exhibit higher amounts of BCR, phosphorylated CD19 and phos-
phorylated lyn in cytoskeletal-associated membrane fractions compared
with CD19highIgD+ B cells. Clinically, the number of circulating
CD19lowIgD+ B cells in SLE patients is greater in those with normal com-
plement levels. Treatment of SLE patients with a blocking anti-CD154
antibody diminishes the presence of circulating CD19lowIgD+ B cells.
Together, these results indicate that CD19lowIgD+ cells in the periphery of
SLE patients may be a functionally anergic population of in vivo stimulated
B cells that disappear when the disease becomes quiescent.
97
Novel B-lymphocyte-deleting agents for the
treatment of autoimmune diseases: induction of
the mitochondrial pathway of apoptosis
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Background To develop new approaches for the targeted deletion of
pathogenic autoimmune B lymphocytes, we have studied a bacterial
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product, protein A of Staphylococcus aureus (SpA). We have previ-
ously discovered that SpA has the properties of a B-cell superantigen,
enabling interactions with conserved variable region framework sub-
domains of the antigen receptors of lymphocytes rather than the com-
plementarity determining region involved in the binding of conventional
antigens [1]. Exposure to SpA can induce immune tolerance affecting a
supraclonal set of lymphocytes [2].
Objective To evaluate the outcome of in vivo SpA treatment.
Results Within hours, a sequence of events is initiated only in targeted
B cells, with rapid downregulation of B-cell antigen receptor and the
coreceptors CD19 and CD21, the induction of an activation pheno-
type, and limited rounds of proliferation. Massive B-cell-specific apop-
tosis then occurs through a process heralded by the dissipation of
mitochondrial membrane potential, followed later by the induction of
the caspase pathway and DNA fragmentation. Post exposure, B-cell
apoptotic bodies are deposited in the spleen, the lymph nodes and
Peyers patches. While in vivo apoptosis does not require a death
receptor, such as Fas, recent studies have demonstrated that apopto-
sis is linked to an induced imbalance in the members of the Bcl-2
family. By microfluorimetry and deconvoluted confocal microscopy,
SpA induced a rapid depletion of Bcl-XL. There was also increased
expression and translocation of a pro-apoptotic BH3-only member,
which can form heterodimers resulting in Bax/Bak-mediated death.
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Background It has been shown that collagen II (CII) peptides com-
plexed with human leukocyte antigen-DR4/1 and recognized by a spe-
cific αβ T-cell receptor (TCR) lead to T-cell activation. This is probably
the initial event in pathogenesis of collagen-induced arthritis (CIA).
Substitution of the TCR binding residues of CII peptides gives rise to
altered peptides that were unable to bind to the TCR. The altered pep-
tides may abolish CII-mediated T-cell activation and CIA.
Objective To evaluate the inhibitory effect of a panel of seven peptides
with single or combined substitutions of TCR binding residues (Glu267-
Lys270) of CII on T-cell activation, and to examine the role of the altered
CII peptides in CIA.
Methods IL-2 production by T cells cocultured with native CII peptide
and the seven altered peptides was measured and analyzed. One of
the altered peptides (P268–270) with the best inhibitory effect on IL-2
secretion was injected subcutaneously (50µg, 3 day interval) into the
CIA Wistar rats after onset of arthritis. Subsequently the swollen joint
score and severity of arthritis were evaluated.
Results All seven altered peptides significantly inhibited IL-2 produc-
tion to a different extent, compared with control peptide (P<0.05 or
P<0.001, respectively). In the CIA model study, the swollen joints
score was much lower in rats receiving the altered P268–270 peptide,
compared with control rats (P<0.01). The swollen joints of CIA rats
waned 1–3 days earlier in the altered peptide group than in the
control rats.
Conclusion Altered CII peptide with substitution of TCR binding
residues inhibited T-cell activation and CIA. This might potentially be a
novel therapeutic approach in rheumatoid arthritis.
Poster Discussion (5) Immunology Group (2)
99
Multiplex autoantibody profiling using ‘synovial
proteome’ microarrays identifies citrulline-
modified peptides as major targets of the
autoimmune response in rheumatoid arthritis
W Hueber1, BJ Lee1, M Genovese1, W van Venrooij2, 
L Steinman3, PJ Utz1, WH Robinson1
1Division of Immunology and Rheumatology, Stanford University School
of Medicine, Stanford, California, USA; 2Department of Biochemistry,
University of Nijmegen, The Netherlands; 3Department of Neurology,
Stanford University School of Medicine, Stanford, California, USA
Arthritis Res Ther 2003, 5(Suppl 3):99 (DOI 10.1186/ar900)
Introduction Proteomics approaches to comprehensively characterize
the spectrum of B-cell autoreactivity in autoimmune diseases are an
exciting new area of research. We have developed autoantigen micro-
arrays for multiplex autoantibody profiling, and have previously demon-
strated specific and sensitive detection of autoantibodies in a variety of
autoimmune diseases, including systemic lupus erythematosus,
Sjögren’s disease and mixed connective tissue disease [1]. Rheumatoid
arthritis (RA) is an autoimmune disease affecting 0.8% of the world pop-
ulation, driven by as yet unidentified autoantigens. Recent research sug-
gests that deimination of certain proteins gives rise to immunogenic
epitopes that may play a key role in RA autoimmunity. This post-transla-
tional modification is characterized by the conversion of the amino acid
arginine to citrulline, catalyzed by peptidyl arginine deiminase.
Objective We use our 1344-feature ‘synovial proteome’ antigen
microarrays to test the hypothesis that microarray-based specific
detection of autoantibodies against candidate antigens enables diag-
nosis and classification of RA.
Methods Our 1472-feature synovial proteome microarrays contain
more than 300 distinct proteins and peptides, representing putative
autoantigens in RA. Antigens include native and citrullinated fibrinogen,
vimentin and keratin, citrulline-modified filaggrin and fibrinogen peptides,
heterogeneous nuclear ribonucleoprotein (hnRNP)-B1, hnRNP-D, and
overlapping hnRNP-A2 peptides, collagen type I, type II, type III, type IV
and type V, overlapping human cartilage glycoprotein-39 peptides,
several heat shock proteins and the endoplasmic reticulum molecular
chaperone BiP, glucose-6-phosphate isomerase, acetyl-calpastatin, and
many other antigens.
Results Statistical algorithms demonstrated specific reactivity in RA
sera against combinations of citrulline-modified filaggrin and fibrinogen
peptides as well as deiminated proteins, but not against corresponding
control peptides and proteins containing native arginine residues. Array
analysis of two separate cohorts of RA patients and control patients for
reactivity against panels of deiminated proteins and peptides provided
a sensitivity of 45% at a specificity level of 95% for the diagnosis of
RA. Reactivity against other antigens was observed but not specific.
Summary The data suggest that multiplex autoantibody profiling allows
for the specific and sensitive detection of autoantibodies directed against
citrulline-modified filaggrin peptides and other deiminated polypeptides in
RA. Array-based studies are underway to determine the fine specificity of
autoimmune responses against panels of citrulline-modified peptides.
Reference
1. Robinson WH, et al.: Nat Med 2002, 8:295-305.
100
Antileukoproteinase: modulation of neutrophil
function and therapeutic effects in anticollagen II
antibody-induced arthritis
H Burkhardt1, B Sehnert1, A Cavcic1, B Boehm1, K Nandakumar2,
R Holmdahl2
1Department of Internal Medicine III, University of Erlangen–Nuernberg,
Germany; 2Section for Medical Inflammation Research,CMB, Lund
University, Sweden
Arthritis Res Ther 2003, 5(Suppl 3):100 (DOI 10.1186/ar901)
Background Secretory leukocyte protease inhibitor, or antileukopro-
teinase (ALP), is a physiological inhibitor of granulocytic serine proteases.
Available online http://arthritis-research.com/supplements/5/S3S32
Objectives The aim of the present study was to investigate the thera-
peutic effects of ALP in an arthritis model induced by the transfer of
monoclonal antibodies (mAbs) to collagen type II (CII). Upon binding to
the intact cartilage matrix, the intraperitoneally injected CII-specific
mAbs provoke a massive infiltration of neutrophils into the joints and
induce the development of an acute polyarthritis, leading to cartilage
and bone destruction.
Methods For arthritis induction, the combination of two mAbs to CII
(CIIC1 and J1) were injected intraperitoneally into QB mice. After
3–4 days, untreated mice developed a polyarthritic disease. Arthritis
severity was quantified by clinical scoring. The therapeutic effects of
ALP upon systemic therapy with recombinant ALP (daily doses of
0.1mg for 1 week, starting immediately after disease induction) were
analyzed in a cohort of 12 mice in comparison with in untreated con-
trols (n=12).
Results First, ALP treatment resulted in a 50% reduction of arthritis
incidence. Also, a marked amelioration of arthritis severity resulting in
the reduction of clinical scores below 50% of untreated controls was
observed in ALP-treated mice (P<0.05). Finally, histopathological
analysis of the joints revealed a protective effect of ALP treatment on
cartilage and bone.
A concomitant functional analysis was performed in an in vitro system of
Fc-receptor-stimulated neutrophils to elucidate immune-complex-depen-
dent pathways that might be modulated by ALP treatment. In this model of
neutrophil stimulation by IgG-coated Latex beads, a marked inhibitory
effect of ALP on the induction of the conformational change of the leuko-
cyte integrin LFA-1 into its active form could be demonstrated. Beyond
this modulatory effect of ALP, affecting neutrophil adhesion to cytokine-
activated endothelium, additional inhibitory effects could be demonstrated
on the phagocytosis of immune complexes and the oxidative burst.
Conclusions Taken together, the data indicate the therapeutic poten-
tial of ALP in the model of CII mAb-induced arthritis. Besides its
antiprotease activity ALP seems to exert a variety of additional blocking
effects on neutrophil functions such as adhesion, phagocytosis and
respiratory burst, suggesting that it might be an important multifunc-
tional regulator of inflammatory responses.
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Complement traditionally represents the first line of defense against
infections. More recently, complement was shown to play a role in
shaping the repertoire of the immune response. However, it is well
established that uncontrolled and excessive complement activation sig-
nificantly contributes to diverse pathologies ranging from inflammation
to autoimmune tissue injury and injury that follows ischemia, hypoperfu-
sion and reperfusion. In addressing the role of complement in tissue
injury, two central questions arise: how complement is activated in
each type of injury, and to what extent is complement activation
responsible for tissue injury? To obtain insight into these questions, we
have adopted a mesenteric ischemia/reperfusion (IR) model of tissue
injury because the local intestinal damage is associated with comple-
ment activation and recruitment and activation of neutrophils. Because
immunoglobulin-deficient, RAG-1–/– mice are protected from IR injury,
and because some Cr2–/– mice have limited numbers of B1 B cells, we
asked whether Cr2–/– mice have an altered response to IR injury.
Cr2–/– mice are protected from IR injury that is completely restored
after injection of normal IgG and IgM. In addition, antibodies with speci-
ficities against negatively charged phospholipids and DNA attach to
injured tissue and activate complement, resulting in damage. Finally,
transfer of normal B cells into the Cr2–/– mouse also restores IR-
induced tissue damage. We propose that certain autoantibodies, pro-
duced by B1 cells and constituting part of the natural antibody
repertoire, bind to cryptic antigens expressed by injured cells and
tissues, activate complement and effect tissue damage.
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Introduction Chronic inflammation is often accompanied by the forma-
tion of ectopic lymphoid tissue, including infiltrations of T lymphocytes
and B lymphocytes, and formation of follicular structures around a
network of follicular dendritic cells (FDCs). Ectopic follicular structures
may serve as survival niches for undesirable B-cell clones, and FDCs
provide powerful survival signals to B lymphocytes [1]. There is broad
consensus that FDCs show phenotypic overlap with fibroblasts and are
of mesenchymal origin, but the formation of FDCs is poorly understood
and a FDC-precursor cell has not been identified [2]. It has been
shown in mice that the expression of members of the tumor necrosis
factor receptor family, especially of the receptor for lymphotoxin-beta
(LTβR), on FDC precursors is a condition for FDC maturation.
Objectives This study aims to identify precursor cells for FDCs, and to
elucidate the crucial steps that induce FDC networks both under physi-
ological and pathological conditions.
Materials and methods Fibroblast-like synoviocytes (FLS) derived
from synovial biopsies of the knee joint of patients with rheumatoid
arthritis (RA) or control arthritides, and fibroblasts from human skin and
tonsils were cultured in vitro as described previously [1]. Mesenchymal
stem cells (MSC) were cultured from human bone marrow biopsies.
The expression of LTβR (as a minimal characteristic of FDC precur-
sors), and of DRC-1 and CD21L (FDC-specific markers) was studied
with both immunocytochemical staining (LTβR and DRC-1) and RT-
PCR (CD21L).
Results None of the FLS or fibroblasts expressed LTβR, DRC-1, or
CD21L, either spontaneously or after coculture with IFN-γ, IL1-β, tumor
necrosis factor alpha, LTα1β2 (gift from Dr Jeff Browning), or combina-
tions thereof. These data suggest that resident tissue fibroblasts or FLS
do not contain significant numbers of FDC precursors. In contrast, pre-
liminary experiments with cultured MSC indicate that these cells express
the LTβR. Further studies are underway to see whether and under what
conditions MSC can be induced to develop the FDC phenotype.
Conclusions Precursors of FDCs could neither be found in resident
tonsillar or dermal fibroblasts, nor in FLS cultured from patients with RA
or other types of arthritis. Of interest, in vitro cultured MSC do express
the LTβR, and hence fulfill a basic criterion of a putative FDC precursor.
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The MHC-dependent presentation of processed tissue-specific self-
antigens maintains peripheral (extra-thymic) tolerance but also can lead
to activation of autoreactive T cells. Although hematopoietic antigen-
presenting cells have been shown to participate in these processes,
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the isolation and characterization of the specific cells responsible for
mediating such diverse events has not yet been accomplished. We
have analyzed the presentation of an endogenous, gastric-specific
H+/K+-ATPase peptide by dendritic cells (DC) in the context of the
MHC class II molecule I-Ad. DC (CD11c+, MHC class IIbright,
CD80low, CD86+/–, CD40+/–) were isolated from the draining gastric
lymph node (gDC) and from the peripheral lymph node (pDC) or
mesenteric lymph node (mDC) of unmanipulated healthy BALB/c mice.
Isolated DC were then assessed for their capacity to induce IFN-γ syn-
thesis by the H+/K+-ATPase-specific CD4+ T-cell clone TXA-23. In
contrast to pDC or mDC, gDC significantly increased IFN-γ production
by TXA-23. Visual evidence for the uptake of H+/K+-ATPase by DC in
the stomach and their apparent migration to the draining lymph node
(LN) was obtained by immunofluoresence staining and confocal
microscopy analysis. Using a monoclonal antibody (2G11) against the
H+/K+-ATPase beta-subunit, H+/K+-ATPase was consistently detected
within CD11c+ DC in gastric LN sections but not in peripheral LN sec-
tions. In addition, we were able to detect CD11c+ DC in close proxim-
ity to H+/K+-ATPase-positive parietal cells in the stomach mucosa.
Upon the induction of experimental autoimmune gastritis, DC were
found among the first cells to infiltrate the stomach mucosa. Moreover,
proportions as well as absolute numbers of DC, along with B cells,
were found to be substantially increased in the gastric LN but not in the
peripheral LN at later timepoints. In line with this, the frequency of
H+/K+-ATPase staining in CD11c+ cells selectively increased in the
gLN. Analysis of DC function further suggests that overall gDC presen-
tation of H+/K+-ATPase increases in diseased animals. These results
provide the first clear identification of DC as the cells involved in the
uptake and presentation of a tissue-specific antigen in normal animals,
and the augmentation of such presentation during the development of
overt autoimmune disease.
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To further understand the role of dendritic cells (DCs) in the immune
tolerance mechanism, we examined the phenotypic distribution and
cytokine profiles of DCs in Payer’s patch, separate from an orally toler-
ized collagen-induced arthritis (CIA) model.
Oral tolerance was successfully generated at 5 weeks after first immu-
nization with type II collagen (CII), showing that the joint inflammations
were significantly subdued in the CIA mice model after six times
repeated administration of soluble CII (100µg) at 2 day intervals. The
distribution of DC subtypes was evaluated by confocal microscopy,
labeled with fluorescent-tagged antibodies of CD8α (lymphoid DC)
and CD11b (myeloid DC) markers. The production and expression of
IL-10 and IL-12 cytokines in each DC subsets were examined by FACS
analysis and confocal microscopy.
In tolerized mice, CD11c(pan DC)+CD11b DCs were clearly present
within the subepitherial dome region of Peyer’s patch and
CD11c+CD8α DCs were not significantly localized in the interfollicular
region. These finding is quite comparable with normal controls or CIA
animals.
When the DCs were cocultured with T cells for 3 days in the presence
of CII, IL-10-producing CD11b+ DCs were increased and IL-12-pro-
ducing DCs were decreased in tolerized mice. CD4+CD25+ T cells in
Peyer’s patch were also induced by consecutive CII stimulation in toler-
ized mice, not in control and CIA model mice. We found that the IL-10-
producing DCs and CD4+CD25+ T cells in tolerized mice were
successfully generated by in vitro culture with CII antigen stimulation.
In conclusion, the data suggest that induction of antigen-specific
myeloid DCs and CD4+CD25+ T cells in Peyer’s patch plays a very
important role in initiation of the oral tolerance mechanism.
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Background and objective Mesenchymal stem cells (MSCs) are bone
marrow-derived progenitor cells, widely investigated for their potential
for differentiation towards multiple lineages, such as osteocytes and
chondrocytes. Recently, we and other workers showed that MSCs
exhibit immunosuppressive properties inducing in vivo tolerance of
T lymphocytes towards allogeneic cells. Moreover, these cells can be
easily genetically modified to express ectopic molecules, such as anti-
inflammatory cytokines. Here, we investigate whether naive and IL-10-
expressing MSCs could display an inhibitory effect towards
self-reactive T lymphocytes in vitro, and could have a biological effect
in the murine model of collagen-induced arthritis (CIA).
Methods We used the murine C3H10T1/2 cell line (C3 MSCs) and
we derived cell clones stably expressing vIL10 (C3-IL10 MSCs).
Secretion of IL-10 was measured in cell culture supernatants by ELISA,
and its immunosuppressive effect was evaluated on the proliferation of
T lymphocytes in a mixed lymphocyte reaction. In the CIA model, C3
MSCs or C3-IL10 MSCs (106 cells) were intravenously injected on the
day of immunization with collagen, and secretion of vIL10 was moni-
tored in the mouse sera during the overall experimental period.
Results First, we tested in vitro the functionality of C3-IL10 MSC clones.
Secretion of vIL10 by C3-IL10 MSCs was up to 500pg/106 cells per
24 hours, and the antiproliferative activity of these MSCs on alloreactive
T lymphocytes was twofold higher than C3-MSCs. Second, we evaluated
the potential immunosuppressive role of MSCs in the CIA murine model.
Using both clinical, radiological and histological analysis, we showed that
disease progression was reduced when MSCs were injected.
Conclusion In this study, we demonstrate that the immunosuppressive
role of MSCs might be of therapeutic value in CIA, and that MSCs may
be used to systemically express anti-inflammatory cytokines
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Introduction Patients who receive organ transplants need life-long
immunosuppression to prevent rejection of their grafts. Induction of
immunological tolerance to the transplanted organs can solve this
problem. However, according to the current opinion in clinical
immunosuppression, administration of cyclosporin A (CyA) prevents
tolerance induction.
In our study, we attempted to find out whether immunosuppression
with CyA is really so harmful for tolerance induction.
Methods We established a high-responder (DA-Lew) kidney transplant
model in rats.
DA kidneys were grafted into unilaterally nephrectomized LEW receiv-
ing no immunosuppression or low (1.5mg/kg), medium (3.0mg/kg) or
high (15mg/kg) CyA for 10 days.
To rule out nephrotoxic effect of CyA, the original DA grafts were
replaced by secondary DA kidneys 30 days after first transplantation;
secondary grafts were followed for 90 days. During the second engraft-
ment, no immunosuppression was administered.
Results Surprisingly, we observed a dramatic difference in secondary
graft survival depending on the dose of immunosuppression. Animals that
had received an initial graft with low-dose CyA survived indefinitely.
Almost no alloantibodies were detectable. By contrast, increased
(3.0mg/kg×10 days) or high-dose (15mg/kg×10 days) immunosup-
pression after first engraftment did not result in acceptance of secondary
grafts. Animals in those groups developed acute rejection of secondary
grafts. High levels of alloreactive antibodies were also detected.
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Discussion Immunosuppression with CyA does not prevent immunologi-
cal tolerance by itself. Rather, higher doses of CyA have a detrimental
effect on tolerance induction. CyA in low doses acts as tolerance inducer.
Whether this sharp dose-dependent effect of CyA on tolerance induc-
tion is a general effect of immunosuppressive agents or is restricted
only to CyA is still to be examined.
107
Antigen-specific suppression of inflammatory
arthritis by dendritic cells
R Thomas, E Martin, B O’Sullivan
Centre for Immunology and Cancer Research, University of
Queensland, Brisbane, Australia
Arthritis Res Ther 2003, 5(Suppl 3):107 (DOI 10.1186/ar908)
Purpose Antigen-specific suppression of a previously primed immune
response is a major challenge for immunotherapy of autoimmune
disease. We have shown that NF-κB inactivation in dendritic cells
(modified DC) converts them into cells that tolerize rather than immu-
nize to specific antigen [1]. Antigen-exposed modified DC prevent
priming of immunity, and they suppress previously primed immune
responses. Regulatory CD4+ T cells, which can transfer antigen-spe-
cific tolerance in an IL-10-dependent fashion, mediate the tolerance.
We hypothesized that modified DC exposed to arthritogenic antigen
would suppress clinical arthritis after disease onset.
Methods Antigen-induced arthritis was induced in C57/Bl6 mice by
priming to methylated bovine serum albumin (mBSA) antigen followed
by challenge injection of mBSA to one knee. Knee swelling was appar-
ent within 2 days, with peak clinical signs apparent at 5 days. Mice
were treated with antigen-exposed modified DC between 2 and 6 days
after mBSA challenge to the knee joint.
Results Clinical arthritis was suppressed in each group receiving
mBSA-exposed modified DC within 4 days compared with mice that
received either no DC or keyhole limpet hemocyanin-exposed modified
DC. Clinical improvement was associated with mBSA-specific toler-
ance in mice receiving mBSA-exposed modified DC. Tolerance induc-
tion was not impaired by concomitant administration of anti-tumor
necrosis factor alpha monoclonal antibody. Subsequent rechallenge
with intra-articular IL-1 induced flare of arthritis in all groups, which
could be effectively suppressed by a second administration of mBSA-
exposed modified DC.
Conclusions The data indicate that modified DC induce antigen-spe-
cific immune suppression in this model of inflammatory arthritis, even
after full clinical expression of the disease. These observations have
important implications for antigen-specific therapy of autoimmunity.
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Fas (CD95/Apo-1) is a cell surface death receptor belonging to the
tumor necrosis factor receptor super family. Fas can transduce an
apoptosis-inducing signal in cells when stimulated by Fas ligand (FasL)
or by agonistic anti-Fas monoclonal antibodies. Mice with Fas-defective
lymphoproliferation and with FasL-defective generalized lymphoprolifer-
ative disease (gld) mutations develop autoimmune disease and lym-
phoadenopathy, indicating that the death receptor Fas is a functional
molecule in eliminating either autoreactive peripheral T lymphocytes
and B lymphocytes or tumor cells. On the contrary, Fas has been also
regarded to work as an inducer of tissue damage in fulminant hepatitis,
graft-versus-host disease and tissue-specific autoimmune disease. In
vivo stimulation of Fas by administration of different agonistic anti-
mouse Fas monoclonal antibodies (mAbs) also induces opposite bio-
logical effects in mice. Administration of antimouse Fas mAb Jo2 killed
mice within 5 hours by causing fulminant hepatitis with hemorrhage,
while administration of antimouse Fas mAb RK8 to FasL-deficient MRL-
gld/gld mice, which never kills mice, not only reduced the autoimmune
symptoms including nephritis, arthritis and vasculitis, but also reduced
lymphoadenopathy.
I shall propose a strategy for therapeutic use of a novel agonistic anti-
Fas monoclonal antibody HFE-7A for autoimmune disease including
rheumatoid arthritis and other diseases including cancer. Antihuman
Fas mAb HFE7A, which cross-reacts with Fas of various mammals,
ranging from humans to mice, can induce apoptosis in vitro both in
human and mouse Fas-expressing T-cell lines. Moreover, HFE7A
shows very interesting in vivo effects of inducing Fas-mediated apopto-
sis in lymphocytes including mouse thymocytes and abnormal gld
T cells and for inhibiting Fas-mediated fulminant hepatitis induced by
Jo2. Not only mice, but also monkeys given a high dose of HFE7A
never showed liver injury. In vivo therapeutic effects of humanized anti-
Fas mAb HFE7A against human rheumatoid arthritis and human adult
T-cell leukemia in SCID mice will be also summarized.
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The role of Fcγ receptors and complement in various immune complex-
mediated diseases has been debated for a long time. The advent of
gene knockout technology as well as the characterization of different
Fc and complement receptors as well as new cytokines have now
allowed one to dissect the different pathogenetic elements of innate
immunity in the autoimmune inflammatory response.
Using various murine knockout models, in particular Fcγ receptor-defi-
cient, mast cell-defective animals as well as complement-deficient
animals, during the past years we have demonstrated that FcγRIII and
the C5a receptor are both critical for induction of immune complex-
mediated vasculitis. In several studies it became clear that mast cells
have a critical role in initiation in some of the inflammatory processes.
This has also been demonstrated for rheumatoid arthritis meanwhile.
On these mast cells, again, FcγRIII is the critical activating receptor
used by immune complexes. When examining the effects of immune
complexes in glomerular mesangial cells as well as glomerular base-
ment membrane nephritis, we could show that IgG immune complexes
had opposing regulatory effects on FcγRII and FcγRIII receptors in
glomerular mesangial cells. Whereas activation by tumor necrosis
factor alpha/IL-1β induces substantial FcγRII expression, IFN-γ showed
a complete downregulation of FcγRII. At the same time, IFN-γ induced
the Fc receptor γ-chain as well as the low-affinity IgG receptor FcγRIII.
Triggering of FcγRIII again induced chemoattractant protein 1, MCP-1,
MCP-5 and RANTES. Examining the regulatory role in the cooperation
of Fcγ receptors and complement in interstitial pneumonitis, we could
demonstrate that C5a is critical in amplifying the inflammatory response
to IgG. On one hand, C5a is important in downregulating the inhibitory
FcγRII; on the other, inducing the activating FcγRIII. Altogether, the dis-
section of the different innate components of pathogenesis allows for
new strategies to intervene in this inflammatory process.
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The Crk-associated substrate lymphocyte type (Cas-L) is a docking
protein that is heavily tyrosine phosphorylated by FAK and Src family
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kinases upon the engagement of β1 integrins in T cells. Transfection of
Cas-L into Jurkat cells markedly enhances cell motility and IL-2 produc-
tion by engagement of β1 integrins through its tyrosine phosphoryla-
tion. These results clearly indicate the involvement of Cas-L in
β1-integrin-mediated costimulation of signal transduction and cell
migration. We have recently reported that expression of Cas-L is
markedly elevated in human T-lymphotropic virus type I (HTLV-I) tax
transgenic mouse, a murine model for rheumatoid arthritis, as well as in
rheumatoid arthritis patients.
In the present study, we show the interaction of Cas-L and Tax, and its
biological significance in detail.
We initially found that tyrosine phosphorylation as well as the expres-
sion of Cas-L was markedly elevated through the induction of HTLV-I
Tax protein in JPX-9 cells, in which Tax is induced under the control of
metallothionein promoter. Biochemical study showed that autophos-
phorylation of Src family PTKs, fyn and lck, were significantly enhanced
in correlation to tyrosine phosphorylation of Cas-L. Consistent with our
previous result, it was revealed that those cells had remarkably
increased motile behavior on a fibronectin-coated Transwell insert.
A two-hybrid screen for Cas-L binding proteins resulted in identification
of Tax as one of the candidates for Cas-L binding partners. We subse-
quently confirmed protein–protein interaction of Cas-L and Tax using
an overexpression experiment and HTLV-I transformed T-cell lines.
Finally, expression of Cas-L was found to inhibit Tax-mediated trans-
activation of NF-κB, whereas it has virtually no effects on Tax-mediated
trans-activation of HTLV-I LTR.
To date, HTLV-I has been associated with a variety of diseases affect-
ing organs other than malignancies arising from the lymphoid system.
Those chronic inflammatory diseases involve the nervous system in
HTLV-I-associated myelopathy, the eyes in HTLV-I-associated uveitis,
the salivary glands in Sjögren’s syndrome, and the articular joints in the
case of HTLV-I-associated arthropathy.
These results may present the basis for a pathological role as well as for
therapeutic application of Cas-L in HTLV-I-related inflammatory diseases.
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Introduction Chronic joint inflammation, as in the case of rheumatoid
arthritis (RA), is characterized by an aseptic disease course. Nonethe-
less, free nucleic acids of bacterial origin are readily found in the
inflamed synovial fluid of RA patients. The aim of the present study was
to assess the potential of exogenous and endogenous nucleic acids to
trigger joint inflammation in a healthy joint.
Materials and methods Isolated and highly purified bacterial DNA,
viral dsRNA, and endogenous mitochondrial (mt) and nuclear DNA, as
well as synthetically produced homologues of these molecules, were all
assessed for their in vitro and  in vivo inflammatogenic potential. In
addition, the intracellular pathways involved in the resulting inflamma-
tory cascades were investigated.
Results Bacterial DNA-triggered inflammatory joint responses were
primarily mediated by macrophages and their products (tumour necro-
sis factor). This inflammation was due to the cytidine phosphate guano-
sine content of DNA, which, as we have previously shown, promotes
both macrophage and polymorphonuclear leukocyte activation and pro-
duction of proinflammatory cytokines. Endogenous mtDNA but not
nuclear DNA also gave rise to joint inflammation. However, in this case
we have shown that the additional driving force for the inflammation is
the oxidation status of the DNA. Importantly, mtDNA was readily
detected in synovial fluid of a great majority of patients with RA. Finally,
dsRNA of both synthetic and viral origin gave rise to joint inflammation,
characterized by influx of both macrophages and T lymphocytes. In
vitro, dsRNA induced NF-κB activation and production of chemokines
and cytokines.
Conclusion The capacities of endogenous and exogenous nucleic
acids to promote joint inflammation depend on the occurrence of cyti-
dine phosphate guanosine moieties, on the oxidation status of the
DNA, and on the double stranded configuration of RNA. These finding
indicate the regulation of inflammatory responses in the joint by specific
interactions between certain exogenous as well as endogenous nucleic
acids and host cells expressing Toll-like receptor 3 and Toll-like
receptor 9.
Poster Discussion (6) RA Group (1)
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Background At the onset of juvenile rheumatoid arthritis (JRA), its
common features including joint damage and cartilage destruction are
absent. Therefore the onset of JRA is often assessed as an event of
arthritis associated with infections (AAI), which precludes an early initi-
ation of aggressive treatment with disease-modifying antirheumatic
drugs to have an impact on the formation of joint destruction mediated
by cathepsins and matrix metalloproteinases (MMPs).
Objectives To determine the differences in serum activity of joint
destruction enzymes between different types of inflammatory arthritis
for differential diagnosis and management of JRA.
Methods The activity of some kinds of cathepsins (B and L) by the
Barrett and Kirschke method, using L-Arg-Arg-MCA and L-Phe-Arg-
MCA as substrates and CA-074 as a selective inhibitor of cathepsin B,
and the general activity of MMPs by the method of Nagase, using
MCA-Pro-Leu-Gly-DPA-Ala-Arg-NH2 as substrate, was measured in
serum of 45 established JRA cases including relapses of disease com-
pared with 23 AAI cases, two cases of lupus-associated arthritis, two
cases of arthritis associated with ankylosing spondilitis, and 10 healthy
children.
Results On admittance to the hospital, all investigated enzyme serum
activity was higher in the group of children with JRA compared with the
healthy controls (P<0.001) and the AAI group (P>0.05) and had no
differences from cases of lupus-associated arthritis and of arthritis
associated with ankylosing spondilitis. But in advanced JRA cases with
marked proliferative changes in the joint tissues, the initial enzyme
activity was lower and increased under the treatment (P<0.001 for
cathepsin L, P>0.05 for MMP).
Conclusion Determining the activity of joint destructive proteinases in
serum could be useful for differential diagnosis between JRA and AAI
cases. Unreliable differences between these groups in our study may
be explained by finding debut JRA cases in the AAI group that could be
solved under follow-up study. Low initial activity with following increas-
ing activity under the treatment has to be suspected to the predisposi-
tion to the proliferative changes in the joint tissues required more
intensive treatment.
Acknowledgement Prof N Katunuma kindly presented CA-074.
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We have undertaken a number of investigations of the rheumatoid
nodule. The infiltrating cell populations are activated macrophages
migrating centrally to the palisade, and a diffuse infiltrate of T cells that
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tend to cluster outside the palisade. In this area we have also demon-
strated the presence of putative dendritic cells, suggesting the poten-
tial for presentation of local antigen within the nodule. Macrophages
within the nodule stain positively for tumour necrosis factor and IL-1.
We have recently used RT-PCR to demonstrate the presence of mRNA
for INF-γ but not IL-4 or IL-5. Monokines included IL-12, IL-15 and IL-
18 as well as tumour necrosis factor alpha and IL-1β. We interpreted
this as best fitting a Th1 profile.
As well as similarities, there are significant differences between the
nodule and the synovial lesions of rheumatoid arthritis. A notable differ-
ence is the lack of B cells and lymphoid follicles in the rheumatoid
nodule. Thus, we were able to demonstrate expression of the follicular
dendritic cell-specific gene CD 21L in synovial membranes but not in
the nodule. However, the chemokine SLC was present in both lesions,
as was BCA-1, despite the absence of B cells in the nodule. Similarly,
lymphotoxin alpha and lymphotoxin beta, which are important in follicle
formation, were present in both lesions. Expression of the SLC recep-
tor CCR7 was rare, but an alternative receptor, CCBP2, was present in
both lesions. CXCR5, the BCA-1 receptor expressed by B cells, was
present in the synovium. Thus, expression of chemokines for B cells
and key cytokines important to follicle formation are present in both the
nodule and synovial membrane. Therefore, other differences must
explain the lack of B cells and follicles in the nodule.
The data suggest that the destructive inflammatory processes in the
nodule and the synovial membrane may be essentially similar T-cell-
driven lesions. Discovering the basis of differences such as the lack of
B cells and follicles in the nodule may help the definition of important
aspects of the inflammatory process in rheumatoid arthritis.
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Background Collagenous colitis (CC), discovered by the Swedish
pathologist Claes Lindström in 1976 [1], is characterised clinically by
chronic watery diarrhoea, and a macroscopic normal colonic mucosa,
where characteristic changes are found microscopically. CC is most
prevalent in middle-aged women and has frequently been associated
with connective tissue diseases, including rheumatoid arthritis (RA) [2].
Objectives To confirm the occurrence of RA in a large series of CC,
and to search for distinguishing clinical features and possible clues to
the connection.
Method Retrospective chart review and follow-up examination of
patients a large referral center.
Results A registry of CC at the Örebro University Hospital contains
163 patients [3]. Sixteen of these patients had a previous diagnosis of
RA. Fifty-three of the patients were residents of the immediate catch-
ment area, and among them eight patients with RA have been identi-
fied, all women. The onset of RA preceded that of CC in seven out of
eight patients by between 1 and 34 years. In the remaining case, CC
started 14 years before RA. Radiographic erosions were present in six
out of eight patients, rheumatoid factor in three out of eight patients,
and seven out of eight patients fulfilled the ACR criteria for RA. Four
out of eight patients had first-degree relatives with RA. Four out of
eight patients had extra-articular manifestations, and three out of eight
patients had monoclonal IgG components in the blood. Three out of
eight patients had Sicca syndrome or full-blown Sjögren’s syndrome.
Conclusions We confirm the occurrence of RA in at least 10% of a
large series of CC, usually present before the onset of CC. This is
further evidence for a real correlation rather than mere coincidence.
We were not able to find any distinguishing features of RA, but it is
suggested that familial RA and extra-articular manifestations are
common. RA as such, or remedies used to treat RA, may contribute to
the pathogenesis of CC
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Apoptosis of the cell is important for the pathogenesis of autoimmune dis-
eases. We identified the death receptor 3 (DR3) gene, a family of apopto-
sis-inducing Fas gene6, containing four single nucleotide polymorphisms
and one locus of a 14-nucleotide deletion within exon 5 and intron 5. This
haplotype resulted in insertion of a portion of intron 5 into the coding
sequence or deletion of exon 6, and generated premature stop codons.
The thus generated mutant DR3 lacking death domain assembled with a
wild-type DR3 molecule to inhibit apoptosis, and apoptosis induction by
anti-DR3 antibody was impaired in the lymphocytes of individuals with
mutation. We also found that experimental collagen-induced arthritis was
ameliorated by anti-DR3 antibody treatment, and the haplotype was clini-
cally found in increased frequency in familial patients with RA and the
patients who underwent joint surgery as compared with controls
(P<0.0006). We surmise that this mutation is responsible for impairment
of apoptosis induction in patients with rheumatoid arthritis, which may pre-
dispose to arthritic joint destruction and autoimmunity.
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Aims To investigate the relationship between ‘lymphoid chemokines’
CXCL13 and CCL21 and the developmental dynamics of organized lym-
phoid tissue in rheumatoid synovitis, by determining their local production
sites in the context of progressively enlarging perivascular cell aggregates.
Materials and methods Forty synovial samples from 20 rheumatoid
arthritis patients were studied. The organizational features of cell aggre-
gates were analysed by staining serial sections for T cell, B cell and follicu-
lar dendritic cell (FDC) markers and peripheral node addressin (a group of
vascular adhesion molecules constitutively expressed by high endothelial
venules in secondary lymphoid tissues). The dimensional grading analysis
was performed according to the radial cell count from the central blood
vessel to the point of widest infiltration: Grade 1 (two to five cells), grade 2
(six to 10 cells) and grade 3 (>10 cells). CXCL13 and CCL21 expression
was analysed by immunohistochemistry and in situ hybridization with radi-
olabelled CXCL13-specific and CCL21-specific RNA probes.
Results In 17 patients grade 2 and/or grade 3 aggregates were demon-
strated. Fully formed follicular-like aggregates, with detectable centrally
located CD21+ dendritic cell clusters and T/B segregation, were identi-
fied exclusively in 7/20 patients (35%) of grade 3 aggregates. CXCL13
was observed in 7.66% grade 1, 39.9% grade 2 and 82.6% grade 3
aggregates, while CCL21 expressing cells were observed in 3.06%
grade 1, 15.93% grade 2 and 43.55% grade 3. CXCL13 and CCL21
were expressed within lymphocytic clusters in 18/20 and 15/20
patients, respectively, both at protein level and mRNA level, in mature
CD21+ FDC containing T/B cell follicular-like structures as well as in not
organized T cell/B cell aggregates devoid of CD21+ FDC networks.
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Conclusions This study demonstrates for the first time, by in situ
hybridization, the site of production of CXCL13 and CCL21 in the
context of synovial ectopic lymphoid tissue. The morphological and
grading analysis provides evidence of the independence, in the syn-
ovial inflammatory microenvironment, between the ectopic production
of lymphoid chemokines and the presence of a mature CD21+ FDC-
rich/germinal centre lymphoid-like structures. This supports the hypoth-
esis, similar to that shown in animal models, of a potential role of these
factors in prefollicular stages of synovial lymphoid neogenesis.
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Evidence suggests that chronic inflammation in several human auto-
immune diseases, such as rheumatoid arthritis (RA), is mediated by
activated Th1 cells. Delineation of the regulatory mechanisms control-
ling a Th1-biased human immune reaction and its pathologic potential
is, therefore, a critical step in the understanding of chronic autoimmune
inflammation. We analyzed T-cell subsets from patients with RA with
regard to their regulatory capacity for Th1 inflammation. Flow cytomet-
ric analysis of freshly isolated peripheral blood (PB) and synovial fluid
(SF) T cells revealed that rheumatoid inflammation is characterized by
the absence of Th2 cells and their cytokines. Moreover, resting T cells
from patients with RA expressed an impaired ability to differentiate into
Th2 effectors with a potential to downmodulate Th1 inflammation.
Thus, altered Th2 cell differentiation might contribute to the imbalance
in favor of inflammatory Th1 cells in RA. Whereas Th2 cytokines, such
as IL-4, play essential roles in regulating the development and perpetu-
ation of Th1-mediated autoimmune responses, a novel subset of regu-
latory CD4 T cells that express CD25 on their surface and perform
their suppressor function on the development of autoimmune inflamma-
tion by cytokine-independent mechanisms has recently been described
in animals and humans. However, their in vivo role in human inflamma-
tion is largely elusive. We identified CD4CD25pos T cells in the PB and
the SF of patients with active RA. Importantly, CD4CD25pos T cells
from both RA PB and RA SF exerted potent suppressive activity as
proliferation of autologous peripheral blood mononuclear cells was sig-
nificantly inhibited by the presence of CD4CD25pos T cells compared
with proliferation in the presence of CD4CD25neg T cells. CD4CD25
regulatory T-cell-mediated inhibition of the proliferation was abrogated
by addition of exogenous IL-2, a characteristic of CD4CD25 regulatory
T cells in animals. Moreover, RA CD4CD25 T cells had a markedly
decreased proliferative capacity in response to anti-CD3 monoclonal
antibody, suggesting an anergic phenotype typical for CD4CD25 regu-
latory T cells. Together, the data indicate that, in contrast to
immunomodulatory Th2 effectors, CD4CD25pos T cells with potent
suppressive potential are present in rheumatoid inflammation. The data
further suggest that CD4CD25pos regulatory T cells are involved in the
continuous regulation of the developing human Th1 inflammation in
vivo. However, their activity appears to be insufficient to silence the
chronic immune response in RA.
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Background Among the autoantibodies (autoAb) described to occur
in patients with rheumatoid arthritis (RA), autoAb to citrullinated anti-
gens (anti-CCP) have proven to be highly specific for RA. Other
autoAb such as anti-RA33 are less specific but may still have some
diagnostic value.
Objectives To assess the diagnostic and prognostic value of RF, anti-
CCP and anti-RA33 autoAb in patients with very early arthritis, and to
investigate the role of autoAb in the pathogenesis of RA.
Methods Patients with very early arthritis of less than 3 months’ dura-
tion were included in this prospective study. So far, a final diagnosis of
RA could be made in 100 patients, while 80 patients developed other
diseases. To investigate pathogenetic involvement of autoAb, tumour
necrosis factor transgenic (TNFtg) mice were used as an animal model
of RA.
Results At first visit, rheumatoid factor (RF) was present in 54% of RA
patients, anti-CCP in 42% and anti-RA33 in 26%, respectively. Speci-
ficity was 89% for RF, 98% for anti-CCP and 90% for anti-RA33,
respectively (Table 1). However, while 46% of RA patients showed RF
>50U/ml, only two non-RA patients were above this value. Thus, RF
>50U/ml and anti-CCP both showed a high positive predictive value
>95%. Although anti-RA33 was less specific, the combined occur-
rence of (low) RF and anti-RA33 was also highly predictive of RA since
it was exclusively observed in 15% of RA patients. Concerning the
prognostic value, we found a significant correlation between anti-CCP
or RF positivity and radiological outcome. To investigate the patho-
genetic involvement of anti-RA33 autoimmunity, TNFtg mice (which
spontaneously develop anti-RA33 autoAb) were immunized with the
antigen or two antigen-derived peptides. Treatment with a peptide har-
bouring a major epitope or the complete antigen enhanced arthritis sig-
nificantly. On the contrary, treatment with osteoprotegerin not only
inhibited bone erosion, but also led to a significant reduction in anti-
RA33 autoAb; a similar observation was made in c-fos-deficient TNFtg
mice that lack osteoclasts.
Table 1
Sensitivity, specificity and positive predictive value of RF, anti-CCP and
anti-RA33 autoantibodies in patients with very early RA
Positive 
RA Non-RA  Sensitivity  Specificity  predictive 
(n = 100) (n = 80) (%) (%) value (%)
RF (≥ 20 U/ml) 54 9 54 89 86
RF (≥ 50 U/ml) 46 2 46 97 96
Anti-CCP 42 1 42 98 97
Anti-RA33 26 8 26 90 76
RF + anti-CCP  32 0 32 100 100
RF + RA33  15 0 15 100 100
Conclusion Determination of anti-CCP and also anti-A2/RA33 in addition
to RF may be very helpful in the early diagnosis of RA. The data obtained
in TNFtg mice suggest a molecular link between inflammation, tissue
destruction and the generation of a pathogenic autoimmune response.
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Introduction The synovial membrane in rheumatoid arthritis (RA) con-
tains large lymphocytic infiltrates, sometimes organized in germinal-like
centres. The presence of plasma cells within the synovium and the pro-
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duction of clonally related immunoglobulin transcripts have been
observed. The exact nature of clonal expansion and its role in genera-
tion of specific, mutated antibodies in RA is not known. Somatic muta-
tions and isotype switching in synovial B lymphocytes might suggest
the antigen-driven process. This would be supported by the expression
of recombination-activating genes 1 and 2 (Rag1 and Rag2).
Objectives To calculate mutational frequencies of immunoglobulin
heavy-chain transcripts in the single plasma cells generated from RA
synovium. To analyze the frequency of isotype-switched plasma cells
and Rag1 and Rag2 gene expression in inflamed RA synovial tissue.
Methods Individual CD19+CD38+ plasma cells were isolated from
digested synovium of two Caucasian RA patients using single-cell
deposition. The cDNA from each single plasma cell was generated and
a nested PCR specific for VH genes and Rag1 and Rag2 genes was
performed. After sequencing, the VBASE database was used to assign
VH, DH and JH gene segments and somatic mutations.
Results Three different subsets of CD19+CD38+ plasma cells were
detected. The first subset represents cells expressing only IgM tran-
scripts (IgM+, 13.5%), cells in the second subset expressed only IgG
transcripts (IgG+, 48.7%), and the cells in the third subset expressed
both IgM and IgG mRNAs (IgM+IgG+, 37.8%). All of these detected
IgVH mRNAs contained mutated sequences, indicating their memory
cell origin. Significant differences in mutational frequencies were found
between the subsets (IgM+ plasma cells, 3.8%; IgG+ plasma cells,
11.2%; and IgM+IgG+ cells, 6.3%). Interestingly, either Rag1 or Rag2
mRNA was observed in 83.3% of all analyzed CD19+CD38+ plasma
cells, with the highest frequency in the IgM+IgG+ subset (71.4%).
Conclusions The population of CD19+CD38+ plasma cells differen-
tially expressing mutated IgVH mRNAs and reinducing Rag1 and Rag2
genes was observed in RA synovium. The IgM+IgG+ cells might repre-
sent cells switching from the IgM to the IgG isotype, and IgG+ plasma
cells might correspond to post-switched cells producing high-affinity
(auto)antibodies. The high mutational rate and reinduction of Rag
genes suggest an antigen-driven process.
Acknowledgement This work was supported by grant NK/7273-3
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Background and objective Cell contact of monocytes with preacti-
vated T cells is one of the strongest known stimuli of monocytic
cytokine production and has been implied in the pathogenesis of
rheumatoid arthritis (RA). T cells from the synovial membrane of RA
patients have been found to induce high levels of tumor necrosis factor
alpha (TNF-α) production in synovial macrophages, and monocytes
from healthy individuals react similarly to preactivated T cells. The
response of peripheral monocytes from RA patients to T-cell contact,
however, has not been analyzed previously, and was therefore investi-
gated in the study presented here.
Methods Peripheral blood monocytes from 20 patients with RA and
from age-matched healthy donors were isolated by immunomagnetic
separation and used in a coculture system with T lymphocytes from
unrelated donors. T cells were stimulated with immobilized CD3 and
CD28 antibodies, subsequently fixed with glutaraldehyde, and then
used in the coculture system at a T cell:monocyte ratio of 7:1. In control
experiments, unstimulated fixed T cells or lipopolysaccharide were used.
Results Lipopolysaccharide-induced TNF-α production of monocytes
from RA patients did not differ from the controls. Upon coincubation
with preactivated T cells, however, monocytes from RA patients pro-
duced significantly lower amounts of TNF-α. This difference was inde-
pendent of previous or current disease-modifying antirheumatic drug
therapy, since it was also found in patients with recent onset RA who
had not received immunosuppressive therapy prior to study inclusion.
Serum transfer experiments showed the presence of inhibitory factors
in sera from RA patients to be one mechanism contributing to the
diminished response of RA monocytes, since those sera were also able
to inhibit T-cell-dependent TNF-α production in healthy monocytes.
Conclusion The suppressed response of peripheral blood monocytes
from RA patients to preactivated T cells shows that they are not likely
to contribute significantly to the excessive levels of TNF-α that are
associated with this disease. The inhibitory activity of sera from RA
patients in the cell contact-dependent system suggests a counter-
regulatory mechanism in the systemic circulation that prevents exces-
sive activation of circulating monocytes in this disease.
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Background Nonsteroidal anti-inflammatory drug (NSAID) gastropathy
is recognized as a major cause of hospitalizations and deaths, with
more than 100,000 annual hospitalizations and more than 10,000
annual deaths in the United States alone. Trends in this epidemic over
time have not been examined.
Objective We studied the possibility that new preventive approaches to
NSAID gastropathy may have reduced the magnitude of this epidemic.
Methods We studied 5598 patients with rheumatoid arthritis from lon-
gitudinal data banks previously employed to help establish the epidemi-
ology of NSAID gastropathy. Consecutively enrolled patients were
followed with bi-annual Health Assessment Questionnaire assessments
and medical record audits between 1981 and 2000. Annual rates of
hospitalization involving gastrointestinal (GI) bleeding, obstruction, or
perforation were calculated and curves fitted using spline regression.
Results Annual GI hospitalization rates rose from 0.6% in 1981 to a
peak of 1.5% in 1992, then declined again to 0.6% again in 2000. The
period of rising incidence was associated with an increase in patient
age and GI risk propensity score. The period of declining incidence
was correlated with use of lower doses of aspirin and ibuprofen, a
decline in use of ‘more toxic’ NSAIDs from 52% to 42%, a rise in use
of ‘safer’ NSAIDs from 19% to 48%, and increasing use of proton
pump inhibitors. The decline was not associated with changes in age,
NSAID exposure, or GI risk.
Conclusions The risk of GI hospitalization for NSAID gastropathy has
declined by 60% in these cohorts since 1992. We estimate a 16%
decline attributable to dose reductions, 10% to use of proton pump
inhibitors, and 10% to use of less toxic NSAIDs. Given continued
trends in these three factors, these declines are likely to continue.
Acknowledgement This study was supported by a grant from the
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Background Fatigue is a frequent and debilitating problem in people
with rheumatoid arthritis (RA). However, there are few prospective
studies evaluating the economic impact of fatigue in people with RA.
Objectives To study the economic correlates of fatigue in patients with
RA, and to evaluate the impact of fatigue on costs of medical care and
missed days of work.
Patients and methods A total of 6551 consecutively diagnosed RA
patients with 35,371 person years of follow-up are currently enrolled in
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the ARAMIS postmarketing surveillance program. Patients complete
semi-annual Stanford Health Assessment Questionnaires on their
disease symptoms, severity, medication use (including over-the-counter
medications), adverse events and healthcare resource utilization includ-
ing hospitalizations and emergency room visits. Patients also report on
measures of indirect costs such as missed days of work and days
when they were unable to do nonemployment-related activities. All self-
reported hospitalizations are audited, and discharge summaries are
reviewed by a physician. Complete ascertainment of all deaths is
obtained from regular searches of the US National Death Index data-
base. Since 1987, all patients were asked to report on the presence of
tiredness or fatigue in their semi-annual assessment. Medical costs of
care are estimated based on 2002 Medicare reimbursement rates and
on 2002 average wholesale medication costs. Statistical comparisons
were made between periods when patients reported fatigue and those
when no fatigue was reported.
Results A total of 2699 patients (mean age, 58.3 years; 78% female)
with 12,458 person-years of follow-up answered the fatigue question.
The point prevalence of fatigue varied from 57.5% in 1987 to 67.2% in
2000 (average, 56.9%). For comparison, the point prevalence of
fatigue in 1916 patients with osteoarthritis (mean age, 66 years; 76%
female) was 49.6% (P<0.001, after adjustment for confounding
demographic variables). Patients with fatigue reported significantly
higher annual direct medical costs of care compared with those who
were not fatigued ($4621.70±241.66 vs $2131.42±265.68 respec-
tively,  P<0.001). During the 6-month periods when they reported
fatigue, patients missed an average of 1.93 days (standard error of the
mean [SEM], 0.11) of work, and were unable to do nonemployment-
related activities for 12.31 days (SEM, 0.34). In the 6-month time
periods when no fatigue was reported, patients only missed an average
of 0.98 days (SEM, 0.10) of work and were unable to do nonemploy-
ment-related activities for 5.44 days (SEM, 0.34) (P<0.001 for both
comparisons). Mutivariate analysis showed that the costs of medical
care were strongly correlated with the presence of fatigue (P<0.02),
after adjusting for age, gender, duration of RA and education level.
Conclusions Fatigue is a common symptom in patients with RA.
Patients with fatigue have significantly higher costs of medical care and
miss more days of work compared with those who do not have fatigue.
It is important to measure fatigue in clinical trials of innovative therapies
since this is an important reason for poor quality of life, and is strongly
correlated with disease severity and direct and indirect medical costs.
Acknowledgement The study was funded by a grant from Wyeth.
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Rheumatoid arthritis (RA) is a chronic inflammatory disease of the
joints, in which T cells are thought to play an important role in the
rheumatoid synovium. We hypothesized that if the T-cell receptor
(TCR) repertoire of infiltrating T cells is shaped by interaction with
common self-antigens or microbial antigens in the context of suscepti-
ble human leukocyte antigen genes, these synovial T cells may share
some TCR structural features in different patients. In this study, syn-
ovial lesion tissue, synovial fluid and blood specimens from 37 RA
patients and seven control patients were analyzed for TCR repertoire.
The results indicated highly skewed BV14 and BV16 in the synovial
lesion tissue and BV16 in synovial fluid of RA, while control synovial
material had diverse BV distribution. A trend for correlation between
the skewed BV16 but not BV14 and the expression of DRB1*0405
was found in this cohort of Chinese RA patients. Immunoscope analy-
sis of the V–D–J region showed oligoclonal expansion of BV14+ and
BV16+ T cells in some cases, while polyclonal patterns were frequently
seen in other specimens. Refinement of the V–D–J region profile by
detailed immunoscope analysis using BV and BJ primers revealed
common clonotypes that utilized the same BV14 or BV16 and the
same BJ, and had similar complementarity-determining region 3
(CDR3) length. DNA cloning and sequence analysis of the clonotypes
confirmed identical CDR3 sequences and common CDR3 sequence
motifs among different RA patients. The findings are important in the
understanding of BV gene skewing and the CDR3 structural character-
istics in synovial infiltrating T cells of RA, and have implications in novel
immunotherapy.
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Purpose Fibroblast-like synovial cells (FLS) have provided consider-
able insight into the mechanisms underlying joint inflammation and
destruction. There is currently an incomplete knowledge of the global
FLS proteome and of how this compares with the proteome of other
fibroblasts. The rheumatoid arthritis synovial microenvironment is
known to be chronically hypoxic. We studied the FLS proteome using
two-dimensional gels and mass spectrometry to evaluate the effects of
hypoxia on the synovial proteome, comparing this with the expressed
genome.
Methods FLS were isolated from rheumatoid arthritis and osteoarthritis
synovia obtained at the time of joint arthroplasty. Cells from passages
2–4 were cultured under normoxic and hypoxic conditions for variable
time points prior to analysis. Total proteins found in whole-cell FLS
lysates were separated on immobilized pH-gradient two-dimensional
(2D) PAGE and stained with Coomassie blue. To date, the in-gel
digests of >300 protein spots have been analyzed using matrix-
assisted laser desorption/ionization time of flight mass spectrometry.
Spectra were analyzed using the Knexus automation client and the Pro-
found search engine (Proteometrics Canada, Winnipeg, Manitoba,
Canada). 2D gels from hypoxic and normoxic FLS were superimposed
using image analysis software and were compared. Differences were
identified, and were related to differences in the expressed genome
demonstrated in a microarray experiment using the same cell lines and
conditions.
Results Under normoxic conditions, more than 300 proteins were fully
characterized in the FLS lines. Of particular note, FLS intensely
expressed uridine diphosphoglucose dehydrogenase, which is an
enzyme needed for the synthesis of hyaluronic acid. Other proteins
identified fell into the following groups: enzymatic, transcription and
cell-cycle regulation, protein binding, cytoskeletal, extracellular matrix,
heat shock, protein synthesis and assembly, and membrane channel. In
comparing the proteome expressed under hypoxic conditions, most of
the apparent differences were quantitative, with shifts in position sug-
gestive of phosphorylation and glycosylation. The microarray data
demonstrated a spectrum of known, as well as novel, hypothetical pro-
teins that were regulated by hypoxia. Identification of these proteins in
the 2D gels is currently underway.
Conclusions We demonstrate techniques used in the detailed explo-
ration of the synovial proteome. These techniques are applied to the
examination of the effects of hypoxic stimulation on FLS. Comparisons
between the expressed proteome and genome provide novel insights
into the response of FLS to hypoxia
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Objective CD44 mediates cell–matrix interaction and is thought to play
a role in cell adhesion, fusion and migration. Blocking of CD44 is con-
sidered a potential target in the therapy of rheumatoid arthritis.
Methods To elucidate the role of CD44 in arthritis, human tumour
necrosis factor transgenic (hTNFtg) mice were crossed with CD44
knockout mice.
Results Clinical evaluation revealed a significantly increased severity of
arthritis in CD44–/– hTNFtg mice than in hTNFtg mice. Wild-type mice
and CD44–/– mice were normal. Histologically, bone destruction was
dramatically increased in the arthritic paws of CD44–/– hTNFtg mice.
Changes were based on a significant increase of size and number of
osteoclasts in the synovial inflammatory tissue. Ex vivo analysis of osteo-
clastogenesis revealed that osteoclasts differentiated more rapidly and
were increased in size and number in CD44–/– hTNFtg mice compared
with in hTNFtg controls. In addition, a bone resorption assay showed
increased ‘pit’ formation by osteoclasts of CD44–/– hTNFtg mice.
Conclusion CD44 deficiency does not block, but rather increases the
severity of TNF-mediated arthritis. This was due to increased bone
damage caused by deregulation of osteoclastogenesis. We conclude
that CD44 is of benefit for TNF-mediated arthritis due to its regulatory
role on osteoclasts.
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Local bone erosions and systemic bone loss are hallmarks of rheuma-
toid arthritis and cause progressive disability. Tumor necrosis factor
(TNF) is a key mediator of arthritis and acts catabolically on bone by
stimulating bone resorption and inhibiting bone formation. We hypothe-
sized that the concerted action of parathyroid hormone (PTH), which
stimulates bone formation, osteoprotegerin (OPG), which blocks bone
resorption, and anti-TNF, which reduces inflammation, could lead to
repair of local bone erosions and to inhibition of systemic bone loss. To
test this, human TNF-transgenic mice with erosive arthritis and estab-
lished systemic bone loss were treated with PTH, OPG and anti-TNF.
Local bone erosions almost fully regressed, suggesting repair of inflam-
matory skeletal lesions. In contrast, OPG or anti-TNF alone led to arrest
of bone erosions but did not achieve repair. Treatment with PTH alone
had no influence on the progression of bone erosions. Local bone ero-
sions showed all signs of new bone formation such as the presence of
osteoblasts, osteoid formation and mineralization. Systemic bone loss
was completely reversed upon combined treatment, and this effect was
mediated by osteoblast stimulation and osteoclast blockade. In con-
trast to local and systemic bone loss, joint inflammation was only
affected by anti-TNF. In summary, we conclude that local and systemic
inflammatory bone loss due to TNF can regress, and that repair
requires a combined approach by reducing inflammation, blocking
bone resorption and stimulating bone formation.
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Macrophage migration inhibitory factor (MIF) is a pluripotential proin-
flammatory cytokine with a possible role in the pathogenesis of rheuma-
toid arthritis (RA). MIF is expressed in RA synovium, and directly
activates RA synoviocyte gene expression and proliferation, as well as
exerting anti-apoptotic effects via inhibition of p53. MIF activates ERK
and p38 mitogen-activated protein (MAP) kinase, but evidence for
direct activation of NF-κB by MIF is lacking.
Anti-MIF monoclonal antibodies prevent IL-1 activation of fibroblast-like
synoviocytes in vitro, implicating MIF in the activation of cells by IL-1. The
mechanism of this action of MIF has not been adduced. We studied the
activation of signal transduction pathways by IL-1 in cells deficient in MIF.
Dermal fibroblasts were cultured from MIF–/– and WT mice, and were
exposed to IL-1. MAP kinase and NF-κB activation were studied by
Western blotting, electrophoretic mobility shift assay (EMSA), and
reporter gene assays.
IL-1 rapidly induced phosphorylation of p38, JNK, and ERK MAP
kinases in WT cells. In contrast, MIF–/– cell p38, JNK, and ERK activa-
tion in response to IL-1 was reduced. Consistent with this observation,
MIF–/– cells were hyporesponsive to IL-1-induced AP-1 DNA binding as
measured by EMSA (P = 0.03). IL-1-induced activation of an AP-1
luciferase reporter gene system was also reduced in MIF–/– cells (P =
0.037). Confirming the functional significance of these results, MIF–/–
cells were hyporesponsive to IL-1-induced proliferation. In contrast,
MIF–/– cells were normally responsive to IL-1-induced MKK3 and MKK7
phosphorylation. No significant difference in NF-κB activation was
detected between MIF–/– and WT cells, as measured by cellular IκB
content, NF-κB EMSA, or NF-κB luciferase reporter gene assay.
These data demonstrate that MIF is required for cellular MAP kinase
responses to IL-1. This represents a novel mechanism of action of MIF
in the support of the inflammatory response. The absence of an effect
on MKK3/MKK7 or NF-κB suggests the effects may be mediated dis-
tally in the signal transduction cascade. Therapeutic MIF antagonism
may limit the cellular effects of IL-1.
128
Regulatory T cells in experimental arthritis
R Bräuer1, O Frey1, PK Petrow1, A Scheffold2, A Radbruch2
1Institute of Pathology, Friedrich Schiller University, Jena, Germany;
2German Rheumatism Research Centre, Berlin, Germany
Arthritis Res Ther 2003, 5(Suppl 3):128 (DOI 10.1186/ar929)
Background It is now generally accepted that central and peripheral
immune tolerance is in part mediated by the action of suppressor cells.
In particular, CD4+ T cells coexpressing CD25 (CD4+CD25+ regula-
tory T cells [Treg]) have been shown crucial for the prevention of autoim-
munity in several animal models. We investigated the role of this cell
population in murine antigen-induced arthritis, a well-characterized
experimental model of human rheumatoid arthritis.
Methods For this purpose, we used two different approaches. First,
the depletion of CD25-expressing cells in vivo using a monoclonal anti-
body against this molecule, and second, the transfer of purified
CD4+CD25+ Treg from naive donors into arthritic mice.
Results Depletion of CD25-expressing cells resulted in a clinical and
histological aggravation of arthritis. The increased severity of arthritis
was due to a lack of Treg cells, since transfer of purified CD4+CD25+
cells from naive donors into depleted animals ameliorated the clinical
signs of arthritis. The aggravated arthritis in depleted mice was accom-
panied by exaggerated humoral (serum IgG) and cellular (ELISPOT)
immune responses against the inducing antigen (methylated bovine
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serum albumin) and to cartilage matrix constituents (collagen type I,
collagen type II, proteoglycans). Thus, CD4+CD25+ Treg cells may reg-
ulate the severity of arthritis by adjusting the systemic immune respon-
siveness to arthritis-related antigens. Furthermore, adoptive transfer of
purified CD4+CD25+ Treg cells, isolated from naive mice, into arthritic
animals resulted invariably in a marked decrease of the severity of
arthritis. Especially with use of in vitro preactivated Treg cells, this effect
could be achieved with very low cell numbers (1×105 cells per
animal). Analysis of cellular and humoral immune responses in the
recipients did not shown signs of systemic immunosuppression. Local
immunoregulatory effects of these cells are possibly involved, but their
exact mechanism of action is hitherto unknown.
Conclusions Taken together, these data implicate a pivotal role of
CD4+CD25+ immunoregulatory T cells in experimental arthritis, and it
can be hypothesized that they are a new diagnostic or prognostic tool
for rheumatoid arthritis patients. Hopefully, enhancement of their func-
tion may be beneficial for these patients and represents a new thera-
peutic strategy in autoimmune diseases.
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Objective Anti-Fas monoclonal antibodies (mAbs) are considered a
potential therapeutic agent for rheumatoid arthritis (RA). However, Fas-
mediated liver and chondrocyte damage is a serious problem in its clin-
ical application. m-HFE7A, a novel anti-Fas mAb, selectively induces
apoptosis in inflammatory cells. We succeeded in humanizing m-
HFE7A to obtain h-HFE7A. We investigated the therapeutic effects of
h-HFE7A mAb in RA.
Methods We investigated the apoptosis-inducing activities of h-
HFE7A on human Fas ligand transfected cells and cultured human acti-
vated lymphocytes (human peripheral blood mononuclear cells and
isolated human RA synovial lymphocytes), synoviocytes, and chondro-
cytes. We then examined the effects of h-HFE7A mAb in vivo using
SCID-HuRAg mice implanted with human RA tissue.
Results Administration of h-HFE7A mAb alone did not induce apopto-
sis in cultured human Fas ligand transfected cells and activated lym-
phocytes. However, apoptosis-inducing activities were noted by this
mAb crosslinking with a secondary antibody or Fcγ receptor-positive
cells. In contrast, no apoptosis induction by h-HFE7A was observed on
cultured synoviocytes and chondrocytes with or without crosslinking.
Thus, the crosslinking with Fcγ receptor-positive cells is essential for
the efficacy of this mAb in vivo. In the implanted tissue of the SCID-
HuRAg mice, the number of inflammatory cells was significantly
decreased in the h-HFE7A mAb-treated group compared with the IgG-
treated control group. Moreover, there were only negligible effects in
synoviocytes and chondrocytes with the h-HFE7A mAb.
Conclusion Administration of this novel humanized anti-Fas mAb may
provide a new treatment for RA by inducing Fas-mediated apoptosis in
inflammatory cells.
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Objectives Gene therapy using electrotransfer (ET) is a safe method
for transferring therapeutic transgenes in vivo. We have used this
method to administer transgenes encoding three human tumour necro-
sis factor alpha soluble receptor I (hTNFRIs) variants engineered in
Scherman’s research unit. The ET parameters and therapeutic effects
in collagen-induced arthritis (CIA) in mice were studied.
Methods The following three plasmids were used: pCOR(hTNFRIs)1,
pCORhTNFRIs/mIgG1, and pCOR(hTNFRIs)2. These encode, respec-
tively, the monomeric (hTNFRIs)1 form, the chimeric hTNFRIs/mIgG1
form or the dimeric (hTNFRIs)2 form of hTNFRIs. They were electro-
transferred in the tibial cranial muscle. The hTNFRIs concentrations
were determined by ELISA. Biological activity (tumour necrosis factor
alpha neutralization) of the fusion protein encoded by each of the plas-
mids was determined using L929 cells. Detection of the plasmid
genome was determined by PCR. CIA was induced in DBA/1 mice
with bovine type II collagen in complete Freund adjuvant.
Results ET of the three plasmids allowed dose-dependent hTNFRIs pro-
duction in sera and muscle after 10 days. Local expression in the muscle
lasted for at least 6 months. Systemic expression in the serum lasted for
at least 6 months for the hTNFRIs/mIgG1 form, while it was shorter for
the two other forms (about 3 weeks). After intramuscular ET of any of the
three plasmids, muscle lysates were able to inhibit tumour necrosis factor
alpha cytotoxicity on L929 cells ex vivo. No plasmid DNA was found in
the organs distant from the injected muscle (liver, spleen, kidney, gonads,
heart, lung, brain and distant muscle). ET of 50µg pCOR/sTNFRI/IgG1
plasmid at the onset of clinical disease induced a clear-cut decrease of
clinical and histological signs of arthritis. The dimeric (hTNFRIs)2 form
was also efficient, although the effect was weaker than with the fusion
protein. The monomeric form had no effect on arthritides.
Conclusion Intramuscular ET of plasmids encoding the three forms of
hTNFRIs (monomeric, dimeric and the IgG chimera) leads to a produc-
tion of biologically active protein and, most importantly, is followed by a
long-term secretion of hTNFRIs in the serum. CIA is efficiently inhibited
when ET of plasmids encoding either the chimera or the dimeric form
of the hTNFRIs was performed at the onset of the clinical signs.
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receptor BV families in rheumatoid arthritis
M Pierer, U Wagner, S Kaltenhäuser, S Arnold, H Häntzschel
Department of Medicine IV, University of Leipzig, Germany
Arthritis Res Ther 2003, 5(Suppl 3):131 (DOI 10.1186/ar932)
Background Treatment of rheumatoid arthritis (RA) with the recombi-
nant p75 tumour necrosis factor (TNF) receptor fusion protein etaner-
cept is clinically highly effective. Clonally expanded, autoreactive
CD4+CD28 null T cells can be found in the peripheral blood of patients
with RA, and have been shown to use distinct BV–BJ combinations in
their T-cell receptor (TCR).
Objective This study was undertaken to investigate the influence of
anti-TNF-α treatment on expanded clonotypes in the peripheral CD4+
T-cell compartment.
Methods We investigated the size of the CD4+CD28 null compart-
ment and the TCR β-chain repertoire of expanded CD4+ clonotypes in
19 patients with RA, before the initiation of treatment with etanercept
and after 2, 4 and 18 months of TNF-α blocking therapy by comple-
mentarity-determining region 3 (CDR3) length analysis (spectrotyping)
in the BV6 and BV14 TCR families. This was done with primers spe-
cific for three arbitrarily chosen β-chain joining elements (BJ1S2,
BJ2S3 and BJ2S7).
Results TNF-α inhibition significantly reduced the total number of
expanded clonotypes found in the TCR BV6 family after 4 months of
treatment, and was even more pronounced after 18 months. In con-
trast, however, the number of detected BV14 clones was not affected.
The percentage of CD4+CD28 null cells, which has been shown to
correlate with expanded clonotypes using BV14–BJ1S2 and
BV14–BJ2S3 combinations, but not with the number of BV6 clones,
remained unchanged under therapy.
Conclusion Therapeutic blockade of the proinflammatory cytokine
TNF-α, which leads to a profound decrease of disease activity in
treated patients, was also found to influence the size of expanded
CD4+ clonotypes in the peripheral circulation in RA patients. This
effect was dependent on the TCR BV–BJ combinations used in the
Available online http://arthritis-research.com/supplements/5/S3S42
clonotypes, however, and was restricted to the BV6 family in our study,
while BV14 clonotypes were not affected.
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Background  In rheumatoid arthritis (RA), chronic inflammation fol-
lowed by the destruction of joints and systemic symptoms is con-
structed and progressed with a continuous inflammatory and
immunological hyperactivity. IL-6 is considered a proinflammatory
cytokine produced in inflammatory synovium in RA, and to participate in
the lymphocyte activation, synovial cell growth, angiogenesis, cartilage
and bone destruction, and generation of AA amyloidosis. However,
precise functions of IL-6 in RA are still unknown.
Objective To know the actual pathogenic roles of IL-6 in RA and to
develop IL-6 blocking therapy on RA, a humanized anti-IL-6 receptor
antibody (MRA) has been used for the treatment of RA as a specific
blockade of IL-6 function.
Method To evaluate the therapeutic effects of MRA to patients with
RA, three clinical studies have so far been performed in Japan: a pilot
study of 11 severe patients, an open-labeled, dose-escalating, multi-
dose clinical study of 15 patients, and a randomized, placebo-con-
trolled trial of a multidose study on 163 patients. In most clinical trials in
Japan, 2–8mg/kg MRA was administered intravenously every 4 weeks.
Results The treatment was well tolerated at all doses. The clinical effi-
cacy of MRA evaluated by ACR criteria seems to be same as or more
than those of tumor necrosis factor alpha blockades. MRA treatment
also improved the abnormal laboratory findings observed in active RA
patients. In most MRA-treated patients, elevated levels of acute phase
proteins, such as C-reactive protein, fibrinogen and SAA, were rapidly
normalized after first administration, and thrombocytosis, anemia and
hypoalbuminemia were improved within 2 months. Rheumatoid factor
levels were gradually decreased.
Conclusion These therapeutic effects and improvements of abnormal
findings by MRA treatment confirm that IL-6 is one of the key cytokines
in the pathogenesis of RA arthritis, and IL-6 blocking therapy is a
cytokine-specific, safe and effective therapy for patients with RA.
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Thirty-seven patients have been recruited to a programme of repeated
B-cell depletion therapy for rheumatoid arthritis. Protocols have been
based on rituximab, combined with cyclophosphamide initially. Sixty-two
treatments have been given over 4.5 years. Patients were withdrawn for
inadequate response (<ACR20), for successful reintroduction of
disease-modifying antirheumatic drug (DMARD) or for toxicity.
Twenty-five patients continue on the programme with evidence of
response, and a further three patients have regained control on reintro-
duction of DMARD (methotrexate, sulphasalazine). All four IgM rheuma-
toid factor-negative patients failed to respond. One seropositive patient
achieved no benefit, and two achieved benefit of 5 months or less. Two
patients have been lost to follow-up. The mean period of benefit
(>ACR20) was 15 months, with a maximum of 35 months. One patient
showed inadequate depletion. Secondary failure of clinical response or
depletion was not observed in up to four repeat treatments. Coexistent
psoriasis on three patients showed no change.
B-cell depletion protocols were well tolerated. Eight febrile episodes
with pulmonary symptoms occurred in 85 patient-years of follow-up. All
settled rapidly on antibiotic. Although most were assumed infective, at
least four may have been late reactions to therapy or been disease
associated. One suspected joint prosthesis infection was sterile on
culture. Three patients who received rituximab in combination with
cyclophosphamide have developed breast carcinoma (two patients) or
carcinoma in situ (one patient), although in one case there was evi-
dence that this predated therapy. (No increase in the incidence of car-
cinoma has been reported in surveillance of rituximab usage
elsewhere.) In three cases who have received three courses of therapy
in rapid succession, serum IgM levels have fallen to undetectable
during the period of depletion. Falls in IgG levels have been modest
and antibacterial antibody levels well maintained.
In summary, experience with repeated B-cell depletion therapy in
rheumatoid arthritis suggests that approximately 80% of seropositive
patients may become susceptible to continuing control of disease, but
seronegative disease appears unresponsive. Secondary resistance
appears not to be a problem over 2–4 years. Susceptibility to chest
infection may be increased. Cumulative effects on immunoglobulin
levels may occur with frequently repeated usage.
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Forced expression of the cyclin-dependent kinase inhibitor gene p21cip1 in
the synovial tissues was effective in treating animal models of rheumatoid
arthritis (RA). Synovial hyperplasia in the treated joints was suppressed,
reflecting the inhibitory effect of p21cip1 on cell-cycle progression. Addi-
tionally, lymphocyte infiltration, expression of inflammatory cytokines, and
destruction of the bone and cartilage were inhibited. To determine why the
cell-cycle regulator gene exerted such anti-inflammatory effects, we inves-
tigated gene expression by rheumatoid synovial fibroblasts with or without
the p21cip1 gene transferred. We have found that p21cip1 gene transfer
downregulates the expression of various inflammatory mediators and
tissue-degrading proteinases that are critically involved in the pathology of
RA. These molecules included IL-6, IL-8, type I IL-1 receptor (IL-1R1),
monocyte chemoattractant protein-1, macrophage inflammatory protein-
3a, cathepsins B and K, and matrix metalloproteinase-1 and matrix metal-
loproteinase-3. Downregulation of IL-1R1 by p21cip1 resulted in
attenuated responsiveness to IL-1. Inhibition of the inflammatory gene
expression by p21cip1 was seen even when IL-1 is absent. This IL-1R1-
independent suppression was accompanied by reduced activity of c-Jun
N-terminal kinase, which was associated with p21cip1, and by inactivation
of NF-κB and AP-1. These multiple regulatory effects should work in
concert with the primary effect of inhibiting the cell cycle in ameliorating
the arthritis, and suggest a heretofore unexplored relationship between
cyclin-dependent kinase inhibitors and inflammatory molecules.
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Rheumatoid arthritis is a chronic inflammatory disease that may be char-
acterized by several phases. In the initial induction phase of the disease
there may be a breech in the normal mechanisms that protect the host
from destruction. In the later phase, pathways that are independent of
the adaptive immune system may perpetuate inflammation. These path-
ways may be active in patients who are refractory to biologic therapies
that target key cytokines, IL-1 and tumor necrosis factor alpha. The Toll-
like receptors (TLRs) are an integral part of the innate immune system,
and are present on synovial lining cells, as well as the cells of the
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immune system, which may amplify their contribution to the inflammatory
cascade. We have found that TLR-4 and its coreceptor CD14 can mod-
ulate arthritis and can modulate inflammatory joint disease in murine
models of arthritis. In particular, exposure to a TLR-4 ligand stimulates
release of IL-6 from synovial fibroblast-like cells in culture, and circum-
vents the requirement for IL-1 receptor signaling in a serum transfer
model of arthritis. These data suggest that triggering the innate immune
response through the TLRs with either microbial or autologous ligands
plays a role in the initiation or perpetuation of rheumatoid arthritis.
Poster Discussion (8) RA Group (3)
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The rheumatoid arthritis (RA) synovial pannus is characterized by a
number of processes, including monocyte recruitment, leukocyte–
endothelial adhesion, and angiogenesis. We have generated a novel
monoclonal antibody (mAb) (mAb 4A11), which detects the blood
group antigens Lewis y and H-5-2 (collectively termed the 4A11
antigen). We have shown that this antigen, in soluble form, as well as a
glucose analog of H-5-2 (H-2g), are potent mediators of angiogenesis.
The 4A11 antigen is selectively expressed in skin, lymphoid organs, the
thymus and synovium, and is upregulated on RA synovium compared
with normal synovium, suggesting a role in leukocyte recruitment and
homing. We have also shown that H-2g significantly upregulates cell
surface expression of the adhesion molecule intercellular adhesion mol-
ecule-1 (ICAM-1) on human dermal microvascular endothelial cells
(HMVECs), but not vascular cellular adhesion molecule-1 or E-selectin.
In accord with this, H-2g induces ICAM-1-mediated leukocyte–
endothelial adhesion. Moreover, H-2g or the 4A11 antigen activate the
endothelial janus kinase 2 (JAK2)/STAT3 pathway, as demonstrated by
inhibition by chemical inhibitors of these pathways as well as antisense
oligodeoxynucleotides directed against these signaling intermediates.
H-2g may also signal via the Erk1/2 and PI3kinase-Akt pathways.
Moreover, H-2g induced endothelial NF-κB activation, and blockade of
PI3kinase or JAK2 inhibited H-2g-induced endothelial NF-κB activation.
These results suggest that the H-2g and the 4A11 antigen are media-
tors of leukocyte–endothelial adhesion via ICAM-1.
We next sought to determine whether H-2g could induce monocyte
recruitment. We performed monocyte chemotaxis in vitro in modified
Boyden chambers. H-2g induced monocyte chemotaxis in the picomolar
or greater range. In vivo, injection of H-2g intraperitoneally into the peri-
otoneum of mice resulted in monocyte recruitment. The migration of
monocytes in vitro, as with induction of HMVEC ICAM-1 expression,
appeared to occur via the mitogen-activated kinase and PI3kinase path-
ways, but also via the Src pathway. These results suggest that H-2g and
the 4A11 antigen are potent mediators of leukocyte–endothelial adhe-
sion and monocyte recruitment, and that efforts aimed at targeting this
antigen or its signaling pathways may be useful in the treatment of RA.
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Galectin-3 (Gal-3) is one of the soluble lectins that has key functions in
inflammation, chemotaxis, cell adhesion and apoptosis. We examined
the role of Gal-3 and Gal-3 binding protein (Gal-3BP) in rheumatoid
arthritis (RA). Localization of Gal-3 and Gal-3BP in rheumatoid syn-
ovium was examined by immunohistochemistry and in situ hybridisa-
tion. Gal-3 and Gal-3BP concentrations in plasma and synovial fluid
were measured by ELISA. Gal-3 protein and mRNA stained throughout
the synovial membrane, and Gal-3BP expressed at the site of erosion
in RA. Lower and scattered expression of both Gal-3 and Gal-3BP
were detected in osteoarthritis synovium and normal synovium. ELISA
revealed a marked increase of Gal-3 and Gal-3BP in synovial fluid of
patients with RA compared with osteoarthritis patients and normal con-
trols. Furthermore, the level of Gal-3 in serum correlated with the level
of C-reactive protein in RA. In vitro, Gal-3 can induce the production of
matrix metalloproteinase (MMP)-1, MMP-3, and MMP-9 in synovial
fibroblasts in a dose-dependent manner. Our data indicate that Gal-3
and Gal-3BP represent novel markers of disease activity in RA. More-
over, Gal-3 might contribute to the destruction of bone/cartilage in RA
by the induction of MMPs.
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Objectives Synovial fluid (SF) contains rare clonogenic fibroblastic
cells, but it is unknown whether these are true mesenchymal progenitor
cells (MPCs) capable of trilineage differentiation or whether they partic-
ipate in the pathogenesis of rheumatoid arthritis (RA). The present work
evaluated SF for the presence of MPCs, to characterize these cells in
relationship to bone marrow (BM) MPCs and to enumerate them in
early and established RA, other inflammatory arthropathies and
osteoarthritis (OA).
Methods One hundred SF samples were evaluated (53 RA samples,
20 OA samples, 27 other samples). To investigate multipotentiality, cul-
tures of SF-derived fibroblasts were subjected to chondrogenic,
osteogenic and adipogenic differentiation assays, with BM-derived and
skin-derived cultures used as positive and negative controls of differen-
tiation. Trilineage differentiation of the individual clonogenic fibroblasts
present was determined by direct measurements of produced Ca2+,
sulphated glycosaminoglycan and lipid. Having established the MPC
nature of individual SF clonogenic fibroblasts, fibroblast-colony forming
unit assays were then used for enumeration of SF MPCs in early and
late RA, OA and other arthropathies. The immunophenotype of SF
MPCs before and after expansion was determined by multiparameter
flow cytometry.
Results Regardless of the nature of arthritis, polyclonal cultures of SF-
derived fibroblastic cells possessed trilineage mesenchymal differentia-
tion potentials. Individual clonogenic SF fibroblasts were also
tripotential, confirming the MPC nature of SF cells. The number of
MPCs in 1ml SF was significantly higher in OA (median, 37) compared
with RA (median, 2; P<0.00001), corresponding to an average fre-
quency of 2000 and 2 cells per 106 of total cells, respectively. These
differences were independent of SF volumes and inflammatory cell
influx. No significant differences in MPC numbers were found between
early and late RA (median, 3 and 2 cells/ml, respectively). Culture-
expanded SF and BM MPCs had a similar phenotype (CD45negD7-
FIBposCD13posCD105posCD55posCD10pos) but rare SF MPCs
expressed low-affinity nerve growth factor receptor prior to expansion,
a distinct marker of in vivo BM MPCs.
Conclusion This work shows the presence of rare clonogenic tripoten-
tial MPCs in the SF, and is the first study to demonstrate that MPCs
from two different anatomic sites have the same distinctive phenotype
in vivo. The relative absence of SF MPCs in early and late RA does not
support the concept of significant involvement in disease pathogene-
sis, but the relative abundance of these in OA provides the first direct
evidence for MPC involvement in attempted joint repair in adults.
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Background IL-15 is involved in all phases of rheumatoid arthritis.
Recently we have shown that rheumatoid arthritis synovial fibroblasts
(RASF) express both IL-15 and functional IL-15 receptor [1].
Objective The aim of present study was to identify pathways that are
regulated by autocrine IL-15 (IL-15R) in RASF.
Methods RASF were transfected with plasmid encoding IL-15R antago-
nist (CRB-15, Cardion AG) or control constructs. RNA from transient
transfectants were used for Microarray analysis. The differential expres-
sion of genes obtained by microarray analysis was verified by SYBR
Green real-time PCR. The expression of IL-15Rα, cell proliferation and
the expression of p16 and p21 were evaluated in stably transfected cells.
Results The IL-15R antagonist produced by transfected RASF
blocked the endogenous IL-15/IL-15Rα interaction, which resulted in
an inhibition of cell proliferation (45±10%) via an increase of the
expression of p16. In addition, we found that inhibition of IL-15Rα
induced the expression of mRNA for FGFR-3. Since two isoforms of
FGFR-3 have been identified (FGFR-3b and FGFR-3c) [2], we tested
the effect of IL-15Rα inhibition on their expression. In contrast to
FGFR-3b, the level of mRNA for FGFR-3c was strongly increased in
cells transfected with the IL-15R antagonist (4.71±2.5 in transient
transfectants and 6.1±1 fold in stable transfectants). FGFR-3c isoform
binds specifically FGF-9, but also FGF-2 [2]. Besides FGFR-3, FGF-2
that is abundant in RA joints binds to FGFR-1. In vitro studies revealed
that FGFR-1 transmits a potent mitogenic signal, whereas FGFR-3
usually has no stimulatory effect or inhibits cell proliferation. In contrast
to FGFR-3c, blocking of IL-15Rα did not change the mRNA expression
for FGFR-1 in RASF. Moreover, we checked whether FGF-2 affects the
expression of IL-15Rα. Indeed, FGF-2 strongly decreased the sponta-
neous and tumor necrosis factor alpha-triggered expression of IL-15Rα
at the mRNA and protein levels.
Conclusion Our findings raise the possibility of a negative loop between
FGF-2/FGFR-3c and IL-15/IL-15R signaling in RASF. Moreover, the acti-
vation of RASF by FGFs could depend on the ratio of FGFR-1/FGFR-3
expression, which is controlled by the endogenous IL-15/IL-15R system.
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We characterized the morphological and immunological features of
adherent synovial fluid cells derived from patients with rheumatoid arthri-
tis (RA), and explored their potential function in vitro and in vivo by focus-
ing on cartilage destruction. Synovial fluid adherent cells were obtained
from patients with RA and from controls, and were characterized by
immunohistochemistry and flow cytometry. In vitro, these cells were cul-
tured in the presence of cartilage particles. Cartilage destruction was
monitored by the release of sulphated glycosaminoglycans (sGAG) into
the medium, and the level of MMP-1 in the cell culture supernatant was
measured by ELISA. To inhibit cartilage destruction in vitro, the matrix
metalloproteinase (MMP) inhibitor Marimastat was tested in this system.
In vivo, in the SCID mouse coimplantation model, RA synovial fluid
adherent cells and RA synovial fibroblasts (as positive controls) were
coimplanted with human cartilage under the kidney capsule, and were
maintained there for 60 days. Synovial fluid adherent cells in vitro consist
of two subpopulations, large round-shaped macrophage-like cells
(CD68+) and spindle-shaped fibroblast-like cells (Thy-1+). When pas-
saged, the latter cells proliferate and organize themselves in three-dimen-
sional formations. The majority (>90%) of passaged RA synovial fluid
adherent cells expressed the Thy-1+, CD68–, CD86– phenotype. Com-
pared with synovial tissue fibroblasts, synovial fluid adherent cells
expressed lower levels of adhesion molecules, including CD54 and
galectin-3. Using RA synovial fluid adherent cells, the in vitro release of
sGAG associated with cell activity was 2.5-fold higher compared with
negative controls. The release of sGAG correlated with the concentration
of MMP-1 and was inhibited by the broad range MMP inhibitor Marimas-
tat in a dose-dependent manner. RA synovial fluid adherent cells coim-
planted with cartilage in SCID mice showed the same invasive behaviour
as tissue-derived RA synovial fibroblasts. Taken together, our data
showed that RA synovial fluid adherent contains ‘floating’ anchorage-
independent fibroblast-like cells similar to tissue-derived RA synovial
fibroblasts, contributing to cartilage destruction independently of the
process mediated by the hyperplastic synovial tissue.
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Background Synovial hyperplasia is a pathological hallmark of rheuma-
toid arthritis (RA). However, the mechanisms that regulate synovial cell
outgrowth are not fully understood. We recently isolated a novel mem-
brane-type molecule named ‘Synoviolin’. This molecule was cloned
from the cDNA library of RA synovial cells by immunoscreening using
antirheumatoid synovial cell antibody. It is thus expected that the mole-
cule plays important roles in synovial hyperplasia of RA. We examine
the pathogenetic role of Synoviolin in RA in vivo and in vitro.
Methods We examined the protein expression of Synoviolin in RA
synovia by immunohistochemistry. We also examined the protein
expression of the molecule in cultured synovial cells by Western blot-
ting. To examine the effects of this molecule on synovial cell prolifera-
tion, the expression of Synoviolin in cultured synovial cells was knocked
down using the RNAi technique.
Results Synoviolin is highly expressed in synovia of RA compared with
synovia of osteoarthritis. Correspondingly, the protein expressions of
Synoviolin in cultured RA synovial cells are higher than that in
osteoarthritis synovial cells. The proliferation of synovial cells is signifi-
cantly inhibited by downregulation of Synoviolin mediated by RNAi.
Conclusion Our results implicate the important roles of Synoviolin in
synovial hyperplasia of RA. These findings will provide a novel patho-
genetic mechanism in RA, and suggest that further research on Synovi-
olin will provide new therapeutic strategies for RA.
142
Transcriptional regulation of Synoviolin is
important for the proliferation of rhumatoid
synovial cells
K Tsuchimochi1, S Yamasaki1, N Yagishita1, T Amano1, 
S Komiya2, I Maruyama2, K Nishioka1, T Nakajima1
1Department of Genome Science and Rheumatology, Immunology and
Genetics Program, Institute of Medical Science, St Marianna University
School of Medicine, Kawasaki, Japan; 2Department of Orthopedic
Surgery and Department of Dermatology and Laboratory of Molecular
Medicine, Kagoshima University, Faculty of Medicine, Kagoshima, Japan
Arthritis Res Ther 2003, 5(Suppl 3):142 (DOI 10.1186/ar943)
We recently cloned Synoviolin, a transmembrane protein, by immuno-
screening from the human cDNA library of rheumatiod synovial cells
(RSCs) using anti-RSC antibodies.
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Synoviolin was highly expressed in rhuematioid synovial fibroblast
cells. The mice overexpressing Synoviolin developed spontaneous
arthropathy. Conversely, synoviolin+/– mice were resistant to collagen-
induced arthritis.
These results indicate that it is important for the prevention of arthritis
to reduce the amount of Synoviolin.
We thus analyzed the transcriptional regulation of Synoviolin promoter
and identified that an Ets binding site (EBS) was crucial for the tran-
scription of Synoviolin in vitro and in vivo.
Furthermore, to investigate the effect of downregulation of Synoviolin in
RSCs, we transfected the EBS decoy oligodeoxynucleotide (ODN) or
Synoviolin antisense ODN into RSCs and carried out a proliferation
assay using Alamar blue reagent, which resulted in the repression of
proliferation activity through the suppression of Synoviolin expression.
Our results suggest that the EBS decoy ODN provides a new thera-
peutic approach for the treatment of arthritis.
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Rheumatoid arthritis (RA) is one of the most critical articular diseases
with synovial hyperplasia followed by impairment of quality of life.
However, the mechanism(s) that regulates synovial cell outgrowth is
not fully understood.
To clarify its mechanism(s), we carried out immunoscreening using
antirheumatoid synovial cell antibody, and cloned ‘Synoviolin’. Synoviolin
was highly expressed in the rheumatoid synovium, and mice over-
expressing this molecule developed spontaneous arthropathy. Thus, it
was demonstrated that Synoviolin is a novel pathogenic factor for
arthropathy.
In this study, to understand the physiological role of Synoviolin in vivo,
we generated synoviolin-deficient (syno–/–) mice by gene-targeted dis-
ruption. Surprisingly, all fetuses lacking synoviolin died  in utero by
embryonic day 12.5–13.5. Histologically, syno–/– embryos showed
generalized low cellular density and aberrant apoptosis. In the
hematopoietic system, apoptosis, nuclear fragmentation of erythro-
blasts, Howell–Jolly body formation and hemophagocytosis were
observed. These results indicate that lack of Synoviolin is associated
with abnormal erythroid differentiation caused by augmentation of
apoptosis, and it was probable that syno–/– embryos died of anemia as
a result of a reduced number of circulating erythroblasts.
In conclusion, Synoviolin has an anti-apoptotic effect, and is essential
for embryogenesis. For further study, clearing the molecular mecha-
nism of Synoviolin in apoptosis could lead to cure of RA.
144
Synoviolin as a novel pathogenic factor for
arthropathy
T Amano1, S Yamasaki1, N Yagishita1, K Tsuchimochi1, 
A Fukamizu2, I Maruyama3, K Nishioka1, T Nakajima1
1Institute of Medical Science, St Marianna University School of
Medicine, Kawasaki, Japan; 2Institute of Applied Biochemistry and
Center for Tsukuba Advanced Research Alliance, University of
Tsukuba, Ibaraki, Japan; 3Department of Dermatology and Laboratory
of Molecular Medicine, Kagoshima University, Faculty of Medicine,
Kagoshima, Japan
Arthritis Res Ther 2003, 5(Suppl 3):144 (DOI 10.1186/ar945)
Rheumatoid arthritis (RA) is one of the most critical articular diseases
with synovial hyperplasia followed by impairment of quality of life.
However, the mechanism(s) that regulate synovial cell outgrowth is not
fully understood. To clarify its mechanism(s), we carried out immuno-
screening using antirheumatoid synovial cell antibody, and identified
and cloned Synoviolin. Synoviolin was highly expressed in the rheuma-
toid synovium, and mice overexpressing this protein developed sponta-
neous arthropathy. Conversely, synoviolin+/– mice were resistant to
collagen-induced arthritis by enhanced apoptosis of synovial cells. We
conclude that Synoviolin is a novel causative factor for arthropathy by
triggering synovial cell outgrowth through its anti-apoptotic effects. Our
findings provide a new pathogenetic model of RA, and suggest that
Synoviolin could be targeted as a therapeutic strategy for RA.
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In rheumatoid arthritis (RA), synovial fibroblast-like cells (SF) contribute
significantly to articular inflammation. They express elevated levels of
cytokines and chemoattractant factors, including IL-16. We analyzed
the induction pathways for IL-16 mRNA expression in synovial fibro-
blasts from eight RA patients in comparison with SF from six
osteoarthritis (OA) patients and dermal fibroblasts (DF) (n=6) by real-
time quantitative RT-PCR. Stimulation of cAMP-dependent signal trans-
duction by forskolin induced a twofold and 2.5-fold enhancement of
IL-16 RT-PCR signals in DF and OA-SF, respectively, whereas the
kinase inhibitor staurosporine induced IL-16 transcripts to a lesser
extent in DF and OA-SF. In contrast, in RA-SF, staurosporine signifi-
cantly augmented IL-16 RT-PCR signals (2.7-fold, P<0.022), but
forskolin failed to do so (1.3-fold, P<0.15). Phorbol ester induced IL-
16 mRNA only in RA-SF (1.5-fold) but not in OA-SF, and reduced IL-
16 signals in DF (0.6-fold). Most interestingly, growth of cells on
laminin significantly induced the expression of IL-16 mRNA (1.88-fold,
P<0.001). Collagen and other matrix proteins had no such effects.
Induction of IL-16 mRNA by laminin was more pronounced in RA-SF
than in OA-SF. Addition of lipopolysaccharide (LPS) to SF induced dif-
ferent cytokines including IL-1a, IL-1b, IL-6 and IL-8, but not IL-16, indi-
cating that induction of IL-16 mRNA by laminin was not a LPS artifact.
Addition of IL-1b or tumor necrosis factor alpha did not upregulate IL-
16 mRNA, indicating that the NF-κB and p38 pathways are not the
main activators of the IL-16 gene. We conclude that OA-SF and RA-SF
differ in their IL-16 mRNA responses, in that OA-SF respond primarily
to adenylate cyclase-dependent pathways while RA-SF respond promi-
nently to protein kinase pathways. Laminin activates the IL-16 gene in
synovial fibroblasts but this activation is not dependent on NF-κB or
p38 signal transduction.
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Introduction Extracts of Tripterygium wilfordii Hook F (TWHF), a tradi-
tional Chinese herb, have been reported to show efficacy in patients
with rheumatoid arthritis (RA). It was also reported that TWHF extracts
suppress inflammation in animal models of RA, and inhibit the produc-
tion of proinflammatory cytokines by several kinds of cells in vitro.
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Objectives Since RA is not only characterized by inflammation, but
also by synovial proliferation in the joints, we examined whether trip-
tolide (a constituent of TWHF) could influence the proliferation of
rheumatoid synovial fibroblasts (RSF) by induction of apoptosis.
Methods RSF were obtained from RA patients during surgery and were
treated with triptolide or other disease-modifying antirheumatic drugs
under various conditions. The viability and proliferation of RSF were
measured by the 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-
1,3-benzene disulfonate assay and by 5-bromo-2′-deoxyuridine incorpo-
ration, respectively. Apoptosis was identified by detection of DNA
fragmentation using an ELISA and terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling. The role of caspases in apoptosis of
RSF was analyzed by measuring caspase-3 activity, and we also studied
DNA fragmentation with or without caspase inhibitors. Activation of the
peroxisome proliferator-activated receptor gamma (PPARγ) was
assessed by a luciferase reporter gene assay using RSF transfected
with a plasmid containing the peroxisome proliferator response element.
Results Triptolide decreased viability, inhibited proliferation, and
induced apoptosis of RSF in a concentration-dependent manner at
very low (nanomolar) concentrations, whereas bucillamine, D-penicil-
lamine and methotrexate did not affect cell proliferation at all. Although
PPARã activation was induced by 15-deoxy-∆12,14-prostaglandin J2,
triptolide did not induce it under the same experimental conditions.
Caspase-3 activity was increased by treatment with triptolide and was
suppressed by a pan-caspase inhibitor. Triptolide-induced DNA frag-
mentation was inhibited by inhibitors of caspase-3, caspase-8 and
caspase-9.
Conclusions Although the mechanism of action remains to be studied,
triptolide may possibly have a disease-modifying effect in patients with
RA.
Acknowledgement This work was supported in part by grants from
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Background In rheumatoid arthritis (RA), the synovial membrane prolif-
erates and invades the underlying tissues. The fibrinolytic cascade is
involved both in the genesis and maintenance of synovial inflammation,
and is pivotal in cell invasion and proliferation.
Aim To evaluate the fibrinolytic pattern and the proliferative potential of
urokinase-plasminogen activator (u-PA) on RA synoviocytes (SY), in
order to establish the role of each component of the fibrinolytic
cascade in the genesis and progression of the RA synovitis.
Materials and methods The levels of plasminogen activators and
inhibitors, and the u-PA-dependent proliferation were studied in vitro
on SY from four controls and four RA patients undergoing joint surgery.
SY monolayers were used within the seventh passage in culture: u-PA
and plasminogen activator inhibitor-1 (PAI-1) were assayed on super-
natants, and urokinase-plasminogen activator receptor (u-PAR) was
determined on cell lysates. Levels of u-PA, u-PAR and PAI-1 were
assayed by specific ELISA and by RT-PCR of mRNAs. To evaluate the
SY proliferative potential, cells were seeded on to multiwell plates with
RPMI 1640 supplemented with 10% FCS and were incubated for
48 hours. The FCS concentration was then reduced to 0.1% for an
additional 48 hours. SY were then treated with 500ng/ml u-PA and/or
antibodies to anti u-PA (5B4) and anti-u-PAR (R3) for 48 hours, and
were counted. Cell invasion was measured with the Boyden chamber.
Results RA SY showed significantly higher levels of PAI-1
(6.3µg/million cells±1.1 standard deviation [SD] versus 2.9µg/million
cells±0.7 SD for controls, P=0.01), lower levels of u-PA (2.6ng/million
cells±1.4 SD versus 10.9ng/million cells±2.1 SD for controls,
P=0.01), and higher u-PAR on their surface (28.5ng/million cells±4.8
SD versus 13ng/million cells±3.0 SD for controls, P<0.05). Treatment
of RA SY with u-PA provided a proliferative effect similar to 10% FCS
(P<0.05), blocked by 5B4 and R3, and different in RA patients with
respect to controls (P<0.05). RA SY are more prone than controls to
spontaneous and u-PA-challenged invasion and proliferation, which are
counteracted by antagonists of the fibrinolytic system.
Conclusions RA SY present the typical fibrinolytic pattern of the inva-
sive tumor-like cells. RA SY proliferation is stimulated by u-PA. The fib-
rinolytic system thus provides the extracellular proteolysis required for
the synovial invasion of articular tissues and for the first steps of synovi-
tis. Antagonists of the fibrinolytic system may revert growth and inva-
sion of RA SY. The components of this system may be a future target
for new RA therapies.
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Cadherins are integral membrane homophilic adhesion proteins that
mediate adhesion between cells of the same type within a tissue. Cad-
herins mediate tissue morphogenesis during development and mainte-
nance of tissue architecture in adults. We recently found that
cadherin-11 is expressed in human fibroblast-like synoviocytes. We
demonstrate that the expression of the synovial cadherin promotes cell
invasion and confers on cells the ability to become organized into syn-
ovial lining-like architecture in vitro.
We generated cadherin-11-expressing fibroblast L-cell clones and empty
vector transfected L-cell controls. Phase-contrast microscopy analysis
demonstrated that cadherin-11-transfected L-cells form extensive and
intimate contacts along their surfaces, and condense together at higher
cell density to form a continuous sheet of cells in vitro. In contrast, L-cells
transfected with control empty vector are loosely organized and do not
form a tissue-like structure. We have established an in vitro model for
synovial lining formation. Interestingly, at the edge of fibronectin-coated
culture areas, the cadherin-11-expressing L-cells piled up and formed a
continuous lining layer-like architecture after 2 days in culture, whereas
the control L-cells failed to form this lining morphology.
Matrigel invasion assays revealed a twofold to threefold increased inva-
sive capacity of the cadherin-11-transfected L-cells when compared with
L-cells transfected with control vector. To determine the molecular mech-
anisms of cadherin-11-dependent cell invasion, we generated cadherin-
11 constructs of the cytoplasmic tail that delete domains implicated in
binding critical intracellular molecules that control cadherin function.
Strikingly, deletion of the juxtamembrane domain, known to bind p120-
catenin, profoundly altered the invasive capacity of these cells.
These  in vitro studies suggest a role for cadherin-11 in tissue and
lining layer formation in the synovium and the invasive nature of fibro-
blast-like synoviocytes in chronic synovitis and in rheumatoid arthritis.
Poster Discussion (9) SLE, Vascuolitis Group
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In a murine model of antiphospholipid antibody (aPL)-induced preg-
nancy loss, we have demonstrated that activation of complement,
specifically C5a–C5a receptor interactions, leads to fetal loss and
growth restriction. Yet, the effectors of tissue injury, the role of individ-
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ual complement activation pathways and the precise targets for treat-
ment remain unknown. Because C5a recruits and activates polymor-
phonuclear leukocytes (PMN) and because PMN infiltration is evident
at sites of fetal resorption, we considered the possibility that PMN are
critical cellular effectors of fetal damage. To assess the effects of aPL
antibodies in mice depleted of granulocytes, we treated pregnant mice
with anti-mouse Ly-6G (α-Gr) or control murine IgG2K prior to adminis-
tration of human IgG containing aPL (aPL-IgG). In the absence of gran-
ulocytes, mice did not develop aPL-induced pregnancy complications.
The frequency of fetal resorptions was similar to that of mice treated
with IgG from healthy controls (NH-IgG), while treatment with control
IgG2bK was not protective (% fetal resorption, aPL-IgG + α-Gr,
8.5±1.5%; NH-IgG, 10±2; aPL + IgG2bK, 39±5%*; fetal weight
(mg), aPL+α-Gr, 352±48; NH-IgG, 370±56; aPL+IgG2bK,
187±28*; * aPL vs NH-IgG, P<0.01).
Immunohistochemical analysis of decidual tissues showed that, in the
absence of neutrophil infiltration, either as a consequence of neutrophil
depletion or due to blockade of the C5a–C5aR interaction, there was
limited C3 deposition coincident with improved pregnancy outcomes. It
has been suggested that neutrophils promote complement activation by
secreting C3 and/or properdin at sites of inflammation, and thereby
amplify complement activation via the alternative pathway. To examine the
contribution of the alternative pathway to aPL-induced pregnancy loss, we
performed studies in mice deficient in factor B (fB). In the absence of fB,
mice were protected from aPL-induced fetal resorption and growth restric-
tion (% fetal resorption fB–/– mice, aPL-IgG vs NH-IgG, 9.5±2.4 vs
10.9±2.1), indicating a role for the alternative pathway in fetal damage.
This report, taken together with our previous work, shows that fB, C5 and
C5aR are required for pregnancy complications triggered by aPL antibod-
ies. Specifically, we identified the proinflammatory sequelae of C5a–C5aR
interactions and the recruitment of neutrophils as the critical intermediates
linking pathogenic aPL antibodies to fetal damage. Our findings identify
the key innate immune effectors engaged by aPL antibodies that mediate
poor pregnancy outcomes and provide novel and important targets for the
prevention of pregnancy loss in antiphospholipid syndrome.
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The molecular mechanisms that lead to autoantibody production in sys-
temic lupus erythematosus (SLE) are poorly understood. There is evi-
dence that pathogenic IgG autoantibodies characteristic of human SLE
may arise from the physiologically autoreactive natural antibody reper-
toire of fetal or CD5+ B cells. To address this hypothesis, the SLE Vλ
repertoire obtained from B cells of three SLE patients was analyzed
and compared in detail with the Vλ repertoire obtained from IgM+
B cells of three human fetal spleens and IgM+CD5+/CD5– B cells of
two normal adults. VλJλ rearrangements were amplified from genomic
DNA of individual B cells by PCR. The expressed Vλ repertoire of SLE
patients contained several similarities with the expressed repertoire of
the fetal and adult CD5+ B cells. The Vλ gene, 1G, was a major com-
ponent of the SLE, fetal and adult CD5+ B-cell repertoire, but not in the
adult CD5– B-cell population. The restriction of junctional diversity by
utilization of homology-directed joining (H-joining) together with the
absence of N-regions was a prominent feature of the fetal and adult
CD5+ B-cell repertoires. This restriction was also observed in the SLE
repertoire, but was less significant in the adult CD5– B-cell population.
Furthermore, profound expansion of Vλ clones employing identical
CDR3s were observed in the adult CD5+ B cells, the fetal cells, and
the SLE repertoire, whereas the frequency of the Vλ clones were much
lower in the adult CD5– B-cell population. Notably, significant numbers
of expanded adult CD5+ B cells, and fetus and SLE Vλ clones utilized
H-joining at the junctions. These data demonstrate that the SLE VλJλ
repertoire harbors characteristics of the natural antibody repertoire.
These observations imply that the fetal antibody repertoire with
restricted antigen specificities can be conserved through development
via CD5+ B cells, and during abnormal immune responses can poten-
tially give rise to SLE-associated pathogenic autoantibodies.
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Objective To investigate the expression of the chemokine receptor
CCR7, which defines distinct subsets of naive and memory T lympho-
cytes with different homing and effector capacities, and the proliferative
capacity of CD4+ T cells by T-cell receptor (TCR) stimulation in
patients with systemic lupus erythematosus (SLE)
Methods Heparinized venous blood from SLE patients (23–53 years
old; mean, 36.7 years) and age-matched and sex-matched healthy con-
trols (HC) was collected. Peripheral blood mononuclear cells (PBMC)
were freshly isolated by Ficoll-Hypaque. We stained 106 PBMC with
anti-human CCR7 antibody, anti-CD45RA, anti-CD4 and anti-CD8 to
characterize the phenotype of T-cell subsets. PBMC were stimulated
with anti-CD3+anti-CD28 monoclonal antibody, and cell division was
analyzed by carboxyfluorescein diacetate succinimidyl ester labeling
and flow cytometry in different subsets of CD4+ T cells. Data was
acquired on a FACS caliber system, and analyzed using Flow-Jo soft-
ware (Tree Star Inc., San Carlos, CA, USA).
Results SLE patients (n=27) had fewer CD45RA+CCR7+CD4+
naive T cells (32.2±13.2 vs 43.5 ± 12.3, P<0.05) and higher
CD45RA–CCR7–CD4+  effector memory T cells (20.1±12.2 vs
12.9±5.6, P<0.05) as compared with the HC (n=27). No significant
differences were found in the CD45RA–CCR7+ central memory CD4+
T cells and the CD8+ T-cell compartment of SLE patients as compared
with HC. The appearance of cell division was more rapid in the popula-
tion of CD45RA–CCR7–CD4+ T cells, and the frequency of
CD45RA–CCR7–CD4+ effector memory T cells did not correlate with
disease activity, disease duration, age, or treatment within the SLE group.
Enhanced cell division was observed in SLE CD4+ T cells by TCR stim-
ulation as compared with HC, but there are no significant correlations
between frequency of effector CD4+ T cells and proliferative capacity
within the SLE group. Furthermore, naive CD4+ T cells from SLE
patients showed increased proliferative capacity compared with that of
HC, but the difference was no so significant.
Conclusion These results suggest that enhanced proliferative
response of CD4+ T cells of SLE by TCR stimulation may be caused by
increased distribution of the effector memory population and intrinsic
defects of SLE CD4+ T cells.
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The Nba2 locus is a major genetic contribution to disease susceptibility
in the (NZB × NZW)F1 mouse model of systemic lupus. We generated
Available online http://arthritis-research.com/supplements/5/S3S48
C57BL/6 mice congenic for this NZB locus, and these mice produced
antinuclear autoantibodies characteristic of lupus. F1 offspring of con-
genic and NZW mice developed high autoantibody levels and severe
lupus nephritis similar to (NZB × NZW)F1 mice. Expression profiling
with oligonucleotide microarrays revealed only two differentially
expressed genes, IFN-inducible genes Ifi202 and Ifi203, in congenic
mice versus control mice, and both were within the Nba2 interval.
Quantitative PCR localized increased Ifi202 expression to splenic
B cells and non-T cells/non-B cells. Moreover, recent results show
Ifi202 shows inducible expression in NZB mice in response to both
type I and type II IFNs, both in vivo and in vitro. Other experiments
using mice with a targeted mutation of the type I IFN receptor show
that this pathway is required for type I interferon-mediated responsive-
ness. Studies using splenic cells demonstrate that multiple subpopula-
tions show enhanced Ifi202 expression in response to type I IFN, and
indicate that dendritic cells show the greatest increased expression of
Ifi202. These results together with analyses of promoter region poly-
morphisms, strain distribution of expression, effects on cell proliferation
and apoptosis, in addition to recent results characterizing responsive-
ness to type I and type II IFNs, implicate Ifi202 as a candidate gene for
lupus.
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Background Dying cells may be the source of the autoantigens that
initiate and/or perpetuate systemic autoimmunity. C1q-deficient mice
develop a lupus-like disease and accumulate apoptotic cells in their
kidneys, and our studies [1] suggested that classical complement com-
ponents facilitate the clearance of apoptotic cells. Mice deficient in
serum IgM (sIgM) also develop a lupus-like disease.
Objective Since IgM binds to apoptotic cells and activates the classi-
cal complement on the apoptotic cells in vitro [2], we asked whether
sIgM was required for complement activation and rapid removal of
dying cells by phagocytic cells in vivo.
Methods Apoptotic thymocytes were injected into the peritoneum of
mice that had received thioglycollate 3 days previously. Thirty minutes
after intraperitoneal injection, apoptotic cell uptake by elicited peri-
toneal macrophages was determined by light microscopy.
Results The percentages of peritoneal macrophages that ingested
apoptotic cells were (mean ± standard error): wild type (WT) (n=12),
31.2±4.7%; C1q–/– (n=4), 9.4±1.8%; sIgM–/– (n=16), 8.5±0.9%.
The differences between C1q-deficient and WT mice as well as
between sIgM deficient and WT mice were highly significant
(P=0.0036 and P=0.0003, respectively). Mice heterozygous for sIgM
showed an intermediate result (17.9±1.8%). To determine whether
the clearance defect in the sIgM-deficient mice could solely be attrib-
uted to IgM deficiency, apoptotic thymocytes were preincubated with
purified murine IgM prior to intraperitoneal injection into sIgM-deficient
mice. IgM completely restored the ability of sIgM-deficient mice to
ingest apoptotic cells. Finally, to prove that IgM and C1q function in the
same pathway to facilitate clearance of apoptotic cells, we created
C1q/IgM double knockout mice. In contrast to the IgM single knockout
mice, addition of IgM to the double knockout mice failed to restore
phagocytosis of apoptotic cells.
Conclusions These findings indicate that IgM plays a pivotal role in
clearance of apoptotic cells, and that this occurs through activation of
the classical pathway of complement. IgM upstream of complement-
mediated opsonization of dying cells provides a unifying mechanism
explaining why mice with either early complement component or sIgM
deficiency develop lupus-like diseases. These findings have important
implications for understanding the pathogenesis of lupus in humans.
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Introduction Impaired clearance of apoptotic cells has been supposed
to be involved in the etiopathogenesis of systemic lupus erythematosus
(SLE). Furthermore, antibodies against retroviral proteins can frequently
be detected in sera of SLE patients without overt retroviral infections.
Decreased levels of serum DNase I activities as well as deficiencies in
components of the classical complement pathway are well established
to predispose to SLE.
Objectives We analysed the role of serum factors that could be
responsible for the degradation and clearance of human chromatin,
and followed up the processing of the HERV-K-10gag polyprotein
during apoptosis of Tera-1 cells. Furthermore, we investigated the
clearance of apoptotic cells in the germinal centers of patients with
SLE and controls.
Methods The chromatin degradation and uptake was monitored by
measuring the residual DNA content by flow cytometry. The HERV-K-
10gag polyprotein was used to investigate the processing of viral pro-
teins during apoptosis. Lymph node biopsies obtained from SLE
patients and non-SLE patients with benign follicular hyperplasia were
stained with monoclonal antibodies against macrophages (CD68) and
follicular dendritic cells (CR2/CD21). Terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick-end labeling (TUNEL) staining was per-
formed to detect apoptotic nuclei.
Results Whereas an excess of recombinant DNase I degraded human
necrotic cell-derived chromatin in the absence of C1q, an efficient
uptake of the predigested material by monocyte-derived phagocytes
required the presence of C1q. During apoptotic cell death, Tera-1 cells
showed an altered HERV-K-10gag processing compared with viable
cells. In addition, granzyme B was able to cleave HERV-K-10gag iso-
lated from viable Tera-1 cells. Regarding the fate of dying cells in ger-
minal centers of SLE patients, we found that the numbers of tingible
body macrophages were significantly reduced in a subgroup of
patients with SLE. TUNEL-positive apoptotic material was observed to
be associated with the surfaces of follicular dendritic cells.
Conclusions We conclude that C1q or DNase I deficiencies may pre-
cipitate human autoimmunity. Furthermore, the immunogenicity of retro-
viral antigens in SLE patients may result from a similar mechanism as
described for nuclear autoantigens. In general, nuclear autoantigens
bound to follicular dendritic cells may provide a survival signal for
autoreactive B cells, thereby over-riding an important initial control
mechanism of B-cell tolerance.
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C-reactive protein (CRP) is an ancient member of the innate immune
system. CRP is also a member of the pentraxin family of proteins and is
a strong acute phase reactant in man. CRP has been shown to bind to
phagocytes through interaction with Fcγ receptors, to affect the produc-
tion of cytokines, and to enhance phagocytosis. CRP has been shown
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to protect mice from infection, to bind to nuclear antigens and to delay
the onset of systemic lupus erythematosus (SLE) in autoimmune mice.
The mechanism for these diverse effects has remained obscure. Both
CRP and serum amyloid P (SAP) have been shown to bind to nuclear
antigens that are targets of autoantibodies in patients with SLE. Addi-
tional studies have shown that CRP and SAP can mediate the uptake
and clearance of apoptotic cells. These studies suggested that the pen-
traxins might prevent exposure and reactivity of the immune system to
self-antigens. Our studies have shown that CRP and SAP can delay the
onset of autoimmune disease accelerated by the injection of chromatin
into autoimmune mice. More recently, it has been demonstrated that
expression of human CRP as a transgene on autoimmune disease can
delay the onset of autoimmune disease. We report now that a single
injection of CRP can delay the onset of proteinuria in NZB×NZW
female mice. In all three cases, CRP failed to substantially decrease anti-
DNA autoantibodies yet protected mice from glomerular injury and
death. We suggest that CRP delays the onset of autoimmune disease
by modulating the effect of immune complexes on inflammatory cells. As
we have shown recently, the anti-inflammatory effect of CRP in the
lipopolysaccharide challenge model requires Fcγ receptor expression. It
is proposed that CRP mediates protection from nephritis in SLE by the
induction of anti-inflammatory cytokines and altering the reactivity of
macrophages to inflammatory stimuli.
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A single infusion of the anti-tumour necrosis factor monoclonal anti-
body Infliximab, given in five patients with Behcet’s disease (BD) and
sight-threatening panuveitis relapse, resulted in rapid and effective sup-
pression of ocular inflammation [1]. Until May 2003, a single Infliximab
infusion (5mg/kg) has been given in a total of 24 such patients (bilat-
eral relapse or unilateral relapse in 18 and six patients, respectively). At
day 1 post-treatment, a significant improvement of visual acuity, a strik-
ing decrease of anterior chamber cells, and a 50% decrease of vitre-
ous haze was evident in all patients but one. Within 2 weeks, acute
ocular inflammation, including retinal lesions and vasculitis, resolved
completely in 26 eyes, and by 80–90% in six eyes. Visual acuity
returned to the prerelapse levels (at least) in all.
We are currently looking at the safety and efficacy of continuous Inflix-
imab infusions (at week 0, weeks 3–4, and every 6–8 weeks thereafter,
at 5mg/kg) in patients who do not respond, or in patients with an inad-
equate response to prednisolone (nine patients), combined either with
cyclosporin A (six patients) and/or azathioprin (five patients), or
cyclophosphamide (one patient). In the 17 affected eyes, visual acuity
has improved by a mean of three lines in the Shnellen chart at 6 months
compared with at baseline. This effect has been sustained during
further follow-up (6 months–2 years). Concomitant immunosuppressive
therapy has been significantly tapered in all. No patient has experi-
enced an ocular relapse requiring other than topical treatment, or a
major extra-ocular relapse of the disease. No possible side effects,
including opportunistic infections or an exacerbation of previous neuro-
logical disease (present in three of nine patients), have been noted.
Similar results have been obtained in a parallel study looking at safety
and efficacy of continuous Infliximab infusions as monotherapy in previ-
ously untreated patients, which is also underway.
Since conventional immunosuppressive treatment BD-associated
acute ocular relapse is often unable to rapidly control ocular inflamma-
tion, which is critical to avoid development of chronic lesions, we
suggest that a single infusion of Infliximab with observation for objec-
tive improvement is the treatment of choice in these patients, and that
continuous treatment of Infliximab is a safe, effective and immunosup-
pressive therapy-sparing approach for patients with refractory, relaps-
ing ocular disease.
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Background Lines of evidence support that an autoantibody reaction
contributes to the immunological abnormalities underlying Behcet’s
disease (BD), yet no specific antibody has been reported in the
disease. In our previous study, common immune reactivities against
unknown cellular proteins were uncovered in 23.1% patient sera from
that of 39 Chinese BD patients as determined by immunoblotting.
Objectives This project set out to identify target antigen(s) in BD in
view of the fact that it may provide new inroads into the immunopatho-
genesis of the disease, and may have serodiagnostic usefulness.
Methods Immnuoscreening of a ZAP cDNA library followed by tran-
scription/translation in vitro of candidate clones in a reticulocyte lysate
system were carried out. The antigenicity of clone product was ana-
lyzed by immunoprecipitation using sera from all 39 BD patients in par-
allel with normal controls and control sera from Lupus and Sjögren
syndrome patients. Three truncated gene products spanning the full
length of the target protein were expressed in Escherichia coli, and
their respective antigenicities in BD were preliminarily analyzed using
an ELISA approach. A full-length gene cloned in the pEGFP vector was
transfected into HEp-2 cells as an overexpression antigen substrate for
immune fluorescent study.
Results Six independent candidate clones were isolated from a gene
library, being identified as overlapping human kinectin cDNA clones. The
antigenic identity of the partial gene product from the largest clone of
the six was preliminarily verified since nine out of 39 (23.1%) BD
patients’ sera could immunoprecipitate the translation product, whereas
sera from controls showed no reactivity. The antigenicity of kinectin was
found to mainly reside in the middle and carboxyl portion of the intact
protein, and the overexpression GFP-kinectin showed distinct perinu-
clear cytoplasmic staining and can be recognized by BD patient sera
but not normal sera under a confocal fluorescent microscope.
Conclusions BD patient sera contain autoantibodies to cellular pro-
teins, and one of the related autoantigens was kinectin, as unraveled by
gene library screening, the antigenicity of which mainly resides in the
middle and carboxyl portion of the intact protein. Further in-depth work
is needed to clarify the significance of kinectin in the disease entity.
Acknowledgement  Chinese National Nature Science Foundation
(2003–2005).
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B-cell development begins in the bone marrow and results in the gener-
ation of immature transitional B cells that leave the bone marrow and
enter the spleen, where they complete their maturation into mature
B cells. Transitional B cells undergo intense selection, resulting in the
survival and entry of only a small fraction into the mature B-cell pool. The
possibility that abnormalities in transitional B-cell biology might con-
tribute to the development of autoimmunity in systemic lupus erythe-
matosus (SLE) stimulated an examination of the phenotype and
immunoglobulin repertoire of transitional B cells in patients with SLE. Ini-
tially, we sought to identify human transitional B cells phenotypically, as
this had not previously been done in humans. This was facilitated by the
identification of an unusual patient with SLE and transient hypogamma-
globulinemia. This patient had a very large population of IgD+CD27–
Available online http://arthritis-research.com/supplements/5/S3S50
naive B cells, which included an expanded population of what we identi-
fied as transitional B cells. These were comparable in phenotype with
transitional B cells that we found in normal human bone marrow. These
were small, CD19+ CD20hi IgDlo IgMhi CD21– CD23– CD10+ CD24hi
CD38hi CD44lo cells. This population was expanded in this SLE patient
and also in children compared with normal adults. Immunoglobulin heavy
chain genes were completely unmutated in this population and the
repertoire differed significantly from that found in normal adult mature
B cells. These results suggest that abnormalities in transitional B-cell
biology may contribute to the development of autoantibodies in SLE.
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The majority of infiltrating cells into labial salivary glands and into lacrimal
glands in patients with Sjögren’s syndrome (SS) is CD4+TCRab T.
Analyses of the T-cell receptor on T cells in both glands support the
notion that infiltrating T cells are induced by antigen-driven stimulation.
Thus, the identification of autoantigens recognized by T cells in inflamed
lesions is important to clarify the pathogenesis of SS. T-cell epitopes on
autoantigens in labial salivary glands have been examined using several
strategies such as T-cell lines, PCR–single-strand conformational poly-
morphism, and West–Western methods. Our results showed the follow-
ing four autoantigens; Ro/SS-A, heat shock protein, α-amylase, and
muscarine receptor 3. Especially, the common T-cell epitope on α-
amylase in HLA-DR B1*0405-positive SS patients was NPFRPWW-
ERYQWPV (amino acids 68–80). The analog peptide of α-amylase
might regulate autoimmunity in an antigen-specific fashion.
Furthermore, TCRAV24+BV11+ double-negative natural killer T (NKT)
cells are thought to be regulatory T cells. In patients with SS, these
NKT cells are significantly decreased in peripheral blood, inducing the
autoimmune response. In vitro stimulation by α-galactosylceramide,
which is one of the antigens for NKT cells, was able to enrich NKT cells
more than 10–100 times. These findings suggest that the upregulation
of NKT cells by α-galactosylceramide might be a new therapeutic strat-
egy in patients with SS.
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Functional anti-muscarinic receptor autoantibodies have been demon-
strated in Sjögren’s syndrome (SS) in a mouse bladder contraction
assay. Most patients with these antibodies complained of severe lower
urinary tract disturbances, not usually recognised as a feature of SS. In
a cross-sectional study, we evaluated urological, sleep and fatigue
symptoms in female SS patients (n=76) compared with osteoarthritis
(OA) controls (n=43), utilising the American Urological Symptom
Index (AUA-7), the Epworth Sleepiness Scale (ESS) and the Facit-F
fatigue instruments. Patients were comparable with respect to
hormone-replacement therapy use, bladder operations, urinary tract
infections, parity and diuretic therapy; OA patients were slightly older.
Sixty-one percent of SS patients reported severe urological symptoms
compared with 40% of OA patients (P=0.04). This difference was
attributable to urge incontinence and not nocturia. Daytime somno-
lence was more severe in SS (P=0.02), independent of nocturia. A
trend towards increased fatigue was observed in SS that did not reach
statistical significance (P=0.15). These results suggest that urological
symptoms may be an under-recognised feature of SS, and that fatigue
in SS may in some cases be secondary to an underlying sleep disorder
such as obstructive sleep apnea due to dry airways, or circadian
rhythm disorder. These symptoms are consistent with functional distur-
bances of muscarinic receptors, possibly mediated by muscarinic
receptor autoantibodies.
Many features of SS overlap with menopausal symptoms. The T allele
of the IVS1-0401 (T/C) polymorphism in the estrogen receptor alpha
gene (ER-α) is thought to be associated with decreased responsive-
ness to estrogen. IVS1-0401 (T/C) genotyping was performed by
PCR-restriction fragment length polymorphism using the restriction
enzyme PvuII. No difference was seen in genotype frequencies
between SS patients (n=154) and controls (n=163, P=0.26). Within
female SS patients who completed the AUA-7 and ESS (n=73), the
ER-α IVS1-0401 T allele was associated, in a dose-dependent manner,
with increasing daytime somnolence (P=0.003) and urological
(P=0.08) symptom severity. This polymorphism appears to influence
the severity of commonly reported symptoms in SS that are also linked
with estrogen deficiency. We predict that it will be a risk factor for
severity of menopausal symptoms and sleep disturbances in non-SS
patients.
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Background Sjögren’s syndrome is a chronic autoimmune and
rheumatic disorder of the mucous membranes caused by lack of proper
exocrine secretions, with prominent sicca complaints. The molecular
mechanisms of the pathogenesis are virtually unknown.
Objectives To investigate functional properties of lymphoid aggregates
and its surroundings observed in salivary glands of patients with
Sjögren’s syndrome and in in vitro systems combined with serological
analysis of blood and saliva.
Methods Biopsy material from 178 inflamed minor salivary gland biop-
sies formed the basis for studies of lymphoid neogenesis. Cell surface
markers, proliferation markers, adhesion molecules, chemokines, B-cell
activating factor (BAFF) and local production of autoantibodies were
investigated by immunohistochemistry, ELISPOT, ELISA and apoptosis
determination.
Results About every sixth biopsy contained lymphoid aggregations
with germinal center-like morphology. Elevation of autoantibody pro-
duction was observed related to inflamed salivary glands. Germinal
center-positive patients had high expression of the lymphocyte-homing
and retention chemokines and adhesion molecules. Induced apoptosis
disclosed subcellular redistribution and cell surface exposure of
autoantigens of high relevance for Sjögren’s syndrome. Attenuated
apoptosis was detected among BAFF+ B cells.
Conclusions Ectopic secondary lymphoid follicles in Sjögren’s syn-
drome contain all elements of relevance for driving an autoimmune
response. BAFF seems to direct the lifespan of infiltrating B cells by
enhancing their proliferation and maturation.
Altogether, the studies have shed light on factors involved in directing
lymphocytes into inflamed tissue and maintaining inflammation in
Sjögren’s syndrome.
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Recently, hepatocyte growth factor (HGF) has been identified by
immunohistochemistry in cartilage and, more particularly, in the deep
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zone of human osteoarthritic (OA) cartilage. By investigating HGF
expression in cartilage, we found that chondrocytes did not express
HGF; however, they express the two truncated isoforms, namely
HGF/NK1 and HGF/NK2. As the only other cells localized near the
deep zone are osteoblasts from the subchondral bone plate, we
hypothesized that they were expressing HGF. Indeed, we found that
HGF was synthesized by osteoblasts from the subchondral bone
plate. Moreover, OA osteoblasts produced five times more HGF than
normal osteoblasts. Because prostaglandin E2 and proinflammatory
cytokines such as IL-1 and IL-6 were involved in OA progression, we
investigated whether these factors impact HGF produced by normal
osteoblasts. Prostaglandin E2 was the only factor able to stimulate
HGF synthesis. However, the addition of NS398, a selective inhibitor
of cyclooxygenase-2, had no effect on HGF produced by OA
osteoblasts. When investigating signaling routes that might be impli-
cated in OA osteoblast-produced HGF, we found that protein
kinase A and protein kinase C were involved. In summary, this study
raises the hypothesis that the HGF found in articular cartilage is pro-
duced by osteoblasts, diffuses into the cartilage and may be impli-
cated in the progression of OA. Furthermore, we investigated joints in
HGF transgenic mice. We found that the subchondral bone was
remodeled and that cartilage matrix was qualitatively different from the
control mice. These results reinforced the idea of a role played by
HGF in the joint.
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Ex vivo gene therapy includes culture-expansion of pluripotent stem
cells, genetic manipulations in vitro and reimplantation into a recipi-
ent. This cell-mediated gene transfer with adenoviral vectors may be
safer than in vivo techniques since it avoids the inoculation of viral
particles into the body. Previous studies have shown that the trans-
duced cells can contribute to bone and cartilage regeneration when
osteoprogenitor cells or mesenchymal stem cells were used as the
carrier to transfer the BMP-2 protein. However, these studies did not
reveal that these infected cells continue to secrete the transduced
protein. Also, the fate of these cells remained unknown, whether they
could become incorporated into host tissue and differentiated into
cartilage and bone. To investigate these parameters, we constructed
an adenoviral vector encoding the myc epitope-tagged BMP-2 gene
(AdBMP-2Myc). Rat bone marrow cells (rBMCs) transduced with
AdBMP-2Myc produced biologically active BMP-2 protein, which was
confirmed by Western blot analysis and alkaline phosphatase assay.
Ex vivo studies using rBMCs infected with AdBMP-2Myc and
implanted into the hindlimbs of SCID mice demonstrated orthotopic
bone formation by 1 week and greater consolidation at the later time
periods. Immunohistological analysis revealed that the Myc-positive
cells differentiated into chondrocytes and became introduced into
the bone during the endochondral ossification process. The different
distribution of BMP-2 and Myc-positive cells suggested that exoge-
nous BMP-2 protein, delivered by infected rBMCs, can induce
endogenous BMP-2 protein expression and bone formation from host
osteoprogenitor cells. Our study indicated that osteprogenitor cells
can be utilized as the delivery vehicle for therapeutic osteochondral
inductive genes, and their transduced cells themselves can develop
into terminal differentiated mesenchymal tissues, like cartilage and
bone. Therefore, the cell selection is critical when using an ex vivo
gene therapy strategy, and this adenoviral construct is useful for the
evaluation of cell-tracing experiments to determine the distribution of
the secreted protein.
164
Oxidative stress induces chondrocyte telomere
instability and chondrocyte dysfunctions in
osteoarthritis
K Yudoh1, N van Trieu1, H Matsuno2, K Nishioka1
1Institute of Medical Science, St Marianna University School of
Medicine, Kawasaki, Japan; 2Bioengineering Research Center, 
Toin-Yokohama University, Yokohama, Japan
Arthritis Res Ther 2003, 5(Suppl 3):164 (DOI 10.1186/ar965)
Objective To clarify the implication of oxidative stress in the progres-
sion to osteoarthritis (OA) from the point of view of oxygen free radical-
induced genomic instability, including telomere instability and resultant
replicative senescence and dysfunction in human chondrocytes.
Methods Human chondrocytes and articular cartilage explants were
isolated from knee joints in patients undergoing arthroplastic knee
surgery for OA. The oxidative damage/antioxidative capacity in OA car-
tilage was investigated in the donor-matched pairs of the intact and
degenerative region that were isolated from same OA cartilage
explants. The results were histologically confirmed by immunohisto-
chemistry for nitrotyrosine, which has been considered a maker of
oxidative damage. Under treatment with reactive oxygen species or
antioxidative agent (ascorbic acid), cellular replicative potential, telom-
ere instability and production of proteoglycan aggrecan glycosamino-
glycan (GAG) were assessed in cultured chondrocytes.
Results Lower capacity of antioxidant and stronger staining of nitroty-
rosine were observed in the degenerative regions of OA cartilages as
compared with those of intact regions from the same cartilage explants.
Immunopositivity for nitrotyrosine was associated with the grade of his-
tologic change of OA cartilage, suggesting the correlation of oxidative
damage with articular cartilage degeneration. During continuous
culture of chondrocytes, the telomere length, replicative capacity and
GAG production were decreased by treatment with reactive oxygen
species. In contrast, treatment with an antioxidative agent showed a
tendency to elongate the telomere length and replicative lifespan in cul-
tured chondrocytes.
Conclusion Our findings clearly showed the presence of oxidative
stress that induces telomere genomic instability, replicative senes-
cence and dysfunction of chondrocytes in OA cartilage, suggesting the
implication of oxidative stress in the chondrocyte senescence and carti-
lage aging responsible for the development of OA. New efforts to
prevent the development and progression of OA may include the
strategies and interventions aimed at reducing oxidative damage in
articular cartilage.
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Objective To investigate expression of the focal adhesion kinase
(FAK), Akt/PKB and the transcription factors Elk-1 and p90RSK in
rheumatoid arthritis (RA).
Materials and methods Synovial tissues from eight RA synovia (FAK,
Akt/PKB) or six RA synovia (Elk-1, p90RSK), one osteoarthritis (OA)
synovia and two normal synovia were investigated by immunohisto-
chemistry with antibodies recognizing the phoshorylated of the respec-
tive molecules. In addition, cultured rheumatoid arthritis synovial
fibroblasts (RASF) and normal (N) synovial fibroblasts were coim-
planted with human cartilage for 60 days. The invasion score was
determined on H & E stained sections, and sections with strong carti-
lage invasion were also stained for the aforementioned molecules by
immunohistochemistry utilizing the avidin–biotin detection system.
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Results In RA tissues, FAK was expressed in the lining, sublining layer
and perivascular layer. Limited perivascular FAK expression was detected
in two normal synovia and no staining occurred in one OA tissue. In the
lining and sublining, Akt/PKB was present in all investigated RA tissue, but
not in the normal synovia and only in a few cells of the OA sample. Carti-
lage invading RASF neither stained for FAK or for Akt/PKB. The transcrip-
tion factor Elk-1 was expressed in RA tissues in both the lining and
sublining layer. No staining was detected in normal synovium, and only
limited Elk-1 expression in the lining layer of one OA tissue. In addition,
p90RSK was also expressed in RA tissues in the lining and sublining
layer; however, no staining occurred in the normal synovium. In OA tissue,
staining was restricted to the lining layer. SCID mice sections with strong
cartilage invasion of RASF did not stain positive for Elk-1 or for p90RSK.
Conclusions We suggest that expression of the phosphokinases FAK,
Akt/PKB and the transcription factors Elk-1 and p90RSK are associ-
ated with inflammation, but not with cartilage invasion in RA. Therefore,
we assume that these molecules might not be therapeutic targets to
inhibit cartilage destruction in RA.
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Objectives Several lines of evidence have recently suggested that
some immune responses are involved in the pathogenesis of
osteoarthritis (OA). Aside from humoral immunity, T cells seem relevant
to the development of OA. Previously, we showed that T cells
responded to autologous chondrocytes only in OA, suggesting involve-
ment in some role in the pathogenesis of OA. In this study, we investi-
gated the response of chondrocytes contacting with autologous T cells.
Methods Human chondrocytes are obtained during arthroplasty for OA
and fracture. The latter samples served as normals. Enzymatically iso-
lated chondrocytes were cultivated and used within the seconnd
passage for the following experiments. Both cells were cultured
together with or without separate wells and the production of matrix
metalloproteinases (MMPs) and RANTES were measured using ELISA
kits. The contact responses were blocked by antibodies for adhesion
molecules (LFA-4 and VLA-4).
Results MMP-1, MMP-3, and MMP-13 were expressed only in chon-
drocytes. The production of all MMPs was enhanced by contact cocul-
ture of chondrocytes with autologous T cells, whereas the production
was not enhanced by separate coculture. Blockade of adhesion mole-
cules had no influence on these responses. RANTES was expressed
both in T cells and chondrocytes without stimulation. RANTES produc-
tion was enhanced both in contact and in separate conditions only in
OA samples, not in normal samples.
Conclusions The augmentation of MMP production required T cell–
chondrocyte contact mediated by mechanisms different from the adhe-
sion molecules tested. As chondrocytes are surrounded by plenty of
extracellular matrix, its contact with other types of cells is extremely rare;
however, the chance of contact will appear with the degradation of carti-
lage. Thus, T-cell-mediated development of OA is supposed possible.
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Pentosidine in serum and synovial fluid in patients
with knee osteoarthritis and its potential role of
prediction of osteoarthritis progression
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Background The role of molecular markers for prediction of osteoarthri-
tis (OA) progression is not yet defined. Pentosidine, one of the well-
characterized advanced glycation endproducts, may be a candidate.
Objectives To study the role of pentosidine as a marker of knee OA, as
a marker of progression of knee OA, and for correlation of pentosidine
in serum and synovial fluid and correlation with other markers.
Methods Pentosidine was estimated by our own HLPC method [1],
and cartilage digomeric matrix protein (COMP) by an original sandwich
ELISA with monoclonal antibodies 16-F 12 and 17 C 10 [2]. MMP-9,
TIMP and YKL-40 were estimated by commercial ELISA kits. Joint
space width was measured in the narrowest point of the tibiofemoral
compartment by 0.1 caliper and magnifying glass.
Results Eighty-nine patients with knee OA were included in the study and
were followed for 2 years. The paired samples of serum and synovial fluid
were obtained from 48 patients in second study. The joint space narrow-
ing in 2 years was 0.4±0.79mm. The patients with knee OA had higher
initial serum values of pentosidine than controls (P=0.04) and also of
TIMP (P=0.04), MMP-9 (P=0.02) and COMP (P=0.05). The patients
with initially higher serum levels of pentosidine had more rapid radiological
progression than controls (r=0.30), and the same was true for hyaluronic
acid (r=0.56). Serum pentosidine levels correlated with synovial fluid pen-
tosidine levels (r2=0.78). Mild correlation occurred between synovial fluid
pentosidine and COMP levels (r2=0.11, P<0.05).
Conclusions Serum pentosidine levels may be a new molecular marker
for prediction of OA progression.
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Many of the 10–60% of the working-age population with knee pain will
develop osteoarthritis (OA), a progressive joint disease with cartilage dete-
rioration and increased disability. In knee OA, exercise decreases joint pain
and improves function. Lack of human in vivo monitoring methods has
made studies of influence of exercise on cartilage composition impossible.
Delayed gadolinium-enhanced magnetic resonance imaging of carti-
lage (dGEMRIC) can estimate joint cartilage glycosaminoglycan (GAG)
content. It is based on the principle that the negatively charged Gd-
DTPA2– ions distribute in the cartilage in an inverse relationship to the
GAG content. A high GAG content results in a low contrast medium
distribution and a long T1 relaxation time that can be measured by mag-
netic resonance imaging. We used dGEMRIC in a cross-sectional
study in healthy subjects with different exercising levels, and in a longi-
tudinal exercise study in patients at risk for OA.
Methods Study 1 included healthy, nonexercising individuals (n=12),
moderately exercising individuals (n=16), and elite male track and field
athletes (n=9). Study 2 included medially meniscectomized patients
that were randomized to exercise three times weekly for 4 months
(n=22) or to a control group (n=23).
T1 measurements were made in sagittal slices in a 1.5T magnetic reso-
nance imaging system, using sets of turbo inversion recovery images
with different inversion times in a region of interest in weight-bearing
cartilage 2 hours after intravenous Gd-DTPA2– injection at 0.3mmol/kg
body weight. T1 (s) was calculated using the mean signal intensity from
each region of interest as input to a three-parameter fit. In study 2, sub-
jects were examined before and after the exercise period.
Results  In study 1, there was a significant relationship between T1
relaxation time and the level of physical exercise, with longer T1 values
in physically active subjects. In study 2, the exercise group showed a
significant higher mean change in T1 than the control group.
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Conclusions In vivo cartilage monitoring by dGEMRIC indicates, for the
first time, that human articular cartilage in mature individuals seems to
adapt to physical activity levels by increasing its matrix GAG content.
This may improve the resistance to mechanical compression, and thus
protect the collagen network and prevent knee OA development.
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Fibromyalgia (FM) is the most common chronic pain syndrome in the
community. The absence of reproducible peripheral pathology has sup-
ported the hypothesis of abnormal central pain sensitisation/process-
ing, with both psychological and biological theories invoked. Seminal
work by Mountz et al. identified reduced regional cerebral blood flow
(rCBF) in the thalamus and caudate nuclei. Our aim was to verify varia-
tion in rCBF of subjects with FM, and to refine its anatomical localisa-
tion and clinical correlation. Twenty-seven females with ACR criteria
FM were matched with 22 age-matched, gender-matched and educa-
tion-matched controls. Detailed physical and psychological inventories,
1.5T T1/T2 magnetic resonance imaging (MRI), and triple-headed 99Tc
single photon emission computed spectrometry (SPECT) scanning
were performed. We have developed a colocalisation of SPECT-mea-
sured rCBF with MRI imaging, accurate to 2mm. This allowed highly
definable quantitative rCBF analysis using statistical parametric
mapping (SPM). Initial studies identified a highly significant 16% reduc-
tion in rCBF of the pontine tegmentum/upper medulla, and less robust
reduction in the thalamus. Clinical correlates favoured physical rather
than psychological variables. In a subcohort of 11 FM subjects and
11 controls, rCBF has been measured twice over a 5-year period.
None of the subjects were cured. rCBF remained significantly reduced
in the pontine tegmentum and midbrain of FM subjects with normalisa-
tion of caudate and thalamic rCBF. In a novel analysis, SPM has been
uniquely used for the detection of subvisual changes on T1 and T2 MRI
scans. The MRI scans of 27 FM subjects were compared with those of
19 controls. Analysis of T1 images identified a 6% reduction in signal
among FM subjects within the cerebellar tonsils and midbrain, the
former in keeping with reports of Arnold–Chiari type 1 malformations.
T2 analysis identified widespread diffuse reduction in the white matter
of FM subjects. Our studies have confirmed and localised objective
abnormalities of rCBF among FM subjects. These changes probably
reflect altered metabolic demands in pain processing centres, and for
the first time have been shown to persist over time. Canonical and dis-
criminant statistical analysis was not able to utilise these findings for
diagnostic purposes. Additionally, subvisual abnormalities on MRI sug-
gested structural and functional abnormalities within the brain.
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Purpose Fibromyalgia syndrome (FMS) is a controversial disorder of
unknown etiology. Because of lack of laboratory and objective findings,
many patients have been ignored, misdiagnosed or referred to a psy-
chiatrist. Recently, the number of FMS patients has been increasing in
Japan. The purpose of this study is to elucidate the clinical feature of
FMS and to evaluate the clinical efficacy of Neurotropin (extracted from
inflammatory cutaneous tissue of rabbits inoculated with vaccinia virus)
for FMS associated with neck or back pain.
Methods Subjective complaints, tender points and clinical findings
were assessed and routine laboratory examination was carried out in
70 FMS patients. Among them, 23 patients were treated with Neu-
rotropin, administered orally and intravenously. Patients’ assessment
and the number of tender points were evaluated after the treatment.
Results Subjective complaints were composed of fatigue, sleep distur-
bance, depression, anxiety and headache, as well as widespread pain.
The mode of pain ranged from cutting pain to touch pain. In serious
cases, patients could not even move the joints nor stand by their
selves. Neurotropin treatment was effective in 16 out of 23 patients.
Further investigation will be needed to comprehend the present status
of FMS in Japan and to elucidate its etiology. The effect of Neurotropin
on FMS also needs to be evaluated.
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The mainstay of management of rheumatic diseases is based on drug
therapy. A number of drugs, from gold salts of yesteryear to methotrex-
ate, leflunomide and the biologicals of today, are in vogue. These are
used both singly and in permutations and combinations. Patient
response varies enormously, from impressive results to abysmal failure.
Why this great variability of response? The following factors would
determine patient response: the choice of drug (factors in the drug and
factors in the patient), the dosage forms, the dose, the pharmacokinet-
ics, the pharmacodynamics, the drug interactions (synergism, additive
effects, and antagonism), the adverse reactions, the pharmacoeconom-
ics, and the patient education.
This presentation highlights nuances in drug therapy that will minimise
failure rate, enhancing the success rate in the realm of rheumatology.
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Selective cyclooxygenase-2 (COX-2) inhibitors were developed to fill
an important medical need. The rationale for the development of selec-
tive COX-2 inhibitors will be discussed using celecoxib as an example.
A brief description of the pharmacology and selective binding to the
COX-2 enzyme will be presented. Both preclinical and clinical data will
be shown to demonstrate important clinical aspects of celecoxib. The
efficacy data will include studies of osteoarthritis, rheumatoid arthritis,
and acute pain conditions. Both gastroenterology and cardiovascular
safety of celecoxib will be discussed. Finally, potential new therapeutic
areas for celecoxib will be presented.
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From the dawn of the time, discoveries have been made to improve the
human condition. Today, science and biotechnology have transcended
to the very essence of life itself. The inexorable urge to extend the fron-
tiers of genetics and biology threatens to impinge on the balance
Available online http://arthritis-research.com/supplements/5/S3S54
between the well-being of mankind and its detriment. UNESCO,
through the Universal Declaration on the Human Genome and Human
Rights (1998) and via the International Bioethics Committee, is drafting
an international instrument of bioethics based on the principles of
human dignity, freedom, autonomy, justice and equity across cultures,
values and religions. It emphasizes the noncommercialization of the
human body, cautions against the pursuit of indiscriminate research in
embryonic stem cells and cloning, gives directives in the collection,
storage and treatment of genetic material, and outlaws the patenting of
human genes. The voice of scientists/physicians in this arena is muffled
and distant. Before binding legislation intended to protect the liberty of
human beings is thrust upon us, scientists need to lead the public
debate. Society, still recovering from the era of eugenics where
science was heralded as being able to provide solutions for social
dilemmas, wants to be fully informed of its choices. The education of
the public requires strategic planning so that efforts may not be coun-
terproductive and generate mistrust. This presentation to scientists/
clinicians who are at the cutting edge of innovative research in our field
will highlight bioethical issues of mutual interest, emphasizing the appli-
cations and implications of scientific advances.
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